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Abstract
Psoriasis is a chronic skin disease that affects up to 2% of the UK population. The clinical
presentation ranges from mild disease to extensive, severe disease that causes considerable
discomfort and distress. Severe disease usually requires photochemotherapy or systemic
treatment. Information about the effectiveness, safety and costs of the different treatments
is required to enable dermatologists to formulate evidence-based treatment guidelines.
Systematic reviews of the four main treatment modalities for moderate-severe psoriasis
(cyclosporin, methotrexate, systemic retinoids and photochemotherapy) were performed.
Randomised controlled trials were located systematically by electronic searching, hand
searching and personal communications. Data on trial characteristics and outcomes were
extracted and tabulated. Where possible data were pooled to give summary effect sizes as
odds ratios, rate differences or numbers needed to treat (NNTs). Firm RCf evidence of
efficacy was found for cyclosporin, oral ret.inoids, particularly in combination with PUV A,
phototherapy, photochemotherapy and for combinations of topical calcipotriol or steroids
with phototherapy. The corresponding NNTs were low, indicating high levels of efficacy.
RCI' evidence of efficacy is lacking for methotrexate. Two observational studies of
patients attending the Psoriasis Specialty Clinic were performed. The first was a cross-
sectional study that used data in existing disease assessment docwnentation to identify the
characteristics of a group of 256 patients. The second was a longitudinal study that
followed the treatment pathways of 166 patients in the first group. These studies confirmed
that this group of patients and their treatments were comparable with those described in the
literature. An economic analysis was performed, using a previously published decision-
analytic model, to compare four treatment strategies for severe psoriasis from the health
service perspective. The results (cost-effectiveness ratios) showed that methotrexate was
the most cost-effective primary treatment followed by cyc1osporin, acitretin and PUV A.
The rank order was not sensitive to changes in response rates. Modifications to the decision
analytic model are proposed including a wider array of pathways and an allowance for
adverse effects of treatment. Future analyses should include narrowband UVB alone as a
primary treatment.
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Chapter 1
Evidence-Based Medicine
Summary
This chapter reviews the background to the development of evidence -based medicine (EBM) and
describes the methodological 'tools' which are used to gather and synthesise the evidence. The
implementmiott ~f EBM is considered brief/yo
1.1 Evidence-based Medicine: Background
Although the-philosophical origins of evidence-based medicine (EBM) date back for many decades,
the current drive for EBM in the NHS was triggered by the combination of rising costs and
evidence of wide variations in medical practice. (Weatherall 1994) There was also mounting
concern that many interventions had little basis other than tradition.
In January 1996 the NHS Executive stated its commitment to ensuring
"that decisions about the provision and delivery of clinical services are driven
increasingly by evidence of clinical and cost-effectiveness, coupled with systematic
assessment of actual health outcomes". (NHS Executive 1996a)
In the same month Sackett and colleagues described EBM as, "t~ conscientious, explicit and
judicious use of current best evidence in making decisions about the care of individual patients".
(Sackett 1996) Itfollows from both statements that the practice ofEBM involves two critical steps,
firstly the identification of "evidence" and, secondly, its application.
This chapter reviews the-methodological tools which are used to identify and synthesise evidence
and the common approaches to implementation of EBM
1.2 Tbe tools of evidence-based medicine
For any therapeutic intervention there exists a body of experience in the scientific literature and in
the memories of clinicians: This, therefore, is "the ~dence' which has to be systematically
extracted and analysed. A critical step in this process is to devise a decision-analytic model which
accurately describes the- options open to a clinician and the- possible decision pathways. Inorder to
do this, the raw evidence has first to be located, sifted, analysed and synthesised to ensure that the
final model is base-d on reliable- material of suitsbleqnality, The techniques of systematic review
12
and economic analysis are employed to analyse and synthesise the evidence. Only when this stage
is complete can the evidence be translated into meaningful therapeutic guidelines. Guidelines
derived through a less rigorous process cannot really be said to merit the description 'evidence-
based'.
1.2.1 Decision analysis
Decision analysis is a systematic, quantitative technique for structuring the decision-making
process. It has been described and recommended as a means of helping clinicians to make
decisions about the care of individual patients. (Weinstein 19&0, So)f 1988) However it can also be
used to analyse treatment strategies for groups of patients and to form the basis for cost-
effectiveness analysis; It has even been used to analyse the cost-effectiveness of medical research
itself. (Drummond 1992) It is particularly helpful when a decision is complex and involves an
element of uncertainty.
There are five steps in a decision analysis (petitti 1994):
• identification of the problem
• structuring of the problem (using a decision-analytic model, 'decision tree')
• gathering information about uncertainties and outcomes
• analysis of the tree
• sensitivity analysis
Clear identification of the problem is the critical first step so that the resulting tree has a
recognisable focus, timing, horizon and perspective. A specific starting point must be identified
along with a realistic time horizon.
The decision tree is a flow diagram showing decisions and outcomes, in time sequence, moving
from left to right. The tree must clearly distinguish between choices (which are under the
decision-maker's control) and chance events (which are beyond the decision-maker's control). It
must also distinguish between outcomes (which describe facts, states of being) and outcome
valuations {utility values) .: Inorder to represent these entities in a decision tree three types of
"node" are used. They are; decision nodes (square), chance nodes (round) and outcome nodes
(triangular). Two basic rules must be obeyed when constructing the tree; firstly, the branches from
a node must be exhaustive and mutually exclusive and, secondly, the sum of probabilities in each
branch must be equal to-one. (figure 1.1 showsan example of a decision tree)
13
Figure 1.1: Measles revaccination decision analysis - decision tree format
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Die (0.0023)
Live (0.9977)
Die (0.00)
Live (1.00)
Die (0.0023)
Live (0.9977)
Die (0.00)
Live (1.00)
Die (0.0023)
Live (0.9977)
Die (0.00)
Live (1.00)
Die (0.0023)
Live (0.9977)
Die (0.00)
Live (1.00)
Gathering the information to fill in the decision tree is the next step. Probabilities must be
determined for each chance event and utility values assigned to outcomes. Probabilities are derived
from systematic review of the literature (see below), primary data collection or consultation with
experts .: By convention, death is given a value of zero and life (survival) is given a value of one.
Values for intermediate states, such as survival with a disability are determined by a standardised
wager-technique. (Jefferson 1996) This involves asking a patient to choose between two
hypothetical options, for example;
• option k: no risk of death bat the certainty of a degree of disability
• option B: a 0.5 chance of complete cure but also a 0.5 chance of death.
Most patients will choose option A .The wager is thenreformulated with a reduced chance of
death. This process is repeated until the patient has difficulty choosing between the two options.
This point will be associated with a value for the chance ofcomplete cure (e.g, 0.95) and a value for
the chance of death (0.OS). This is described as "the level of indifference",
The decision tree is analysed by a process of "folding back" and averaging. This can be done either
with or without utility values. An example of a tree using probabilities alone is shown in figure 1.1,
which describes the probabilities of death or survival depending on whether subjects are re-
vaccinated or not. "Folding back" refers to the process of multiplying together all the probabilities
associated with each outcome: This is more easily seen if the ill1'ol lIlat,ion on the tree is set out as a
spreadsheet (see table I. I). "Averaging" refers to the summation of the products of the rows that
lead to the same outcome.
This example only has two outcomes-(die or don't die (1il'e))ho.wever, for a problem with
intermediate outcomes, the utility value of each outcome may be included The option with the
highest utility value can then be computed,
Finally, the robustness of the model is tested by means of sensitivity analysis. In this process the
values of one or more key parameters are varied totest the effect on ~ final result. In the measles
re-vaccination example, the probability of exposure to measles was estimated to be 20010although in
practice it varies between 1% and 400'" A sensitivity analysis, would examine the effects of
substituting values between 1 and 40 on the number of lives saved by re-vaccination. This
identifies weaknesses in the model and may be-used to guide future research.
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Table 1.1 Measles Re-vaccination Decision Analysis - Spreadsheet Format
Sum for deaths (sum of products for lines 1,3,5 & 7) = 0.000152
Difference between revaccination and no vaccination = 0.000152 - 0.000023 = 0.000129
Difference as events per 100,000 = 12.9 deaths
(After Pettiti 1994)
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1.2.2 Systematic review
The purpose of a systematic review is to summarise and present both published and (if possible)
unpublished data in a comprehensive form. This information may be used as the basis for a meta-
analysis or may be used directly to estimate a probability for cost-effectiveness analysis. The
process of systematic reviewing involves the location. appraisal and synthesis of evidence from
scientific studies in order to provide informative empirical answers to scientific research questions.
(NHS CRD 1996) A systematic review differs from a traditional review paper in that the
methodology is explicit, the review attempts to capture all relevant data and the analysis should be
free from bias.
There are eight steps in the preparation of a systematic review: (Lefebvre 1994)
• statement of the objectives of the review
• definition of the eligibility criteria
• search for eligible studies (information retrieval)
• assessment of the quality of each study
• application of the eligibility criteria and justification of any exclusions
• analysis of the results of the eligible studies (data extraction)
• data synthesis
• preparation of the report
It is recommended that the whole review process should be planned in advance and recorded as a
written protocol. (Meade 1998) In this way it should be possible to ensure that the methods are
driven solely by the aims and bias is avoided. The protocol should specify the question(s) to be
answered. the strategies for information retrieval and data extraction, the screening criteria and the
means by which the data will be synthesised: The protocol should provide a framework to ensure
that the research question is answered rather than specifying narrow, untested selection criteria
which may exclude. all the available studies.
It has been suggested that each review question should describe three elements, (1) the participants
(subjects) in the primary studies and theirdiseasestatus, (2) the intervention under consideration
and (3) the outcomes which evaluate the success of the intervention, (NHS CRD 1996)
Before the search for suitable studies is started, eligibility criteria must be defined Most systematic
reviews are based on randomized controlled trials (Rcrs) as this methodology is most likely to
distinguish reliably between theeffect5 of an intervention and the effects of bias or chance. If
sufficient Refs are not available then the next best quality evidence must be used. Table 1.2 shows
the conventionally accepted hierarchy of evidence.
17-
Table 1.2: Hierarchy of Evidence
(Eccles 1998)
It is important that the information retrieval process is scientifically defensible and free of bias. It
follows that all the available information needs to be identified. Inpractice it may not be possible
to locate unpublished information and there may be considerable difficulties in trying to retrieve
information published in foreign languages. The reviewer needs to be aware of the phenomenon of
publication bias. This is the bias introduced because studies with positive results are more likely to
be published than those with negative results. Thus, even if a comprehensive search is successfully
performed, the results may not represent all the work that has been done in that field Electronic
databases may identify as few as 50010 of the relevant studies and so the information retrieval
strategy must go beyond electronic searching alone. The ideal approach is summarised in Table 1.3
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Table 1.3: Steps for comprehensive retrieval of published information on a specific topic
(After Petitti 1994)
The computerised search must be designed with care. Most systematic reviews set out to retrieve
randomized controlled trials, however, until recently bibliographic databases, such as Medline and
Embase were inadequately designed for this purpose and lacked suitable indexing terms, (Lefebvre
1994) Inorder to maximize the chances of identifying all the available RCI's optimally-sensitive
search strategies (OSSS) have been devised. (Dickersin 1994, NHS CRD 1996) The search strategy
recommended by the NHS Centre for Reviews and Dissemination is shown in Appendix 1.
Once all the relevant articles have been assembled. they must be screened for quality and eligibility
using the criteria established at the outset Some general criteria for assessing the quality of Rcrs
have been identified (see Table 1.4) but other specific criteria relating to the question under
investigation may need to be added. After screening the remaining papers can then be used for data
extraction. It is recommended that data-extraction forms be prepared in advance so as to minimise
bias. (Meade 1998) This process should involve extensive testing and consultation with experts in
the field to ensure that critical elements of data are not overlooked. Data extraction forms vary
considerably, depending on the area of investigation. An example is shown at Appendix 2.
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Table 1.4: Generic criteria for assessment of randomised controlled trials
1 Was the assignment to the treatment groups really random?
2 Was the randomisation of the participants blinded?
3 Was relatively complete follow-up achieved?
4 Were the outcomes of people who withdrew described and included in the
analysis?
5 Were those assessing outcomes blind to treatment allocation?
6 Were the control and treatment groups comparable at entry?
7 Were the groups treated identically other than for the named intervention?
(CRD Report Number 4. 1996)
The results of the primary studies are then drawn together to provide a broad, qualitative overview.
It may also be possible to undertake a quantitative synthesis using the techniques of meta-analysis.
In this way a summary measure of effect size can be derived from pooled data As with any
statistical method. it is important that the most appropriate method is selected for the data in
question, (This will be discussed.in more detail in Chapter 6)
The final report of a systematic review should include a clear description of the purpose, methods,
results and implications of the review.
1.2.3 Economic analysis
Several different types of economic evaluation are possible but some elements are common to all.
Generally. two or more interventions are considered and the inputs (resources) needed to deliver it
are compared with the outputs (res~effects). It follows, therefore, that cost-of-illness (COl)
studies, which consider inputs only. are not considered to be true economic evaluations. Different
types of economic evaluation measure inputs and outputs indifferent units. The characteristics of
the four main types of economic analysis are summarised in Table 1.5.
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Cost-effectiveness analysis (CEA)
It can be seen from Table 1.5 that CEA compares the outcome of decision options in terms of cost
per unit of effectiveness. In practice, this type of analysis is most widely used in healthcare and so
this will described.
Cost-effectiveness analysis contributes to and builds on to decision analysis. using a decision tree as
its starting point. The following additional steps are necessary:
• Definition of the perspective of the analysis
• Identification Of cost data
• Analysis of cost data
• Sensitivity analysis
The perspective of a CEA must always be stated explicitly as this will determine which costs are
included For example, an analysis from a provider perspective would include direct and indirect
costs of providing 3 treatment, whereas an analysis of the same treatment from the patient
perspective might include travelling expenses for clinic visits and loss of income.
Cost data must becarefuUy researched and the difference between costs and charges must be clearly
understood. For example, it might cost 3hospital laboratory £5.00 to carry out a test (including
reagents, labour and overheads) but the hospital might charge £IO.00 to perform the test for 3
private clinic. In this case the cost to the hospital is £5.00 but to the private clinic the cost is
£10.00. The figure used in an economic evaluation will depend on its perspective. In general, cost
data are either taken from administrative sources or are gathered de novo in suitable observational
studies.
Cost data can be added to the decision tree so that the net cost of each.of the decision options can be
calculated
Sensitivity analysis is anesseotial part of 3CEA as it allows the researcher to test the effects of the
assumptions that have been made. It may also help to identify cost elements which are critical to
the model and which may be liable to change. An example of this is.a study which examined the
cost-effectiveness analysis of screening for and eradication of Helicobacter pylori. (Briggs 1996) In
this study the authors. examined the .effects of varying 18 different parameters on their model. They
were able to show that the cost of anti secretory medication had 3 more significant effect on the
payback period than allother factors. including the accuracy of.endoscopy and the effectiveness of
eradication treatment.
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1.3 Implementation of EBM
Sackett and colleagues explained how it should be possible to apply epidemiological and
biostatistical evidence to improve the clinical care of patients in 1991. (Sackett 1991) Since that
time this group has lead the field in developing techniques that clinicians can use to make their
practice 'evidence-based'. (Sackett 2000).
In 1996 the NHS Executive issued guidance which called on chief executives to ensure that sound
information was available, including decision-support systems, in order to improve clinical
effectiveness. (NHS Executive 1996a) This was rapidly followed by a document which described
how clinical guidelines should be developed and used in clinical practice. (NHS Executive 1996b)
Understanding of the principles of EBM is gradually spreading through professional communities,
and over the next few years it is likely that healthcare providers and consumers will increasingly
ask for evidence-based approaches to treatment and care, This is already clearly reflected in the
guidelines produced by the National Institute for Clinical Excellence (NICE) which commonly
recommend an evidence-based approach to treatment.
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Chapter 2
Psoriasis and its Treatment
Summary
This chapter reviews the. clinical presentation, pathology and epidemiology of psoriasis. Licensed
treatments for psoriasis, including phototherapy, are described. Topical treatments are considered
briefly and systemic treatments are considered in detail: Unlicensed treatments are mentioned
briefly.
2.1 Psoriasis
2.1.1 Clinical presentation
Psoriasis occurs in.several.differentfcrms; Chronic plaque is the most common and it accounts for
more than 90010 of cases. (Stem 1997) It is characterised by plaques on the trunk and extensor
surfaces of the limbs that are typically well-demarcated, reddened. thickened and covered in silvery
scales. They may be small and discrete or large and confluent and the skin may be up to sixteen
times thicker than.normal.skin, (Clark1999).Patients may also have psoriatic lesions affecting the
scalp and in this area thick scales may be a major problem. In some Patients. psoriatic lesions
occur in the flexures (armpits, groin, infra-mammaryarea). and in these areas plaques are typically
red and inflamed but lack the covering of silvery scale.
Removal of the silvery psoriatic scales causes characteristic "point bleeding" although superficial
scales from the surface of plaques are shed freely. Inaddition, patients complain of itching.
extreme dryness of skin and painful cracking and bleeding.
Inmany patients characteristic changes are seen in nails (both fingers and toes). These include
pitting. "oil spots" and onycholysis. Fifteen percent «pat~nts also have a sera-negative
arthritis.(Stern 1997)
Guttate psoriasis is SO named because lesions are scattered over th~ skin surface like droplets of
liquid spattered from a paintbrush. The individual lesions are small, round, red macules. This
form of psoriasis is usually seen in children and adolescents and is often triggered by a
streptococcal throat infection
24
Palmo-plantar pustular psoriasis is a relatively rare condition in which multiple sterile pustules
appear on the palms and soles.
Generalised pustular psoriasis and erythrodermic psoriasis are rare but serious conditions which
usually require immediate in-patient treatment
2.1.2 Pathological processes
In earlier times psoriasis was described simply as a hyperproliferative disease in which skin cells
were formed more rapidly than usual. In the past 10 years there have been considerable advances
in the understanding of the pathological processes that give rise to the clinical manifestations of
psoriasis. Although the full picture is still not clear, it seems that T -lymphocytes play a central
role. A recent hypothesis suggests that the first step is the presentation of antigens or
superantigens, by antigen-presenting cells (APes) to CD4 helper T lymphocytes in the epidermis.
This induces the release of cytokines from both APCs and the T -lymphocytes. The cytokines in
tum bring about keratinocyte proliferation and the release of adhesion molecules from endothelial
cells. The presence of adhesion molecules allows leucocytes, including skin-homing, memory CD4
T-lymphocytes, to infiltrate the area These mechanisms may be responsible both for inducing and
maintaining psoriatic lesions. (Ortonne 1999)
2.1.3 Epidemiology
Psoriasis affects 1-3% of the general population in Europe. (Farber 1998) The prevalence varies
considerably between racial groups for example, rates of 0% have been reported in Samoa and in
the South American Andes but 4.8% in Norway and 11.8% in the Arctic Kazach'ye. Genetic
factors play a role but environmental factors are also relevant A child has a 16% risk of developing
psoriasis if one parent is affected and a 50% if both parents are affected. (Stem 1997) Factors,
which have been shown to precipitate or exacerbate psoriasis, include trauma, infection, hormonal
disturbances, sunlight, cigarette-smoking, alcohol and emotional disturbances. (Hunter 1995)
Drugs which trigger or exacerbate psoriasis include, ACE inhibitors, beta-blockers, chloroquine
and hydroxychloroquine, granulocyte colony stimulating factor (GCSF), gold, interferons, lithium,
NSAIDs and tetracyclines. (Lee 1999)
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2.2 Pharmacological and ultraviolet light treatments
2.2.1 Topical treatments
For many years topical treatments were the only treatments available and they still represent the
mainstay for the majority of patients with mild-moderate psoriasis. Topical treatments include
emollients, corticosteroids, vitamin D analogues, dithranol, tar preparations and retinoids.
Emollients form the mainstay of topical treatment. Their use reduces scaling and itching. Products
that contain keratolytic agents such as salicyclic acid or alphahydroxy acids are helpful in
converting rough, scaly or cracked plaques into smooth plaques. Cream formulations are
cosmetically more acceptable and are often used for visible areas whereas ointment formulations are
useful on large areas of dry skin and for overnight treatment. Zinc oxide (in Lassar's paste) is used
to deliver dithranol to psoriatic lesions because of its "non-smudging" property.
Topical corticosteroids classified as 'potent' or 'very potent' , such as betarnethasone or clobetasol
propionate cause flattening of psoriatic plaques and reduce inflammation, Very potent steroids may
have a role where the skin is very thick (in conditions such as hyperkeratosis of the palms or soles).
(Drug & Therapeutics Bulletin 1996). Prolonged use of steroids may lead to cutaneous atrophy
with striae and telangiectasia The skin of the face and flexures is particularly susceptible to these
effects. Occlusive dressings increase the effectiveness of topical steroids but also increase
absorption and the chances of local side effects (Stem 1997). Withdrawal of steroids can produce
exacerbations of psoriasis. Because of the adverse effects, topical steroids are not recommended for
long term or extensive use in the management of psoriasis, although they can playa useful role on a
short-term basis. Some clinicians find alternating treatment, using a topical steroid in the daytime
and calcipotriol in the evenings, helpful in minimising the side-effects of both treatments (Hunter
1995)
Calcipotriol is a synthetic vitamin D analogue (a 1,25(OHh~ analogue) which, when applied
topically, inhibits epidermal proliferation without having cytotoxic effects. (Lea 1996) Calcipotriol
is odourless and non-staining and is available as cream, ointment and scalp solution. Its
effectiveness is similar to that of moderate-high potency steroids. Some patients experience skin
irritation with calcipotriol. As the facial skin is particularly susceptible to irritation its use should
be avoided for facial psoriasis. (Drug & Therapeutics Bulletin 1996). Small amounts of calcipotriol
are absorbed from the skin (Lea 1996) but its effect on calcium homeostasis is 100-200 times
weaker than that of calcitriol. (Fogh 1997) Nevertheless, the Summary of Product Characteristics
(SPC) recommends that the weekly dose should not exceed l00g of cream or ointment. (BNP 1998)
Because of its perceived benefit-to-risk profile calcipotriol is the topical treatment of choice for
patients who are treated at home for moderate generalised psoriasis.
26
Tacaldtol is a newer, synthetic vitamin D analogue (l,24(OHhD3) which need only be applied
once daily. It has a more marked effect on calcium homeostasis than calcipotriol (Fogh 1997) and
dosage is limited to a maximum of 5g per day and two, twelve-week courses per year.
Dithranol (dihydroxyanthrone) has been the mainstay of topical treatment for psoriasis in Europe
for many years. In the nineteenth century the use of Goa powder for skin diseases, including
psoriasis, was observed in India (MaMIe 1997) Goa powder is crude chrysarobin and comes from
the Araroba tree (Andira araroba, Leguminosae). It was applied using a cut lime fruit, which was
dipped in the powder and dabbed on the skin. (Martindale 1915) Chrysarobin is a mixture of
anthroquinones. During World War I there was shortage of the natural product and the synthetic
l,8-dihydroxy-9-anthrone was introduced into clinical use in Germany in 1916.
Dithranol stains the skin (and also clothing and bath fittings) and may cause serious inflammation
or blistering of normal skin or skin in sensitive areas. It is commonly prepared in Lassar's paste so
that it can be applied to the affected skin and is unlikely to spread on to healthy skin. For many
years dithranol treatment involved application for 12 hours but "short-contact" treatment, inwhich
the application lasts for 30-60 minutes, is now the recommended procedure. (Drug & Therapeutics
Bulletin 1996) Dithranol is available in a range of concentrations and it is usual to start with the
lowest (0.1 %) and increase the concentration every few days up to the maximum (2%) or to the
maximum tolerable concentration that produces a therapeutic effect. Dithranol treatment can be
used at home but may be practically difficult to manage. It is often delivered at an out-patient
"daily dressing" clinic but is, inevitably. a time-consuming treatment
Coal tar has been used for many years and is helpful for patients with mild psoriasis. It has anti-
inflammatory and anti-proliferative effects. (Arnold 1997) It is available as crude coal tar, BP
preparations such as Coal Tar Paste BP, Calamine and Coal Tar Ointment BP, and is an ingredient
in a wide range of proprietary products. Crude coal tar is difficult to use, stains clothing and
smells unpleasant to many people. Modem preparations are more acceptable in use. Coal tar is
often combined with UVB (as in the Goeckerman regime, see below). This combination is said to
increase the effectiveness of the coal tar (Drug & Therapeutics Bulletin 1996) and the coal tar
prevents the side effects of maximal erythemogenic UVB monotherapy (Arnold 1997)
Crude coal tar contains a number of carcinogens and percutaneous absorption of mutagens in
patients receiving crude coal tar has been demonstrated (Arnold 1997) This does not appear to
translate into a risk for cancer amongst psoriasis patients who receive long-term, intermittent tar
treatment A cohort study of 719 patients failed to show an increase in the number of cancers
compared with the general population. (Jones 1985) Nevertheless, in view of the known absorption
and the observed risks to workmen who are chronically exposed to industrial tar, long term
treatment with concentrations of crude coal tar above 5% should be avoided. (Arnold 1977)
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Tazarotene is a topically active retinoid It is available as a gel formulation (0.05% and 0.1%) for
once-daily application. It is licensed for use in mild-moderate psoriasis affecting up to 10% of body
surface area. Local irritation is more commonly reported with the higher concentration.
2.2.2 Phototherapy and photochemotherapy
The beneficial effects of sunlight on psoriasis have been known for many years and artificial UV
light has been used alone and in combination with photosensitising agents to treat psoriasis.
Ultraviolet light comprises the UVA, UVB and uve bands of the electromagnetic spectrum (see
figure 2. 1).
Figure 2.1: The electromagnetic spectrum
Increasing wavelength
Infrared light Visible light Ultraviolet light
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2.2.2.1 Ultraviolet B therapy
The mechanism of action of UV light in psoriasis treatment is not fully understood. The shorter
wavelength UVB is largely absorbed by the epidermis. It is highly energetic and is known to cause
a number of photochemical reactions. It is now thought likely that the effects of UVB in psoriasis
are due to cytokine modulation, thereby interfering with the pathophysiological processs of the
disease (Taylor 1998). 'Broad-band' UVB (wavelength 290-320 nm) has been used widely in
combination with coal tar and dithranol (see below). In recent years, work has suggested that
'narrowband' (305-315 nm) UVB treatment on its own maybe effective for some patients (Parrish
1981). One of the benefits of narrow band UVB is that the shorter, more erythemogenic
wavelengths have been removed, so that the risk of burning is reduced
The long-term risks of carcinogenesis as a result ofUVB treatment are as yet unknown. It is
known that UVB is a carcinogen and that male patients undergoing UVB treatment have an
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increased risk of developing tumours in genital skin (Stern 1990), but the risk of non-melanoma
skin cancer occurring elsewhere is not known. Furthermore, the relative risks of broad band and
narrow band UVB treatment are not known. The erythema action spectrum is believed to parallel
the carcinogenesis spectrum and, therefore, narrow band UVB should carry a lower risk of tumour
induction. However, the absence of erythema may permit larger doses of radiation to be delivered,
and this may be also be an important factor.
UVB with coal tar and UVB with dithranol
(UVB) (wavelength 290-320 nm) in combination with coal tar is one of the oldest treatments for
moderate-severe psoriasis. In 1925 Goeckerman devised a regime which involves the combined use
of crude coal tar and UVB. (Lowe 1997) (Table 2.1) The Goeckerman regime is only suitable for
use on an inpatient setting. as it involves 24-hour treatment with tar products. UVB may also be
used in combination with dithranol (Ingram 1953) (Table 2.2).
Table 2.1: Goeckerman regime (UVB + tar) - General scheme
STEP PROCEDURE
1 Apply coal tar (3-5% in yellow soft paraffin) to whole
body. Re-apply as necessary to maintain contact
between tar and skin
2 After 24 hours clean excess tar off with vegetable oil
3 Give minimal erythematous dose of UVB
4 Remove remaining tar, using soap/shampoo in a
warm but not hot bath. Add bath oil to prevent drying
of skin
5 Repeat daily for 14-21 days
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Table 2.2: Ingram regime (UVB + tar + Dithranol) - General scheme
STEP PROCEDURE
1 Clean off old paste with nut oil
2 Soak in a tar bath for 20 minutes
3 Descale the lesions with a towel
4 Give a sub-erythematous dose of UVB
5 Apply dithranol in Lassar's Paste accurately to each
plaque. Start with a low concentration such as 0.25%
and increase gradually through 0.5%,1%,2%
according to patient's response.
6 Dust with zinc oxide or starch powder
7 "Suit up" with Tubegauze or stockinette where
possible. Leave for 12 hours or overnight.
8 Repeat daily if possible for 20-30 days
The main drawbacks of these treatments are the time required, the unpleasant smell of the tar
preparations and the skin staining caused by dithranol.
UVB phototherapy is contra-indicated in patients who are taking photo-sensitising medications (eg
thiazide diuretics. tetracyclines) and in patients with underlying photosensitive disease (eg systemic
lupus erythematosus, polymorphous light eruption). (Tham Siew Nee 1997)
1.1.1.1 Photochemotherapy with oral psoralen and UVA (pUVA)
UVA is less energetic than UVB and penetrates deeper into the skin. PUVA treatment relies on
UVA (wavelength 320-400 nm) irradiation of skin which has been primed with suitable
photosensitisers, such as psoralens. A number eX naturally-occurring psoralens are known to be
effective in this way, and in the 19505 oral 8-methoxypsoralen was introduced, (Ortel 1998) but it
was not until 1974 that PUV A treatment as it is known today was first described. (Parrish 1974)
Once the psoralen is activated by UVA irradiation, a phototoxic reaction takes place. which results
in anti-proliferative, anti-inflammatory and immunosuppressive effects. (Lauharanta 1997) The
photo-activated psoralens form adducts with pyrimidine bases and cross-links between
complementary strands of DNA As a result, DNA synthesis and epidermal cell division is
inhibited. (Hunter 1995)
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A critical element of PUVA therapy is ensuring that the psoralen is present in the skin. in suitable
concentrations. at the time of irradiation. Oral 8-methoxypsoralen (8MOP) is widely used but other
psoralens and alternative presentations have also been tried (see summary Table 2.3)
Table 2.3: Psoralen summary table
(Table after Lauharanta 1997)
Patients must be selected carefully for PUVA Prolonged exposure is associated with an increased
risk of non-melanoma skin cancer and photo-ageing of the skin and fair-skinned individuals are
more susceptible to these effects (Ortel 1998).
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2.2.3 Systemic treatments
Systemic treatments are generally reserved for patients whose psoriasis has failed to respond
adequately to topical treatments or phototherapy. (Gawkrodger 1997)
Three agents are available (licensed for use) in the UK, they are cyclosporin, methotrexate and
acitretin. Their properties and dosing recommendations are reviewed briefly below.
2.2.3.1 Cyclosporin A
Cyclosporin A is a cyclic undecapeptide that was originally isolated from the soil fungus
Tolypocladium inflaium Gams. It has a molecular weight of 1202.6 Daltons. Cyclosporin has been
used for many years as an immunosuppressant in transplant surgery and its effects in psoriasis are
thought to be due to its immunomodulatory activity. In psoriasis it has been shown to prevent the
proliferation ofT-helper cells and cytotoxic lymphocytes, both of which playa part in the
pathogenesis of psoriasis. (de Rie 1997)
Cyclosporin is a highly lipophilic molecule, which is effectively insoluble in water. (Wood 1983)
For this reason it was first presented as an oral liquid (dissolved in alcohol and olive oil) and as a
com oil-based soft gelatin capsule. It follows that the drug had to be emulsified in vivo before
absorption could take place. Both formulations were associated with profound inter- and intra-
individual variations in bioavailability. (Mueller 1994, Kahan 1994) Two factors contributed to
this, namely, variable absorption and extensive first-pass metabolism. Oral absorption of
cyclosporin occurs primarily in the upper small bowel, and is affected by the rate of gastric
emptying, the presence of bile, concomitant food intake and gastro-intestinal disease. (Kahan 1989)
25% of the absorbed dose is removed by the liver before it reaches the general circulation. (Kahan
1989)The result of these effects is a mean bioavailability of 30010(range 5-900/0). In 1997 a "micro-
emulsion preconcentrate" formulation was introduced which, when it comes into contact with water
in gastric fluid, forms a stable microemulsion. This formulation does not rely on the presence of
bile salts or mechanical agitation and it has been shown to increase mean bioavailability by 30%, to
reduce inter- and intra-individual variability and to improve the relationship between dose and
blood levels. (Ritschel 1996) 'One-to-one' dose conversion was recommended on the basis that it
would make little difference to those who absorbed cyclosporin well, and would improve the
response to treatment amongst the 'poor-absorbers'. (1(00 1997)
As cyclosporin is metabolised via cytochrome p450 3A, it interacts with a number of drugs that
compete for this pathway (see Table 2.4)
32
Table 2.4: Drugs that interact with cyclosporin (after Koo 1997)
After oral dosing peak plasma levels are reached at 2-4 hr. The mean plasma half-life is 19 hr
(range 8-24 hr). Cyclosporin is extensively metabolised and eliminated mainly in the bile, although
small amounts (- 6%) are eliminated via kidneys. (Kahan 1989)
Cyclosporin use is indicated in patients who have failed to respond adequately to other treatments.
This includes topical treatments and, in some cases, other systemic treatments. It also has a place in
the treatment of patients with widespread, severe or disabling disease. (Gawkrodger 1997)
Although doses of 8-16 mg/kg/day are common in transplant surgery, the maximum dose
recommended for psoriasis is Smglkglday. Opinion differs as to whether dosage should start high
and be adjusted downwards or the other way round (Berth-Jones 1997) Lebwohl and colleagues
recommend that severe, inflammatory exacerbations of psoriasis should be treated initially with
high doses whereas patients with stable, generalised disease should be started on low doses.
(Lebwohl 1998) Doses should be calculated on the basis of ideal body weight (obese patients may
33
be overdosed if actual body weight is used). The dose should be divided into two equal doses.
(Berth-Jones 1997) Once a marked improvement has been achieved. the dose of cyclosporin should
be adjusted to the lowest effective dose for maintenance therapy or it should be discontinued.
Several authorities advocate the intermittent, rather than continuous, use of cyclosporin. (Berth-
Jones 1997)
The most serious side effects of cyclosporin are nephrotoxicity and hypertension Both are dose
dependent and of gradual onset. Cyclosporin can give rise to hyperuricaemia by reducing renal
clearance of uric acid It is also associated with neurological side effects including. dysaesthesiae,
tremors and headaches. In spite of its immunosuppressive activity, its use in dermatology does not
appear to cause internal malignancies or increased susceptibility to infection It is recommended
that hypertension should be treated. using agents. such as nifedipine or isradipine, that do not
interact with CSA (to alter blood levels). (Koo 1997) Renal function should be monitored using
serum creatinine. If this rises above 1300/0of the baseline value then CSA dosage should be
reduced It is of interest that in 1998 the FDA recommended that the upper dosage limit should be
4 mg/kg/day and that the creatinine threshold level should be 125% of baseline instead of 130%.
(Koo 1997)
The contra-indications and monitoring recommendations are summarised in Table 2.5.
2.2.3.2 Methotrexate
Methotrexate has immunosuppressive and cytotoxic effects. It has been used in the treatment of
psoriasis since the 1960s. It is thought to exert its effects in psoriasis through its immuno-
modulatory effects. (Said 1997) It is recommended for short-term treatment, to gain control of
unstable (pustular or erythrodermic) psoriasis and for long-term maintenance treatment. It is also
indicated for patients with extensive chronic plaque psoriasis whose disease is inadequately
controlled by topical therapy alone. (Chalmers 1997)
Methotrexate is well-absorbed from the gastro-intestinal tract (in doses of less than 25 mg) (Said
1997) and is usually given orally. The majority of the dose (60-900/0) is eliminated via the kidneys.
with biliary elimination accounting for less than 100/0.
A single weekly dose is recommended, starting with dose of 5 - 7.5 mg and increasing in 2.5 mg
increments according to clinical response and toxicity. A test dose of 5 mg should always be given,
followed by a full blood count 7 days afterwards to identify patients who are exceptionally sensitive
to the effects ofbone marrow suppression Few patients are expected to need more than 20 mglwk
to control their disease. Once satisfactory control has been achieved. the dose is adjusted to the
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lowest dose needed to maintain control and the patient is monitored for adverse effects. Table 2.5
summarises the contra-indications to treatment with methotrexate and monitoring requirements.
The most common side effect is nausea, which characteristically appears within 12 hours of taking
the weekly dose, and may persist for up to 3 days. It is usually mild but can be severe enough to
warrant treatment. Folic acid has been found to be more helpful then conventional anti-emetics.
Folic acid (5 mg) is given either daily or in a once-weekly course of three doses around the
methotrexate dose.
Toxic effects on the bone marrow and liver are potentially serious. Acute myelosuppression
requires immediate treatment with folinic acid A rise in mean corpuscular volume (MeV) is
commonly seen with long-term methotrexate therapy and is thought to reflect a relative folate
deficiency. If the MCV does not return to normal with folate treatment then methotrexate should
be discontinued. Hepatotoxicity is conventionally monitored using aminotransferase levels, which
are unreliable indicators of hepatic fibrosis. Amino-terminal pro-collagen illprovides a more
accurate index of liver damage, and avoids the need for a liver biopsy, but is not yet in common use.
(Chalmers 1997)
2.2.3.3 Etretinate and acitretin
Etretinate and acitretin are synthetic derivatives ofvitarnin A. They are thought to exert their
effects in psoriasis through a variety of effects at cellular level, including effects on proliferation,
keratinization and differentiation of epithelial cells and anti-inflammatory and immunomodulatory
effects.
Etretinate was introduced first but was superseded within a few years by acitretin, which is its free
acid metabolite. The two drugs have similar efficacy but acitretin was thought to have a better side-
effect profile. Etretinate is strongly lipophilic and is sequestered in body fat where it has been
detected as long as two years after discontinuation. Typically it has a half-life of up to 120 days
whereas acitretin and the 13-cis-acitretin isomer have half-lives of 50 and 7S hours respectively.
(Brindley 1989) Acitretin is negatively charged at physiological pH and is fifty times more
hydrophilic than etretinate. (Wiegand 1998)
Oral acitretin has a bioavailability of approximately 60010, in the presence of food. (Brindley 1989)
It is reversibly isomerized to 13-cis-acitretin in vivo and is eliminated in urine and in bile.
Further experience with acitretin has shown that some of the drug is re-esterified in vivo and so the
advantages may be fewer than originally anticipated. (Almond-Roesler 1996)
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Acitretin is indicated in patients with severe, extensive chronic plaque psoriasis whose disease has
failed to respond to other treatments. It is also indicated for localised or generalised pustular
psoriasis and for erythrodermic psoriasis.
Treatment should be started with a dose of2S-30 mg and increased after 2-4 weeks up to SOmg (or
7Smg) according to response, for a further 6-8 weeks. (BNF 1998) Chronic plaque psoriasis
responds slowly and the best effect is expected 2-3 months after the start of treatment. After
clearing of the disease a maintenance dose of O.2-0.4mg'kgfday is recommended for 3-6 months.
(Gollnick 1997) Adjuvant topical treatment or phototherapy is recommended throughout the period
of acitretin treatment. Suitable agents include, tar, dithranol, vitamin D3 analogues, UVB or
PUVA treatment. Experts recommend that the combination of acitretin with other systemic agents,
such as methotrexate, cyclosporin or fumarates, should be avoided because of the dangers of
additive toxicity. (Gollnick 1997)
A large number of common side effects is associated with the use of acitretin. Mucocutaneous
effects, such as drying and cracking of the lips, are seen frequently. Dryness of the nasal, buccal
and conjunctival mucosae and peeling of the skin on the palms and soles are moderately common
effects. An increased rate of loss of scalp hair is occasionally sufficiently severe to be noticeable.
Other common complaints include skin "stickiness", skin fragility, nail fragility and itchiness.
Acitretin use is associated with a number of potentially serious side effects. There is a high risk of
teratogenicity if acitretin is administered in the first three months of pregnancy and malformations
of craniofacial, thymic, cardiac, skeletal and central nervous systems have been reported. Because
of the persistence of the drug in body tissues, it is recommended that pregnancy be avoided for 2
years after the end of treatment
Elevations of plasma lipid levels (increased LDL, decreased HDL) are relatively common as are
elevations of liver enzymes.
Bone toxicity, including ossification of ligaments and tendons, bony spurs and diffuse hyperostosis,
is common in patients receiving long term (1-3 years) treatment. Premature epiphyseal fusion has
occurred and for this reason it is not recommended for use in children.
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Table 2.5: Contra-indications and monitoring of systemic agents for treatment of psoriasis
(after Gawkrodger 1997)
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2.2.3.4 Other systemic treatments including alternative and unlicensed treatments.
Azathioprine and hydroxyurea have been used for psoriasis but tend to be less effective than
methotrexate and more likely to cause myelotoxicity. (Hunter 1995) Sulphasalazine has been
found to be helpful in small number of patients. (Gupta 1990) Fumarates (a mixture offumaric
acid and its esters) are used in the Netherlands and in Germany but there is no licensed preparation
in the UK. Newer immunosuppressive agents such as tacrolimus and mycophenylate mofetil are
under investigation. Future treatments are likely to involve agents which modify T -lymphocyte or
cytokine functions (Clark 1999)
2.3 Conclusions
Psoriasis affects a large number of people and accounts for substantial morbidity. The ideal
treatment would be efficacious, present few risks, be convenient to use and be inexpensive. The
available treatments combine these attributes in varying proportions. but none is ideal. The
selection of a treatment depends on the site and severity of disease and the patient's preferences.
Patients with severe psoriasis require careful monitoring because the disease is dynamic and may
require periodic modifications to treatment Furthermore, several of the available treatments are
associated with cumulative toxicity. Regular monitoring and review of treatment therefore provides
the opportunity to maximise the benefit/risk ratio for the individual patient
38
Chapter3
Outcome measures in psoriasis treatment
Summary
Outcome measures are required to assess efficacy in trials and to monitor the responses to
treatment. Outcome measures for psoriasis can be measures of the physical effects, measures of
the impact of the disease or composite measures. Investigators or doctors administer the majority
of outcome measures but the self-administered PAS] has been developedfor use by patients.
Standardised. valid, reliable outcome measures are important in the assessment of any drug
treatment. Ideally, outcome measures should also allow comparison of drug treatment with other
forms of treatment. Thus, in psoriasis, the ideal outcome measure would allow comparison between
topical treatment, systemic treatment and phototherapy.
The outcome measures that have been used in psoriasis can be broken down into two categories,
namely, measures of the physical effects of the disease and measures of the impact of the disease.
(see Table 3.1)
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Table 3.1: Outcome measures for psoriasis treatment
Category Outcome measure Scale/Units
Trans-epidermal water loss (TEWL) G/m2/hour
Chromameter readings Erythema "a" scale
Cutaneous blood flow (measured by Laser-Doppler
laser velocimetry) velocimetric reading
Erythema 5 & 7 point scales
Induration 5 & 7 point scales
Measures of the Desquamation 5 & 7 point scales
physical effects of
psoriasis Surface area affected %
Psoriasis Area and Severity Index 0-72
(PAS!)
Self-administered PAS! (SAP AS!) 0-72
Clearing %
Overall skin condition Subjective description
Handicap
) Numerical value
Social disability ) depending on
) instrument
Measures of the impact Quality of life
of psoriasis Impact on life (patient's assessment) Visual analogue seale
Days of hospitalisation Days
Days of remission Days
Salford Psoriasis Index x.x.x (3 figure score)
Composite measures
Dennatology Index of Disease
Severity (OIDS) 5 point seale
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3.1 Measures of the physical effects of psoriasis
Measures of the physical effects of psoriasis range from objective, instrumental measures such as
trans-epidermal water loss and cutaneous blood flow measurements using laser-Doppler
velocimetry to subjective assessments such as the extent of disease clearing.
Objective measures have been sought for each of the prominent features of psoriasis, namely the
erythema. induration (thickening) and scaling of the psoriatic plaques. In some trials attempts have
also been made to correlate instrumental measurements with clinical gradings. In one study a two-
week bilateral comparison of betamethasone valerate against white soft paraffin, the subjective
scores assigned by a single observer (erythema, plaque elevation, scaling and a composite seore)
were similar to objective measures (computer image analysis, erythema reflectance, nitric oxide
production, ultrasound scan for thickness, scale and echo-poor zone. (Ormerod 1997) Other studies
have also demonstrated that visual assessments of skin erythema correspond with measurements
obtained by a laser Doppler flowmeter, a spectroradiometer and erythema meter and a
chromarneter. (Serup 1990~ Lahti 1993) Measures of sealing are less well-developed, and although
optical profilometry and seanning macro-photographic densitometry methods have been used, the
clinical relevance of the results is not yet clear. (Marks 1996) Plaque thickness has been measured
using mechanical callipers and ultrasound (Lawrence 1986) Exudation of tissue fluid during the
use of the callipers has been a problem and the ultrasound method has been recommended as the
more accurate of the two.
A further practical drawback of the laboratory type of measurements is that they can only be applied
to small areas, whereas the disease often affects several areas of the body and there may be
considerable differences between the plaques in different areas. Instrumental measurements may
therefore be more suitable for monitoring drug effects on two comparable lesions than for overall
monitoring of disease progress.
It has been suggested that plaque thickness is the most reliable of the clinical signs of psoriasis.
(FDA Advisory Committee (1998». The main reason for this is that erythema is affected by factors
such as blood flow and ambient temperature and may be exacerbated by some treatments. Scaling
can be reduced considerably by treatment with keratolytics and emollients.
Many trialists have chosen to monitor outcomes in psoriasis by estimating clinically the extent of
erythema. induration and desquamation, the three main features of the condition. These have been
assessed in a quasi-objective fashion using five or seven point seales. The proportion of the body
surface affected by the disease has also been used as an outcome measure.
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In 1978 a composite measure, the Psoriasis Area and Severity Index (PAS!), was devised to take
account of both the extent and severity of the disease (Fredriksson 1978). The formula for the PASI
can be written as:
Where E= erythema, I =infiltration (thickening) and D = desquamation, each assessed on a scale of
0-4~A= area affected by psoriasis: 0 = none, 1 = 10010,2 = 10-29%,3 = 30-494'10,4 = 50-694'10,5 =
70-894'10and 6 = 90-100%.~ h = head, t = trunk, u = upper limbs and I = lower limbs.
The PASI is widely, although not invariably, used in clinical trials, however it remains unvalidated
It is also used routinely in specialist psoriasis clinics. Its appeal is that it relies on clinical
assessments that can be made easily by an experienced practitioner, without need for additional
equipment. The main disadvantages are the relative insensitivity to some changes in the pattern of
disease and the risk of inter-assessor variation. For example, mild, extensive disease could achieve
the same PASI score as severe disease affecting a small area In the clinical context this could
mean that a case of psoriatic erythroderma, with widespread, moderate erythema, induration and
scaling could have an identical score to a case of chronic plaque psoriasis involving 10-30% of the
body surface area (van der Kerkhof 1992). Whereas the second case is relatively easy to treat, the
first is severe and almost invariably requires hospital admission.
In 1998 Finlay (Finlay 1998) drew attention to the fact that an error in the original description of
the PASI may have given rise to some inconsistencies in its use. In the original description, 30% of
the body surface areas was assigned to the trunk and 20% to the upper limbs, but these proportions
were transposed in a later paragraph. The test error has been repeated but it is not known to what
extent, if at all, the incorrect formula has been used.
3.1.1 Body surface area estimation
Given the patchy distribution of much psoriasis, the assessment of the amount of skin involved is
not always straightforward As this is a major component of the PAS!. a number of methods have
been devised to improve the accuracy and reproducibility of this measurement
Ramsay and Lawrence (Ramsay 1991) compared three methods, clinical estimation, image analysis
of traced plaque outlines and image analysis of whole body photographs.
The rule of nines, which was originally devised to estimate the surface area of burns, was used to
estimate body surface area It assumes that the total body surface comprises 94'10for the head and
neck, each arm, the front and back of each leg and the four trunk quadrants, leaving 1% for the
genitalia Using this as a guide, the clinician then estimates the proportion of each area affected by
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the disease and calculates the grand total. In the study, four untrained observers estimated the
average extent of psoriasis to be 14-33% of body surface area Measuring the areas of tracings of
plaque outlines by computerised image analysis gave a mean value of 9% while image analysis of
whole body photographs gave a mean value of 7%. The authors concluded that untrained observers
using the 'rule of nines' would always overestimate the extent of the disease.
Another popular clinical measure uses the flat, closed hand The area that it can cover has been
assumed to be 1% of body surface area, and in some cases this offers an easier way to estimate the
total area affected by psoriasis. (Stem 1986) Planimetric measurements now suggest that a hand
area actually represents 0.070 -0.076% of the BSA, (Long 1992) and therefore the hand measure
could be expected to overestimate the BSA affected
Bahmer explored the use of grid point counting to improve the accuracy of body surface area
estimation. (Bahmer 1989) This involved laying a grid over photographs of psoriatic plaques and
counting the number of intersections over each plaque. The main drawback of this technique is the
time involved It seems likely that future methods for estimating the extent of disease are more
likely to rely on developments in the field of computerised image analysis. Early instruments were
unable to handle curved surfaces but this technical problem may be solved in future.
3.1.2 Assessment by patients
Investigators or doctors administer all of the measures described so far. In 1994 Fleischer devised
the 'self-administered PASI' (SAPASn as a means of enabling patients to estimate the physical
effects of their own disease. (Fleischer 1994) The general formula for the Patient PAS! (later called
the self-administered PASI) is:
SAPAS!=(O.lAH+ 0.2Au+ 0.3 AT+ 0.4AL)(4x (VA~VAS.+VASs»
Where AH= head area score, Au = upper extremity area score, AT = trunk area score, AL.lower
extremities score, VA$,:. = VAS erythema score, VASt = VAS induration score, VASs = VAS scale
score. Area scores were assigned a numeric value of 1- 6, corresponding to ()o1o to 100% body
surface area affected These were derived from line drawing silhouettes on which the patients
shaded the areas affected An investigator who had not evaluated the patients then estimated the
proportion of the total area affected and assigned the numerical value. For the VAS scores, patients
were asked to score an average psoriatic lesion for erythema, induration and scaling on separate,
12D-mm VAS scales. Each of these was labelled with descriptions, for example, the induration
scale had the descriptions: no thickness, feels firm, raised, thick and very thick VAS scores were
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recorded in millimetres. Like the conventional PASL the SAPASI returns a maximum possible
score of72.
A later study showed that the method had good test-retest reliability (r = 0.82, p=0.0001) and that
the results correlated well with PASI scores assigned by physicians (Feldman 1996). They also
reported that the SAPASI varied in parallel with the PASI as patients' clinical status changed
Given that the SAP ASI was administered by untrained individuals, these findings suggest that it
could be a useful measure for estimating disease severity and responses to treatment when trained
personnel were not available. for example. for remote monitoring of disease progress.
3.2 Measures of the impact of psoriasis
Dermatologists' assessments of psoriasis have tended to focus firmly on the physical effects of the
disease whereas patients have a different viewpoint and, when asked to assess disease severity take
into account other factors. In one study 21 dermatologists and 56 patients were asked to rank a list
of SO features considered to be characteristic of psoriasis. (Baughman 1970) Patients rated
'embarrassment over appearance' as most characteristic of severity, while dermatologists
considered this to be the least important. This is one of the factors that have prompted growing
interest in quality of life (OOL) measures in psoriasis. (McKenna 1996)
OOL measures may be generic, disease-specific or specialty-specific. Generic instruments are
designed to assess a complete spectrum of dimensions applicable to a variety of health states or
diseases. They have the advantage that they allow comparisons of the impact of different diseases
and may uncover non-specific effects of a disease or its treatment The disadvantage of generic
measures is that they may not include elements specific to skin diseases and may therefore be
insensitive to changes in the severity of psoriasis.
A number of specific OOL instruments have been developed for use in psoriasis (see Table 3.2).
These instruments differ considerably in the ways in which they have been constructed and in the
domains covered. Two of the instruments, the Psoriasis Disability Index (pDn and the Psoriasis
Life Stress Inventory (pLSI have been compared with PASI In the case of the PDL the correlation
coefficient (r .) was 0.40 (p<0. OS, n=32), indicating a modest correlation between the two measures.
(Finlay 1990) However. in a larger study. a comparison of the PLSI and the PASI in 132 psoriasis
outpatients found that the PLSI scores were independent of clinical severity assessed by PASI
(Fortune 1997)
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Ashcroft and colleagues conducted a critical appraisal of the available QOL measures for psoriasis.
(Ashcroft 1998) The authors noted that interpretation of QOL scores and changes in the scores
over time had to be approached with caution. Improvements in QOL scores may reflect
psychological adaptation to the condition rather than actual changes in health or symptoms.
Table 3.2: QOL measures for patients with psoriasis
Instrument Source Features
Psoriasis Disability Index Developed after questioning 54 15 questions covering 5 domains (daily
(pOI) psoriasis patients activities. work or school. personal
relationships, leisure and treatment)
Based on previous month
Psoriasis Life Stress Originally based on experience 15 questions (cosmetic disfigurement,
Inventory (pLSI) with 50 patients; modified with social stigma, coping with physical
responses from 217 further aspects of disease, treatment)
patients. Based on previous month
Dermatology Life Quality Responses from 120 outpatients 10 questions to assess disability
Index (DLQI) with a range of skin complaints. Based on previous 7 days
Children's Dermatology Responses from 169 children 10 questions to assess disability in
Life Quality Index with a range of skin complaints. children
(COLQI) Based on previous 7 days
Dermatology Quality of Derived from responses from 50 41 questions covering 3 domains
Life Scales (DQOLS) dermatology outpatients. (psychosocial aspects, physical
activities, symptom scales)
Designed to complement the OLQI
Skindex Based on a literature view and 6l-question and 29-question versions
responses from clinicians and
patients.
3.3 Composite measures
Many published studies have included 'global scores' for psoriasis. Whilst at first sight these are
highly subjective and therefore likely to show wide inter-assessor variation, it could be argued that
they represent dermatologists' legitimate attempts to capture the severity, extent and impact of the
disease in one figure. Recently, two composite measures have been developed in order to tackle the
shortcomings of the PASI and, effectively, to codify the global assessments. These are the Salford
Psoriasis Index (SPI) and the Dermatology Index of Disease Severity (DIDS).
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The DJDS was developed for staging inflammatory skin diseases and uses the percentage body
surface area affected and functional limitations to score on a five-point scale. (Faust 1997)
Concerns have been expressed that the DJDS may not be sufficiently sensitive to track changes
during treatment and that it fails to take account of psychological morbidity. which does not always
correlate with the extent of disease. (Williams 1997)
The Salford Psoriasis Index (SPI) was developed to match the clinical decision-making process by
providing an assessment of three main factors taken into account when planning treatment for a
patient with psoriasis. (Kirby 2000) These are clinical signs, psychosocial disability and previous
treatment The index takes the form of three figures and is analogous to the
tunour:nodes:metastasis (TNM) grading that is used for cancer staging. In this case the first figure
is derived from the PASI score, using a scale that converts it into a point on a 0-10 scale. PASI
values above 37 score 10, and this in keeping with the observation that scores above 37 are rarely
seen in practice and so the upper end of the PASI scale is practically redundant. The second figure
indicates the psychosocial impact of the disease, and is assessed by the patient using a visual
analogue scale graduated from 0-10. The third figure reflects the historical severity of the disease
as shown by the number of episodes of erythroderma. the number of admission to hospital and the
need for systemic treatment (including PUVA). Each systemic treatment, including PUVA, is
given a score of 1 if given for less than 12 months or 2 ifgiven for longer. One extra point is added
(i) for every five admissions for inpatient treatment, (ii) if the total cumulative dose of PUV A
exceeds 200 treatments or 1000 J/cm2, and (iii) for each episode of erythroderma The individual
components of the SPI have been validated by comparison with known measures of disease severity.
When tested on a cohort of 20 patients before and after a period of six weeks' treatment, the first
two figures decreased significantly, but as expected, the third figure, which reflects historical
severity, did not change.
3.4 Conclusions
The availability of a suitable outcome measure is essential for the assessment of response to
treatment. In practice, outcome measures are required for two main reasons, first to measure
efficacy in clinical trials and second to monitor the response to treatment in day-to-day practice. It
can be argued that the former requires a dichotomous endpoint (clearing vs. no clearing or
clear/almost clear vs. no clearing) but the latter requires a measure that is sensitive to progressive
changes. The PASI has been widely, but not universally, used in both situations. In clinical trials,
some authors have used the PASI score to show their results both as continuous variables and as a
dichotomous variable, using a 75% decrease in the PASI as the cut-off point This seems to be
analogous to 'almost clear'. Others have preferred the 'physician's global assessment'.
Randomised, controlled trials published to date have mainly used one of these two outcome
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measures. Itmay be that, in future, the SP! may offer a transparent, systematic way of deriving a
global assessment
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Chapter4
Previous analyses of psoriasis treatment
Summary
Nine reports of economic analyses of psoriasis treatment have been published and one systematic
review. (see Table 4.1) None has so far provided a comprehensive basis for decision-making or for
the formulation of prescribing guidelines in the UK Nevertheless, these studies have served to
identify some of the problems associated with systematic reviews and economic analyses of
psoriasis treatment.
4.1 Introduction
Analyses of treatment may take the form of systematic reviews. with or without meta-analyses and
economic analyses. They may also take the form of economic analyses based on theoretical
(decision-analytic) models. The main purpose of any of these analyses is to synthesise the available
information in such a way as to provide robust estimates of effect sizes and costs. It follows that any
analysis of treatment must make explicit its sources of data. analytical methods and the assumptions
that have been made in performing the analysis.
Systematic reviews are primarily focused on the effectiveness of treatments. whereas economic
analyses are focused on costs and consequences of treatment (as described in Chapter 1). Both can
be used to inform decisions about treatment for individuals and for populations. and are essential if
an evidence-based approach is required
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Table 4.1: Analyses of psoriasis treatment
Author/year Study type Treatments included Methods
country
Chen 98 CEA(CUA)& Methotrexate vs. Utility values determined by
USA CBA Goeckerman therapy VASandWI'P
Cork 93 Cost analysis Impact of introduction of Costs of treatment
UK calcipotriol on treatment
costs
Davies 97 CEA Cyclosporin dithranol & Decision analytic modelling;
UK UVB summary estimates of success
rates and relapse rates drawn
forma small number of trials.
Einarson 94 CMA(CEA) Cyclosporin, Meta-analysis to derive
Canada methotrexate, retinoids, summary estimates of clinical
PUVA success. relapse rates and side
effects + decision analytic
modelling.
Ellis 87 CEA(?) Etretinate vs inpatient Estimates of treatment costs
USA treatment and episodes of
hospitalisation before. during
and after etretinate treatment
Feldman 97 Cost analysis AJl (not spectlled) Postal survey, patient-reported
USA costs and SAPASI
Krueger 84 Cost estimates AJl (not specified) No details given.
Sander 93 Cost analysis Phototherapy Costs of treatment for ten
USA (Goeckerman, PUV A patients receiving each of
and outpatient UVB) and seven types of treatment
oral therapy including
hydroxyurea
Snell man 98 Cost analysis Heliotherapy Follow up of 46 patients.
Finland Direct and indirect costs
estimated
Sputs 97 Systematic Systemic treatments One third of trials included
The review (including UVB) were not Rcrs.
Netherlands Analytical methods not
clearly described.
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4.2 Economic analyses
An economic analysis considers both the inputs and the consequences. The majority of the studies
in this review considered only the input costs and are therefore better described as cost-analyses.
4.2.1. Economic analyses of psoriasis treatment conducted in the UK
Cork 1993
Cork (Cork 1993) reported a preliminary, retrospective study of the economic impact of the
introduction of calcipotriol in the UK. Referral patterns did not change but the number of in-
patient admissions was reduced by 50% (for one consultant). There was also a 75% reduction in
the use ofUVB phototherapy, a 60010 reduction in the use of methotrexate and a 50% reduction in
the use of psoraIens for PUVA According to the author these observations suggested that
calcipotriol use obviated the need for second line therapies such UVB and methotrexate. However,
it is also possible that this change in prescribing patterns was a "new drug phenomenon", that is the
characteristic surge in prescribing of a new product This could have been confirmed or refuted had
there been a rigorous evaluation of the patient outcomes as well as the input costs.
Davies 1997
Davies and colleagues (Davies 1997) compared the benefits, risks and costs of cyclosporin
treatment with day-care treatment They reported that the average total cost to treat a patient for
one year with short course cyclosporin at Smglks'day was £1473 whereas the corresponding
daycare treatment cost was £2815.
4.2.2. Economic analyses of psoriasis treatment conducted outside the UK
Krueger 1984
Krueger and colleagues (Krueger 1984) reported estimated costs for out-patient and in-patient
treatment of psoriasis but gave no details of the methods used to gather the data. Patients with
psoriasis were reported to spend $650 per year on medication costs, laboratory tests and physician
fees. Inpatient treatment was estimated to cost $10,000 per year (on the basis that each hospital
stay lasted 21 days at a cost of $500 per day).
SO
Feldman 1997
Feldman and colleagues (Feldman 1997) conducted a postal survey of 578 patients with psoriasis to
obtain an estimate of treatment costs faced by the patients. Patients were asked to complete a
questionnaire covering time spent on psoriasis care, total charges/expenses, out-of-pocket expense
for psoriasis care, number of prescriptions and arc medicines. Psoriasis severity was assessed
using the Self-administered PASI (SAPASI) which had been previously validated. No results are
presented to show the types of therapy that the patients were receiving.
The SAPASI scores correlated positively with total costs (r=0.26, p=O.OOOI),bothersomeness
(r=0.30, p=0.0001) and time required for treatment (r=0.38, p=0.000l). It can safely be concluded
that costs increase with disease severity.
The estimated total annual expense in caring for psoriasis was $800 per patient, which was similar
to Krueger's 1984 estimate of $650 (Krueger 1984). However, the authors point out that their
method (which is not described in detail) understates the effect of extreme expense values. As a
result, PW A, Goeckerman therapy and cyclosporin costs may exceed the values which they used
however, no data on comparative treatment costs are presented
Sander 1993
Sander and colleagues (Sander 1993) set out to calculate comparative costs for seven different
treatment modalities - Goeckerman therapy, PW A, WE, methotrexate, etretinate, hydroxyurea
and cyclosporin. For each modality. ten patients (except for cyclosporin where six were used) who
had received it as monotherapy were selected and their records were used to identify costs. The
clinical response rate was derived from physicians' global assessments in the medical records and
presented as percentage clearance from baseline. The results of the analysis were expressed as
annual costs in US dollars (mean + range). Mean costs ranged from $1131 (hydroxyurea) to $6648
(cyclosporin). The authors concluded that their data would help practitioners and health care
organisations to select appropriate therapy.
The use of real-life data extracted from medical records should provide a sound basis for economic
analysis. However, in this study a small number of records was used and it is questionable whether
the data would be representative for the authors' institution. For example, there was a five fold
variation in the annual costs for out-patient WE treatment This level ofvariance makes it
unlikely that the results could be generalised to a wider population. Although the authors presented
a table of clinical response rates these data were not used in the interpretation of the cost data The
final cost analysis compared all regimens as though they were equally effective. Had the differing
outcomes been taken into account, a different picture may have emerged
Ellis 1987
Ellis and colleagues (Ellis 1987) investigated the impact of etretinate therapy on inpatient
treatment costs in a group of 26 patients with histories of hospitalisation for psoriasis. During the
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etretinate treatment period patients were hospitalised for 0.2 ± 0.1 days per year compared with
13.8 ± 2.4 days per year in the pre-etretinate treatment (control) period. The authors estimated the
corresponding treatment costs to be $2,300 per year (on etretinate) and $10,000 (control, pre-
etretinate) per year. The calculations for the costs of inpatient treatment (pre-etretinate) did not
take account of additional outpatient expenses, lost working days or intangible costs.
Snellman 1998
In 1998 a Finnish study examined the effect of heliotherapy on the costs of psoriasis. (Snellman
1998) The costs of psoriasis treatment in 46 patients were monitored for one year before, during
and for one year after a 4-week heliotherapy course. The authors concluded that heliotherapy
reduced costs only in patients with severe psoriasis who required expensive medication or in-patient
treatment. As the heliotherapy was delivered in the Canary Islands and all other costs related to the
Finnish health care system. it would clearly be impossible to generalise Snellman's results to other
populations.
Elnarson 1994
In 1994 Einarson and colleagues (Einarson 1994) reported an economic analysis of four systemic
treatments for severe psoriasis; cyclosporin, methotrexate, etretinate and PW A. The analysis was
conducted from the perspective of the Canadian government as payer. A decision-analytic model
was constructed and used as the basis for the calculations. Clinical outcome data for the model
were derived from meta-analysis of the literature. Overall costs included the costs of drug
acquisition, drug administration, routine medical care, adverse event management and laboratory
tests.
The authors concluded that cyc1osporin was the most cost-effective treatment for severe psoriasis.
The dose of cyclosporin was Smglkglday for a period of 6 weeks. They also pointed out that,
because of the reimbursement paid by the province, their results might not be generalisable to other
provinces or countries. Two other criticisms may be levelled at this study. First, some details of
the methods used to calculate cost avoidance were not explicit Second, the trials used for the meta-
analysis of etretinate therapy concerned mainly palmo-plantar pustular psoriasis, which is believed
to respond better to retinoid treatment than does chronic plaque psoriasis. Furthermore, the
methotrexate data were based on a single study. As this analysis assumed that the outcomes from
all treatments were the same it is probably best described as a cost-minimisation analysis.
Chen 1998
Chen and colleagues (Chen 1998) reported a cost-effectiveness and cost-benefit analysis of using
methotrexate vs. Goeckerman therapy for psoriasis. They constructed a decision-analytic model
and included a measure of patient preference (utility) in their calculations. The authors concluded
that in severe psoriasis only methotrexate demonstrated a net benefit. The results of the CEA were
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highly sensitive to the utilities used. which were generated from three groups, patients, healthy non-
experts and dermatologists. The CEA showed that for all three groups, Goeckermann therapy
should be chosen in preference to liquid methotrexate for severe psoriasis. This contrasted with the
CBA, which suggested that liquid methotrexate rather than Goeckermann therapy should be
provided for psoriasis of all grades of severity. This clearly illustrates the point that an analysis
based on patient preferences may have very different results from an analysis of same situation
based on costs alone.
Although the authors described this as a CEA, the method appears to describe a cost-utility
analysis. The decision-analytic model includes both the possible outcomes and corresponding
utilities. The authors say that the "effectiveness" calculation is described in the methods section but
it appears to be absent and so it is not clear how the terms described as cost-effectiveness ratios
were derived It is confusing that the results of the analysis are expressed in a dollar value alone
and not, for example, dollars per Quality Adjusted Life Year. The authors say, "to be considered
effective, the CE ratio cannot exceed the traditional threshold of $35,000. This threshold is derived
historically from the CE ratio of haemodialysis compared with no dialysis for chronic renal failure"
However, this figure is usually quoted as the cost per QALY.
The CBA in this study was based on the differences between the costs of providing treatment and
the monetary value of the benefits determined by willingness to pay.
4.3 Systematic review of psoriasis treatment
The only previously published systematic review of treatments for severe psoriasis was carried out
by Spuls and colleagues in The Netherlands. (Spuls 1997) In this study the authors systematically
reviewed the evidence concerning the ability of five systemic treatments to induce remission in
patients with severe psoriasis. They analysed 129 patient series, reporting on 13,677 patients.
They concluded that PUVA therapy was associated with the highest proportion of patients with
clearance (70%) followed by UVB (68%) and cyclosporin (64%). They also noted that side effects
were most frequent in patients treated with retinoids and least frequent in the phototherapy group.
Unfortunately the methods that this group used were not described explicitly. It is of particular
concern that only one third of the trials included in the analysis were randornised-controlled trials.
The authors commented that their review could not focus on an estimate of the treatment effect
based on comparisons of outcomes in parallel groups randomly allocated to the treatments under
study, because of the "absence of suitable comparative clinical trials". Instead, they focused on
treatment outcomes in patient series. (Thus. for example, a study comparing cyclosporin with
PUV A would generate two patient series) For each series, the proportions of patients achieving
complete clearance (9S-100% clearance), good (more than 7S% clearance), moderate (S0-7S%
clearance) and poor (less than SOOIo clearance) responses were extracted In each case the outcome
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measures used by the original trial authors were used These included PAS!, body surface area
affected and average global scores. The results were pooled using size-weighted averages. These
were then presented as measures of effectiveness. The study also reported the frequency of side
effects and drop-outs due to side effects, however the authors noted that a number of the trials
included in the review did not report these items.
Spuls and colleagues acknowledged that the inclusion of non-randomised trials could have led to
some problems. They suggested that there may have been selection biases in the original studies,
resulting in. for example. patients with more severe disease being recruited to cyclosporin trials
than for PUVA trials. Another issue was the use of different trial endpoints; phototherapy trials are
invariably based on disease clearance (full remission) whereas the induction of remission is usually
the endpoint for trials of other systemic therapies. Other issues identified included the use of
different outcome measures and variable reporting of drop-outs and side effects. These
considerations mean that the response rates reported in this study cannot immediately form the
basis for further analyses.
4.4 Conclusions
What is required is a systematic review of randomised, controlled trials of treatments for severe
psoriasis that could provide meaningful estimates of effect sizes. with confidence intervals. This
type of information would be helpful to clinicians in formulating treatment strategies and to
patients in determining the balance of risks and benefits associated with each type of treatment
In addition. as a first step, cost-effectiveness analyses of the main systemic treatments, in the
context of the UK healthcare system, are needed These would form useful benchmarks against
which future treatments could be evaluated and could lay the foundations for future cost-utility
analyses.
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Chapter 5
Decision-analytic model for treatment of moderate-severe, chronic plaque
psoriasis
Summary
A decision-analytic model is central to any decision analysis. Such models must follow a set of
accepted conventions. A model has been proposed for analysis of the treatment of moderate-
severe, chronic plaque psoriasis. The assumptions that underpin the model are explored and the
strengths and weaknesses of the approach evaluated.
S.l Decision-analytic models
Decision analysis is a systematic, quantitative technique for structuring the decision-making
process. Each analysis hinges on the construction of a decision analytic model that structures the
problem in such a way as to show the decisions and outcomes, in a time sequence. For convenience
this is often depicted as a 'decision tree'. The tree must distinguish between choices (which are
under the decision-maker's control) and chance events (which are beyond the decision-maker's
control). These are represented by 'nodes' in the model. Two basic rules must be obeyed when
constructing the tree; firstly, the branches from a node must be exhaustive and mutually exclusive
and, secondly. the sum of probabilities in each branch must be equal to one. This process has been
described in detail in Chapter 1.
S.l Decision-analytic model for treatment of severe psoriasis
Einarson and colleagues, in Canada, (Einarson 1994) proposed a decision analytic model for the
treatment of severe psoriasis. (Figure 5.1). This was constructed using information from current
treatment guidelines and meta-analysis of published trials and was validated by a panel of
dermatologists. The treatments compared were cyclosporin, methotrexate, etretinate and PUVA
The model was applicable to each of the four treatments and assumed that if the primary treatment
failed, a secondary (back-up) treatment would be used If cyclosporin was the primary treatment
then methotrexate was the secondary treatment. Cyclosporin was the secondary treatment for
methotrexate, etretinate and PUVA
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The decision analytic model can be written in spreadsheet form (as explained in Chapter 1). In the
model there are four stages at which there are chance nodes with associated probabilities. These
are shown in table 5.1 as Probability 1, Probability 2 etc. The overall probability of an outcome is
calculated by multiplying the probabilities in the row together and then adding together the results
for all the rows with the same outcome. In this case, rows 1,2,3,5 and 6 should be added for the
overall probability of treatment success, using a specified combination of primary and secondary
treatments.
Table 5.1: Einarson's model- general scheme in spreadsheet format
No Description prob prob prob prob Outcome
factor 1 factor 1 factor 3 factor 4
1 Total success PSR I-PRR 1 1 success
2 success,relapse,success PSR PRR PRSR 1 success
3 success,relapse,failure.success PSR PRR I-PRSR SSR success
4 success,relapse,failure,failure PSR PRR 1-PRSR l-SSR re-evaluate
5 failure,success 1-PSR SSR l-SRR 1 success
6 failure,success,relapse,success 1-PSR SSR SRR SSR success
7 failure.success.relapse,failure 1-PSR SSR SRR l-SSR re-evaluate
8 Total failure I-PSR l-SSR 1 1 re-evaluate
PSR Primary treatment success rate
PRR Primary treatment relapse rate
SSR Secondary treatment success rate
PRSR Primary retreatment success rate
SRR Secondary treatment relapse rate
Many of the assumptions made by the Canadian group were not made explicit in the report and
close examination of the model suggests a number of issues that need to be taken into account if it
is to be used for future analyses.
5.2.1 Duration of treatment
It is not clear from the report whether the model assumes that treatments are given continuously or
intermittently. Although, at first glance it, appears that intermittent treatment was envisaged, the
fact that the relapse rates quoted were derived mainly from groups of patients receiving
maintenance treatment (with one of the four agents in the comparison) suggests that continuous
treatment was, in fact, expected. This presents some problems in the light of current knowledge.
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For example, it would no longer be acceptable to offer continuous treatment with either PUV A or
cyclosporin
5.2.2 Estimation of success rates
It is logical to use the pooled results of RCTs to estimate the success rate as RCTs provide the most
stringent test conditions for a treatment. In this study no details were given about the search
strategy for trials concerning the four treatments involved in the analysis and, therefore, it was not
clear which types of trial were eligible for inclusion Furthermore, there was no indication of how
'success' had been defined. This is also important, as has been argued earlier. As different
definitions of success clearly influence the eventual success rate.
The trials used for the meta-analysis of etretinate therapy concerned mainly palma-plantar pustular
psoriasis, which is believed to respond better to retinoid treatment than does chronic plaque
psoriasis. This almost certainly over-estimated the probable succe~s rate in the more common,
chronic plaque psoriasis, which was the subject of the analysis.
Cyclosporin response rates were derived from four trials. Three were RCTs comparing cyclosporin
with placebo (Ellis 1991, Guenther 1991 and van Joost 1986) and one was a non-randomised
comparison of cyclosporin and PUVA (Petzelbauer 1990). Curiously, the other placebo-controlled
RCT that had been published in the same period (Bngst 1989) was not included.
Methotrexate response rates were based on a single study that focused primarily on the treatment of
psoriatic arthritis. (Willkens 1984)
5.2.3 Estimation of relapse rates
Relapse rates were appropriately derived from a mixture of randomiSfd trials and long-term open
trials. The main difficulty here was the lack of clarity about the definition of 'relapse'. In
attempting to reproduce the figures cited in Einarson's study it became clear that the relapse rates
quoted were derived mainly from groups of patients receiving maintenance treatment (with one of
the four agents in the comparison) (See 5.2.1). Two examples serve to illustrate this point: First,
the report cites a relapse rate of 62% (81111308) derived from the trial ofPUVA therapy by Melski
and colleagues (Mel ski 1977). There were 1308 patients in the trial; after induction of remission,
they were divided into 4 groups, three of which received ongoing, low dose PUVA Only one group
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received no maintenance treatment and this is the group from which the relapse rate should be
derived. As the reported relapse rate is based on the total number of patients in the trial, it must
also include those receiving maintenance treatment. Second. they cite a trial of PUV A and UVB by
Momtaz and Parrish (Momtaz 1984), from which a relapse rate of 31.3% (5/16) has been derived
This represents the relapse rate for the patients given maintenance PUVA, whereas in the five
patients who had no active treatment there were three relapses in two months, that is a relapse rate
of 60010 in two months.
This is particularly confusing as Einarson's report says, 'We did not incorporate maintenance
therapy into the PUVA regimen as we could find no studies that fit the criteria of the meta-analysis
and that assessed this question." While these figures might be appropriate if continuous treatment
is envisaged. other estimates would be needed if intermittent treatment were planned. to reflect
relapse rate after treatment is discontinued. The situation was further complicated by the fact that
relapse rates appeared to relate to varying time periods.
S.2.4 Handling of side effects
The report refers to a meta-analysis for side effects and yet it is not clear how this was used in the
final analysis.
SoloS Appropriateness of economic analysis
In the report by Einarson and colleagues, the analysis is described as both a cost-effectiveness
analysis and a cost-minimisation analysis. Cost-effectiveness analyses express the results in terms
of natural units, for example, cost per life saved or cost per episode of infection avoided. Cost-
minimisation analyses compare only costs because, by definition, they assume that the outcomes of
each of the treatment options are the same. The only situation in which these two types of analysis
are interchangeable is when the outcomes of each of the treatment options are identical. Ifdifferent
treatments are associated with different success rates and different patterns of relapse then a cost-
effectiveness analysis may be more meaningful. This could result in an analysis that compared the
modelled strategies and expressed the results as cost per flare up avoided or cost per treatment
failure avoided.
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5.2.6 Application of the model
It is not clear from the report whether the model is intended to cover a one-year time period.
although this is implied The method says simply, "Because the analysis was extended for one year,
therapeutic relapses were included." In addition the details of the sensitivity analyses are sketchy
and insufficient to allow reproduction.
5.3 Discussion
It would have been reasonable to assume that the trials selected for the estimations of success rates
would be Refs, concerned with the treatment of chronic plaque psoriasis, using up-to-date doses or
regimens, however, this is not the case in Einarson's study. The fact that at least one RCI' that had
been published within the same time frame as those used was missing suggests that the process for
gathering the trials was not systematic. This could have influenced the estimate of pooled effect
size. Furthermore, the very small standard errors cited would give rise to very narrow confidence
intervals. These appear to have arisen due to the method used for pooling the data (which was
Bayesian rather than one of the conventional approaches)
Overall the data collection appears to have been incomplete (in that at least one Refs was
missing), inconsistent (in that Refs and other trials were admitted) and inappropriate (in that data
were taken from trials concerned with palma-plantar pustular psoriasis for application in chronic
plaque psoriasis).
Given the number of inconsistencies and gaps in information it is difficult to feel confident about
the results of Einarson' s analysis. One element of the studies reported here was to populate
Einarson's model with more robust data Effectiveness data was obtained from a systematic review
of the literature concerned with treatment of chronic plaque psoriasis and UK cost data were
gathered.
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5.4 Conclusions
Einarson's analysis should be repeated using values derived from the systematic reviews described
in chapters 7-10 for effect sizes (success rates) and data derived from recent trials for relapse rates.
Economic analyses should then be performed using current UK costs. All analyses should make
clear whether continuous or intermittent treatment is under consideration. If trial data exist to
show the pattern of relapse and re-treatment in real life then it may be possible to incorporate these
into a revised model and compare the results.
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Chapter 6
Meta-analyses of treatments for severe psoriasis
Summary
This chapter describes the methods of meta-analysis and the general approach used in this project
for meta-analyses for psoriasis treatments.
6.1 Methods
6.1.1. Definition and description of meta-analysis
Meta-analysis is a technique for combining quantitatively the results of previous studies to derive
summary conclusions about a body of research. It is particularly useful to summarise research
where individual studies have been too small to yield conclusive results on their own. The results
of meta-analyses are usually displayed as 'forest plots' in which the effect size from each trial is
shown with its confidence interval. 'The line of no difference' (which corresponds to the value of
unity for odds ratio and rate ratio but corresponds to zero for rate difference) is marked and the
pooled effect size is shown. The advantage of this form of display is that it conveys a clear visual
image of the results. For example, Collins and colleagues conducted a meta-analysis of randomised
trials of diuretics for pre-eclampsia in pregnancy. (Collins 1985) They found nine trials; five
showing a positive effect and four showing equivocal results. A meta-analysis of the data showed
an overall positive result (Figure 6.1)
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Figure 6.1: Odds ratios for pre-eclampsia and 95% confidence limits in nine trials of diuretics.
(Odds ratios less than unity represent beneficial effects of diuretics. Meta-analysis based on fixed
effect assumption) (Collins 1985)
Meta analysis is often applied to randomised controlled trials (RCI's), however it is also possible to
combine the results of case-control studies in this way. This is useful when there are many studies
of low statistical power. As the treatments for psoriasis (both drugs and phototherapy) are
amenable to Rcrs, the remainder of the discussion will relate only this type of study.
6.1.2 Identification of studies for meta-analysis
The studies included in a meta-analysis must be closely similar in terms of patients and the
intervention under investigation. Sackett and colleagues suggest that "Meta-analysis is on the
strongest ground when the methods employed in the primary studies are sufficiently similar that
any differences in their results are due to the play of chance." (Sackett 1991) If this is not the case,
it may still be possible to combine the results statistically but the result may have little value in the
clinical situation. It is important that the component studies are free from bias (or minimally
biased) and therefore they should be randomised trials, ideally with intention-to-treat analysis,
complete follow-up information. and objective or blinded outcome assessment (Peto 1987)
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The search for studies should be exhaustive and should follow the steps outlined in Chapter 1.
Once eligible studies have been identified they are retrieved and checked. This is an important step
as it is not always possible to tell from the title and abstract whether a study will conform to the
predetermined criteria for a meta-analysis. The final list of studies is then generated.
6.1.3 Data-extraction
Some authors recommend that a data-extraction document is drawn up in advance (CRD 1996)
however, others argue that where systematic revie-ws are essentially "data-driven" rather than
"question driven" then it makes more sense to compile the data extr~ion documentation as the
data are uncovered. The important element is to ensure that all data are extracted so that studies
can be examined critically and bases for comparison established Although studies will have been
selected for their similarities in patients and interventions, it does not follow that all studies will
have used the same outcome measures. Rather than using a simple data extraction (as shown at
Appendix 2) it is better to construct detailed data extraction tables to organise the data on each
aspect of the studies under review. In this way, aspects such as trial design, input criteria. outcomes
measured. can be displayed Data can be entered directly in to a computerised database, such as
Minitab or Access and may then be readily modified for analysis.
This also provides an opportunity to compare studies and check for obvious heterogeneity. At this
stage it may become clear that pooling of the results by means of meta-analysis is not valid or
sensible.
6.1.4 Data analysis and presentation
6.1.4.1 Dicbotomous results
The first step in a meta-analysis is to find a consistent way of describing the results from each trial.
One of the most common approaches is to "dichotomise" the results, that is, to tum them into
yes/no, cured/not cured, died/survived format which can then be manipulated in a number of ways.
Although many trials do not have results presented in this way, there are often sufficient data in the
published report to make it possible. A clear understanding of the clinical issues is important to
ensure that logical cut-off values are used
Example: In a controlled trial of a new psoriasis treatment, the resul~ may be presented as mean
decreases in PAS! score for the control and test groups. If sufficient information were given it
would be possible to dichotomise the results - into 'cleared' or 'not cleared' categories for each
treatment group. First it would be necessary to decide on a suitable cut-offvalue for the PASI A
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reduction of 75% from baseline or a reduction to a value of less than 8 would make sense in a
clinical situation and would be consistent with values used in published studies. The results could
now be shown as the numbers in each group which did/did not achieve the cut-off value.
6.1.4.2 Risk ratio versus odds ratio
Risk describes the probability that an event will occur (the number of subjects who experience the
event 1 the total number in the group). Conventionally, 'risk' is a term related to adverse effects but
the concept can also be applied to beneficial events and. in this case. i~ more often described as a
Crate'. Odds describe the probability that an event will occur against the probability that it will not
occur.
Example:
Table 6.1: Effect of antenatal steroid for prevention of respiratory distress syndrome (RDS)
(Morales WI 1986)
In the example shown, the risk of RDS in the control group is O.S 1 whereas the odds of developing
RDS are 1.03. Odds may be converted to risk using the relationship:
Risk = 0ddsI(1+ Odds)
but this is rarely done. (Sinclair 1994)
The relative risk (RR) (or risk ratio, event rate ratio) describes the relative probability that an event
will occur when two treatment groups are compared. In this example, the relative risk ofRDS is
given by (30/121)1(631124) = 0.49. The relative risk reduction (RRR) is given by (1- relative risk).
In this example the RRR is O.S 1 which means that there is a SI % reduction in RDS in the treated
group compared to the control group.
6S
The odds ratio (OR) describes the odds of an event in the treated group compared with the control
group. In the example the odds ratio is 30:91163:61 = 0.32. The relative odds reduction (ROR) is
given by (l-odds ratio).
The odds ratio can be converted in to a risk ratio, but because the ratio is a comparison of two
groups. a term for the incidence of the event in the control group is also required:
OR
Risk ratio =
1+ L.(OR.l)
where L.= incidence of the event in the control group
6.1.4.3 Relative and absolute estimators of effect
The risk difference (absolute risk reduction, ARR) describes the absolute difference in event rates
between treated and control groups. In the example this is 0.25 • 0.51 ~ -0.26, that is, the absolute
risk of RDS is reduced by 26% as a result of steroid treatment The reciprocal of risk difference
(l/risk difference) gives the number of patients that need to be treated (NNT) in order to prevent
one event (although the calculation is only valid if the confidence interval around the RD is
relatively narrow) In the example, the NNT is l/0.26 = 4.
Where the outcome of a trial is an increase in a positive effect rather than a decrease in a negative
effect, the risk difference is sometimes described as the "absolute benefit increase', This is explored
in more detail in Chapter 11.
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Table 6.2: Relative and absolute estimators of effect
Estimator Abbreviation Question answered
Relative risk What is the proportion of treated patients,
(risk ratio) RR relative to control patients who experience an
event?
Odds ratio OR What are the odds of the event occurring in the
treated patients relative to the odds of its
.occurring in control patients?
Relative risk reduction RRR By how much in relative terms is the event rate
reduced?
Absolute risk ARRorABI What is the absolute difference in event rates
reduction or absolute (RD) between the treated and control groups?
benefit increase
(risk difference)
Number needed to NNT How many patients need to be treated to
treat prevent one patient from experiencing an
event?
The odds ratio and the risk ratio give similar results where the risks are small, that is less than
approximately 20010.(Thompson 1991) Above this value the two estimators diverge. The odds ratio
is used to provide an approximation of relative risk in case-control studies, in which patients and
controls are selected because they have or do not have the outcome of interest Laupacis and
colleagues observed that the odds ratio has become the preferred statistic for pooling data across
trials in meta-analyses, partly because of the simplicity of statistical methods. (Laupacis 1988)
6.1.4.4. Pooling metbods - random and ru:ed effects models
Dichotomous data can be pooled using random or fixed effects models. The differences between the
two models are summarised in Table 6.3.
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Table 6.3: Random and fixed effects models for meta-analysis (after Petitti 1994, Egger 1997)
The choice of model for analysis is linked to the degree of inter-study variance (heterogeneity). If
studies are homogeneous (i.e. there is no interstudy variance) then both methods will yield identical
results, however, if they are heterogeneous then the random effects model should be used. The
random effects model is relatively conservative and produces estimates with wider confidence
intervals, (Berlin 1989) however, it may also give undue weight to small trials. (Thompson 1991)
6.1.4.5 Heterogeneous data
If the results of trials are very different then it may not be appropriate to combine them. A
statistical test of heterogeneity is often used as the deciding factor. This procedure tests whether
results reflect a single underlying effect or a distribution of effects. Although this is superficially
elegant, the main drawback is that this type of test lacks power (i.e. it may fail to reject the null
hypothesis that results are homogeneous even when substantial differences exist). The identification
of heterogeneity should not merely prompt the use of a random-effects model. but should also lead
to a critical search for an explanation. This may lie in features of trial design. characteristics of
patients included or other clinically-relevant aspects of a trial. (Bailey 1987. Thompson 1991.
Thompson 1994) Indeed Jenicek cautions, "it is better to analyse differences and to draw new
hypotheses and test them rather than to try to obtain some universal protective ratio which applies
to neither group in the original studies."
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6.1.4.6 Sensitivity analysis
Because a number of methods of meta-analysis could be applied to most groups of studies, it is
important to examine the robustness of the results by means of a sensitivity analysis. This process
involves repeating the analysis whilst making small changes. (Greenhouse 1994) In this situation
this could involve using both fixed effects and random effects models to calculate the overall result
and, for example, checking the effect of removing trials of doubtful quality, small trials, trials of
shorter/longer duration.
6.1.4.7 Publication bias
Publication bias is the systematic error induced in a statistical inference by using only published
trials in an analysis. The error arises because research with significant (and usually positive)
results is more likely to be submitted and published than studies with null or non-significant results.
Published studies, therefore, are not representative of all the studies which have been performed in
a given area One method ofchecking for the presence of publication bias is to construct a "funnel
plot". (CRD 1996) This is done by plotting sample size against effect size (typically as an odds
ratio or risk ratio). It is expected that the points will fill an inverted funnel shape. Large gaps in
the funnel shape may indicate "missing" studies. Characteristically the missing points will
correspond to negative trial results. Figure 6.2 shows examples ofnw situations. The right-hand
plot shows a clear inverted funnel shape. In this case the effect size obtained by meta-analysis of
the available trials was very close to the value obtained in subsequent large trials. The left-hand
plot is less obviously funnel-shaped, which raises the possibility that trials with negative results are
missing. The pooled effect size obtained by meta-analysis was strongly positive, suggesting that
intravenous magnesium was more efective than streptokinase in preventing deaths due to
myocardial infarction. A later large trial (lSIS-4) refuted this hypothesis.
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Figure 6.2:
Funnel plots for meta-analyses refuted and confirmed by subsequent mega-trials: intravenous
magnesium (left) and streptokinase (right) in acute myocardial infarction
(Egger 1995)
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6.2 Meta-analyses of treatments for severe psoriasis - methods
6.2.1 Objective and search strategies
6.2.1.1 Objective
The objective of the meta-analyses was to evaluate the comparative efficacy and tolerability of oral
treatments and PUV A for severe psoriasis through systematic reviews of randomised controlled
trials. Only trials for moderate-severe, chronic plaque psoriasis were included Trials for guttate
psoriasis, palmo-plantar-pustular psoriasis and erythrodermic psoriasis were excluded
6.2.1.2 Selection criteria
A broad search strategy was used initially in an attempt to identify all the studies concerned with
treatment of severe psoriasis. Specific drug or treatment tenus were used after this stage and finally
randomised, controlled studies were extracted from the database and used for the review. Studies in
all languages were included
6.2.1.3 Search strategy
Medline (1966 to June 1999) and Embase (1980 to June 1999) searches were conducted using the
tenus 'psoriasis' and 'treatment' and 'psoriasis-drug-therapy'. The additional tenus, 'study'.
'trial?", 'random'" in the text, 'compar*' in the title and 'clinical-trial' in the subject heading were
used to increase the specificity of the search. The subject tenus were then inserted, for example,
'cyclosporirr" or cic1osporin' was then used to locate trials concerned with cyc1osporin use.
The Cochrane register of randomised controlled trials was searched for trials involving specific
treatments and psoriasis.
Manufacturers were approached to identify additional studies. Recent conference proceedings were
hand-searched Recent issues of key dermatology journals were hand-searched As papers were
retrieved the references were checked to identify additional trials. Dermatologist colleagues were
asked to review the lists of reports generated to identify missing reports.
6.2.1.3 Data extraction
All potentially comparable input and outcome data were extracted and recorded in tables using
Minitab® software v. 10.2,1994 (Minitab Inc USA). In this way a consistent dataset was identified
and used to compile the tables that show the design and outcomes of the trials under review. The
numbers of patients enrolled in the trials were extracted so that all analyses for this project could be
performed on an 'Intention-to-treat' basis. This was done by calculating the success rates for each
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trial as a proportion of the total number of patients enrolled rather than the number of patients who
completed the trial.
6.2.1.5 Statistical analysis- Outcome measures
The PAS! score is frequently used to assess the outcome of psoriasis treatment but it was not used
for all of the ReTs included in the following overviews. Furthermore. the authors who did use it
presented the results in two different ways. Some presented average scores for study groups before
and after the intervention whereas other reported the average percentage decrease in PASI
Clearly, the first approach works best when the groups contain patients with disease of similar
severity and the second approach works well when there is a wider range of baseline disease
severity. The results from these two different approaches cannot readily be inter-converted using
the information available in the published papers. Although the PAS! initially appeared to be the
most satisfactory outcome measure, its use for analysis would have resulted in the loss of too much
information to make it useful.
Another common approach in this situation is to find a way to dichotomise the results (i.e. tum
then into a yes/no, alive/dead. cured/not-cured format). Several authors had presented their results
in this form already. In the context of psoriasis, results can be divided into cleared/not cleared, or
more conservatively. successfuVunsuccessful. Tables in chapters 7. 8 and 10 show the criterion
adopted by each study for success. The most widely used criterion was a decrease in PASI score of
at least 75% or a decrease to an absolute value of 8 or less. Itwas assumed that this would
correspond to the category of "clear or almost clear" used by Ellis (Bllis 86, Ellis 91) and other
authors. The benefit of this approach is that it reflects the way in which patients assess the
effectiveness of treatments, that is to say, they either clear the condition or they do not. It is well
known that it is possible for a trial to show statistically significant changes that are clinically
insignificant and this approach avoids the risk of including this type of result The potential
weaknesses of the approach are that small differences on the original scale may be magnified by
dichotomising the data and that the results can be influenced by the use of different cut points. The
worst possibility is that trialists choose the cut point after seeing the results rather that using a
protocol-defined cut point In the case of psoriasis, the cut-point (75% decrease inPASI or absolute
value below 8) is widely recognised and commonly included as an a priori outcome measure.
Several statistical methods exist to derive pooled estimates of effect~ from dichotomous data In
this study. both odds ratios and risk differences have been used. The risk difference is needed in
order to calculate the number needed to treat (NNT) (see Chapter 11).
Odds ratio
The Mantel-Haenzsel method (Petitti 1994) or Peto method (Petitti 1?94) can be used to calculate
an odds ratio after a 2x2 table has been constructed for each trial in the overview.
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Table 6.4: Arrangement of data for Mantel-Haenzsel (MH) method and Peto methods
TREATED NOT TREATED TOTAL
Diseased a b ~
Not diseased c d h
Total e f n
The odds ratio for the trial is then, a x d
bxc
The MH pooled odds ratio (OR mh) is calculated as
Sum(weight; x 0&)
Sum weight;
where weight; = l/variance, and variance; = 11; I (b; x e;)
The 95% confidence interval for the odds ratio is derived from the standard error of the logarithm
of odds ratio, which is given by
SE(ln OR)=
The 95% confidence interval for the log odds ratio is therefore
In OR-1.96 x SE (In OR) to In OR + 1.96 x SE (In OR).
The 95% confidence interval for the odd ratio is therefore from el_JimI to eupp«limit.
This is described in full by Altman (Altman 1991)
Difficulties arise with these methods when a value of zero appears in one of the cells, causing the
OR to be either zero or infinity. Some statisticians recommend that 0.5 should be added to each
cell in this situation, although this does not work well if the total sample size is small (Shadish
1994). For the analyses in this project, this procedure was followed.
Several formulae exist to calculate a statistic (0) that is used to test for homogeneity. The general
principle is to calculate the sum of the weighted difference between the summary effect measure
and the measure of effect from each individual study. The resulting value is referred to the Chi-
square distribution. The number of degrees of freedom is equal to the number of studies minus one.
If the value is greater than the cut-offvalue for the selected p-value (usually 0.05) then the null
hypothesis of homogeneity is rejected.
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For the Mantel-Haenszel method the calculation is:
Q =sum [weight i x (In OR mb -Jn OR i )J
(pettiti 1994, Chapter 7)
For estimations of effect size pooled odds ratios were calculated using the Mantel-Haenszel (fixed
effects) method when data were not heterogeneous; the DerSimonian & Laird (random effects)
methods was used for heterogeneous data (petitti 1994).
Rate difference
Rate differences (also known as risk differences, absolute benefit increases and therapeutic gain)
were also calculated A pooled rate difference can also be calculated as a summary measure of
effect.
Summary rate difference (RD.):
RD. = Sum (weight x ROi)
Sum (weight)
Where
Weight; _ 1/ variance;
Variance (Vi)of a rate difference = p;,(1- Pi,)I 11;, + Pi2(1- P;2)1ni2
where Pi, and Pi2 are the proportions of individuals in the experimental and control groups who
have the condition (treatment success); rate difference = (1';, - 1';2)
Homogeneity is tested using the Q statistic:
Q = Sum [weight; x (RD. - ROiJ
Q is referred to the chi-square distribution with degrees of freedom equal to the number of studies
minus one.
The 95% confidence interval for the pooled estimate is given by
RD +/- (1.96.J variances)
where variance. = lI(sum weight)
This described in detail by Petitti (Petitti 1994)
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Relative risk
For estimations of the relative risk of withdrawal from trials due to side effects the risk ratio was
calculated (when sufficient data could be extracted from the trial reports).
Meta-analyses were performed using Intercooled Stata 6.0 for Windows (Stata Corporation, Texas).
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Chapter 7
Systematic review of trials of oral cyclosporin
Summary
Nineteen eligible RCTs, were locatedfor this review. Fourteen were concerned with induction of
remission andfive with maintenance treatment. The trials are grouped according to the types of
comparisons involved: placebo controlled trials of cyclosporin; comparisons with retinoids;
comparisons of dose levels; cyclosporin in combination with calcipotriol and comparisons of
cyclosporin formulations. The results of similar trials were pooled using different measures of
effect size and both fixed and random effects models. A meta-regression analysis showed a
relationship between dose and effect size. Potential sources of heterogeneity are identified.
7.1 Search results
Trials of oral cyclosporin were identified using the search strategy described in Chapter 6. This
identified 169 citations. Of these, 88 were reports of therapeutic trials, including randomised
controlled trials, controlled trials (non-randomised), cohort studies, retrospective studies, case
reports & small series. Titles and abstracts were reviewed by two people independently (the author
and a consultant dermatologist) to identify randomised controlled trials (Rcrs). Thirty-seven
records appeared to be reports of Rcrs and of these, 31 concerned the use of systemic cyclosporin
and five concerned the use of topical cyclosporin. All of these were retrieved and read.
Eighteen studies were excluded from the final review (see Table 7.1) Two of the reports were
duplicate publications (Bagot 1994/Grossman 1994; Mrowietz 19911Christophers 1992) two were
subsets (BayerlI992, Schulze 1991) of a multicentre study (Mahrle 1995) and five were non-
randomised studies.(Blaszczyck 1997, Gottlieb 1995, Kokelj 1997, Timonen 1995, Wanqing 1995)
One had been superseded by a later, more detailed report. (Nakayma 1996) These ten reports were
excluded from the final list along with the five reports of topical or intralesional
cyclosporin.(BaykalI994, Bunse 1990, Gajardo 1994, Ho 1990, Petronic-Rosic 1997)
Studies included in the final review were restricted to those which were concerned with the
treatment of moderate-severe or severe psoriasis and which contained sufficient data for analysis.
Three studies, which failed to meet these criteria, were excluded (Levell 1995, Dubertret 1989,
Bngst 1989)
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Figure 7.1: Flow chart to show cyclosporin trials excluded
I 37 apparent ReTs I
n n~--------~----~~--------------~
5 trials:
topical or
intralesional CSA
Non-random trials 5
Duplicate publications 2
Subsets of «hers 2
Insufficient data 2
2
1
Mild psoriasis.
Report superseded
Totall3
32 trials:
systemic CSA
Trials included
14 - Induction of remission
5 - Maintenance of remission
The final list contained nineteen randomised trials of cyclosporin; fourteen were concerned with the
induction of remission and five were concerned with maintenance treatment. These are
summarised in Tables 7.4 and 7.S.
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Table 7.1 Cyc1osporin (CSA) trials excluded
First author and year of Reason for exclusion
publication
1 Bagot 1994 Same data as Grossman 1994
2 Bayer11992 Data are a subset of Mahrle 1995
3 Baykal1994 Intralesional cycIosporin
4 Blaszczyk 1997 Not a randomised study of CSA CSA used in
non-randomised pre-study phase
5 Bunse 1990 Topical cyc1soporin
6 Dubertret 1989 Insufficient data for analysis
7 Engst 1989 Insufficient data for analysis
8 Gajardo 1994 Topical cyclosporin
9 Gottlieb 1995 Nou-randomised study
10 Ho 1990 Intralesional cyclosporin
11 Kokelj 1998 Non-randomised.study
12 Leve111995 Mild-moderate psoriasis
13 Mrowietz 1991 Same data as Christophel'S 1992
14 Nakayama 1996 Report superseded by more detailed report
(Ozawa 1999)
15 Petronic-Rosic 1997 Intralesional cyclosporin
16 Schulze 1991 Data are a subset ofMahrle 1995
17 Timonen 1990 Non-randomised study
18 Wanqing 1995 Non-randomised study
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7.2 Description of Trials
Inorder to determine whether or not the data from the separate trials could reasonably be pooled
statistically the reports were examined to determine the degree of similarity between them. Table
7.4 shows that the trials differ considerably with respect to four main variables, namely, initial
severity of disease, cyclosporin dose, success criterion and duration of treatment and it is likely that
these differences account for the marked variations in success rates although other factors, such as
interacting drugs or variable compliance with the dosage regimens cannot be excluded.
The severity of disease was described in several ways. In seven of the trials, a threshold level of the
Psoriasis Area and Severity Index (PAS!) was used, usually in conjunction with other, secondaty
criteria (such as percentage ofbody surface area affected, failure to respond to at least one other
systemic treatment or prolonged duration of disease). Two trials expressed disease severity as
percentage of body surface area affected and used threshold values qf 200/0and 25% (Ellis 1986,
Ellis 1991) and the remainder simply described the disease as 'moderate-to-severe' or 'severe'.
The threshold levels for the PAS! ranged from 8 to 20.
The criterion for success was expressed as a change in the PAS! score for 10 of the trials. The
remaining two used the descriptions of "clear", "almost clear" or "markedly improved". Seven
trials used a 75% decrease in PAS! or a final PAS! score of 8 or less as the criterion for success.
Guenther used a decrease in PAS! of 50010as the criterion for success and reported a successful
outcome in 11 out of 12 patients (92%) (Guenther 1991). At the other end of the scale, Grossman
used a 90% decrease in PAS! as the success criterion and reported a successful outcome in 4 out of
34 (12%) patients (Grossman 1994). Meffert used a success criterion of 75% decrease in PASI but
included patients with PAS! scores as low as 8 (Meffert 1997). These authors reported successful
outcomes in 4 of 41 (10%) and 12 of 44 (27%) patients on daily doses of 1.25 mg/kg and 2.5 mg/kg
respectively.
The dosage of cyclosporin ranged from 1.25 mg/kg/day to 14 mg/kg/day, Two patient series
received doses of 1.25 mg/kg/day and achieved successful outcomes in 4 out of 41 (10010)and 7 out
of 36 (18%). Six patient series received doses of 5.0 or 5.5 ms'kglday and achieved successful
outcomes in 50-97% of patients.
The duration of treatment ranged from 4 weeks to 12 weeks. This may also account for some of the
variability of the results. Trials which have reported cumulative success rates (e.g. Koo 1998) have
shown that the response curve does not level until12 or 16 weeks, which suggests that trials which
ended earlier are likely to show variable results.
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Table 7.S shows the outcomes of trials of cyclosporin for maintenance of remission. Two trials
(Ellis 1995 and Shupack 1997) compared two doses of cyclosporin with placebo. Ozawa compared
intermittent and continuous dosing (Ozawa 1999) and Zachariae compared two formulations of
cyclosporin (Zachariae 1998). The success criteria were slightly different for each study. Ellis used
an increase of no more than two points on a global assessment scale (Ellis 1995), Ozawa used an
increase to no more than 50% of the pre-study baseline PASI score (Ozawa 1999), Shupack used an
increase to no more than 50% of the pre-study baseline body surface area affected (Shupack 1997)
and Zachariae used an increase of less than 8 in the PASI score or an increase of less than two
points in a global score (Zachariae 1998). The doses of cyclosporin also varied between 1.5 and
Smg/kg/day, In the placebo-treated groups the proportions of subjects remaining in remission at
the conclusion of the trials were 5% (Ellis 95) and 16% (Shupack 97)
7.3 Comparative efficacy of cyclosporin
7.3.1 Induction ofremission
Cyclosporin compared with placebo
In total. 298 patients participated in six placebo-controlled trials of cyclosporin. All except two
trials (one using a low dose of 1.25 mg/kg/day and one with only 6 subjects in each group) showed
a positive odds ratio (favouring cyc1osporin). (see table 7.4, figure 7.2) The pooled odds ratio
(random effects) was 18.36 (95% Cl 5.35 - 62.96). The trials differed considerably with respect to
four main variables, namely. initial severity of disease, cyc1osporin dose, success criterion and
duration of treatment.
Cyclosporin compared with etretlnate
Two trials involving 286 patients compared cyc1osporin with etretinate. In each trial cyclosporin
was significantly more effective then etretinate (ORs 13.28,95% Cl 1.62 -109.00 and 8.80, 95%
Cl 4.2S -18.25). The pooled OR (fixed effects) was 9.34 (95% Cl 4.69 - 8.62). Although the two
trials used very different doses of cyclosporin and etretinate (see Table 7.4 and Figure 8.6), there
was no statistical evidence of heterogeneity.
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Calclpotrlol and cyclosporln
One trial (69 patients) compared low-dose (2.0 rug/kg/day) cyclosporin and calcipotriol with
cyclosporin and placebo ointment. The trial had a very strict success criterion (> 90010 reduction in
PAS!) and yet, at six weeks, the combination was significantly better than cyclosporin alone (OR
7.08, 95% Cl 2.06 - 24.38).
Cyclosporin dosage comparisons
Three trials (Christophers 92, Laburte 94, Meffert 97) involving 553 patients, provided patient
series in which different doses of cyclosporin were compared The results showed that, at 12 weeks,
Smglkslday was significantly superior to 2.5mgtkgtday (pooled OR 3.52, 9S% Cl 2.30 - S.36). At
10-12 weeks 2.5mglkgtday was significantly superior to 1.2Smglkgtday (pooled OR 3.86, 9S% Cl
1.87 - 7.96).
Cyclosporin formulation comparisons
Two trials (382 patients) compared the traditional cyclosporin formulation (Sandimmun®) with the
newer micro-emulsion (Neoral®). Neither trial showed any difference between the two products in
terms of success rates at 12 weeks. The pooled odds ratio was 1.16 (9S% Cl 0.68 - 1.97)
7.3.2 Maintenance of remission
Cyclosporin compared with placebo
Two trials (202 patients) compared two different doses of cyclosporin (1.S mg/kg/day and 3.0
mg/kg/day) with placebo in the maintenance treatment of psoriasis. Results were reported at 16
weeks and 24 weeks. The higher dose was significantly superior to placebo whereas the lower dose
was not significantly different from placebo. At 16 weeks, the pooled odds ratio for the 3mgtkgtday
dose compared with placebo was 8.37 (95% Cl 3.97 -17.61)
Cyclosporln treatment schedule comparisons
Ozawa and colleagues compared continuously-dosed cyclosporin with intermittently-dosed
cyclosporin for maintenance treatment. (Ozawa 1999) They analysed the results from patients who
had completed a minimum of 36 months of treatment The periods of relapse were longer in the
intermittently treated group and the periods of remission were shorter.
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Analysis of their results shows that an average daily dose of 3.2 +/- 0.21 mglkg, delivered as
continuous therapy, kept patients in remission for 69<'10 of the time whereas an average daily dose of
3.06 +/- 0.21 mg/kg (+ topical steroids), delivered as intermittent therapy, kept patients in
remission for 32% of time.
Cyclosporin formulation comparisons
The one study that compared the traditional and micro-emulsion formulations of cyclosporin
(Sandimmun® and Neora1®) for maintenance treatment showed no significant difference in
effectiveness over a 24 week period. (Zachariae 1998)
7.4 Withdrawal from treatment due to adverse effects or lack of efficacy
Amongst trials of cyclosporin for induction of remission of psoriasis. withdrawals from treatment
because of side effects or lack of efficacy were reported in adequate detail in only five of the trials
(Finzi 1993, Mahrle 1995, Koo 1998 & Guenther 1991, Engst 1989). One study reported only
adverse effects in the cyclosporin-treated group (van Joost 1988). In other reports it was not clear
when subjects had been withdrawn or from which group.
In the two trials comparing cyclosporin with etretinate (Finzi 93, Mahrle 95) withdrawals due to
side effects or lack of efficacy were fully reported. The pooled risk ratio (fixed effects) for
withdrawal was 0.78 (95% Cl 0.30 - 2.01, Q= 0.2, p=0.658), which fails to demonstrate a
difference in the risk ofwithdrawal due to side effects or lack of effect with cyclosporin treatment
compared to etretinate treatment
Studies of cyclosporin for maintenance of remission of psoriasis reported adverse effects in different
ways.
Ellis (Ellis 1995) and Shupack (Shupack 1997) both compared cyclosporin with placebo. Ellis, in a
16-week study, reported that no patient demonstrated signs of important clinical side effects. In
Shupack's 24-week study five patients were withdrawn from the group receiving cyclosporin 3.0
mglkglday due to "renal causes" (increased serum creatinine - 3, decreased creatinine clearance - 1
and decreased glomerular filtration rate - 1). They reported that 17% of those receiving cyclosporin
3.0 mglkg./day and 10% of those receiving placebo showed new or worsening creatinine
abnormalities. Nevertheless they reported that there was no overall worsening of the glomerular
filtration rate.
Zachariae (Zachariae 1998) and colleagues compared Neora1® and Sandimmun® for continuous
maintenance treatment of psoriasis over 24 weeks. There was one withdrawal in each group
because of side effects or lack of efficacy. Raised serum creatinine levels (>130% baseline value)
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were reported in 6/20 and 5/14 patients receiving Neora1® and Sandimmun® respectively. New-
onset hypertension was reported in 3/20 and 1114. These differences were not statistically
significant
Ozawa and colleagues compared intermittent and continuous dosing «cyclosporin. In their safety
sample of 94 patients (50 continuous treatment. 44 intermittent treatment) three and two patients
respectively, were withdrawn because of side effects of lack of efficacy. Other side effects occurred
with similar frequency in both groups (hypertension - 21. raised blood urea nitrogen -17. raised
creatinine [no definition given]- 9)
In a multicentre study involving 400 patients receiving cyclosporin intermittently. the authors
concluded that there were no statistically significant changes in mean creatinine and diastolic blood
pressure during the study. (Ho 99)
7.5 Sources of heterogeneity
This overview has demonstrated marked heterogeneity among the RCI's that have been conducted
The understanding of the sources of heterogeneity is recognised to be as important as performing a
formal statistical analysis. (Thompson 1991, Bailey 1987) In terms of clinical understanding it
may be more relevant. Identifiable sources of heterogeneity included initial severity of disease,
cyclosporin dose, success criterion. duration of treatment and formulation of cyclosporin.
Compliance and interacting drugs may represent further sources of heterogeneity.
In trials for induction of remission of psoriasis the duration of treatment ranged from four to 12
weeks. Trials which have reported cumulative success rates have shown that the response curve
does not level out until after 12 or 16 weeks of treatment (Laburte 1994, Finzi 1993, Koo 1998)
therefore any trial which reports results at less than 12 weeks is bound to show greater variability in
outcomes. Three of the six placebo-controlled trials reported results at four weeks.
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7.6 Meta-analysis of results
Meta-analyses of the results from trials of cyclosporin compared with placebo were performed using
several different methods in order to test the robustness of the pooled values to fixed and random
effects assumptions. (See Table 7.2) The results were displayed as forest plots. (See figure 7.2).
The results were not unduly sensitive to changes from fixed to random effects models.
Table 7.2: Comparison of different methods of analysis for trials of cycloporin vs. placebo
Analytical method Effect Pooled effect size Q-test for
measure (950/0 Cl) heterogeneity
Idf= 8) (p)
Fixed effects- Odds ratio 12.84 (6.61- 24.93) 18.33 (0.019)
Mantel-Haenszel
Fixed effects - Risk ratio 8.21 (4.50 - 14.98) 11.42 (0.179)
Mantel-Haenszel
Fixed effects - Rate (risk) 0.39 (0.32 - 0.46) 85.61 (0.000)
difference
Random effects - Odds ratio 18.36(5.35 -62.96) 18.33 (0.019)
DerSimonian & Laird
Random effects - Risk ratio 6.71 (2.96-15.22) 11.42 (0.179)
DerSimonian & Laird
Random effects - Rate (risk) 0.51 (0.28-0.74) 85.61 (0.000)
difference
The use of different effect size measures did, howevere, throw up SOn1edifferences. When effect
size was measured by risk ratio (RR) and meta-analysed using either a fixed or random effects
model, there was no statistical evidence of heterogeneity (Q values were below the cut-off value, the
p value was greater than 0.05). However, when effect size was measured by odds ratio (OR) or by
rate (risk) difference a lack of homogeneity was demonstrated. This was to be expected, in view of
the clear evidence of methodological differences described above and suggests that a number of
confounding factors may be present The most obvious candidates were dose, duration of treatment,
baseline severity and the success criterion. The fact that one of the three approaches failed to
demonstrate heterogeneity serves to underline the importance of considering both the statistical and
qualitative analyses of the data
In view of the heterogeneity of the data set, the best estimate of effect size is given by a random
effects model. Such models tend to give conservative estimates with wide confidence intervals. In
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this case the odds ratio, estimated by the method of DerSimonian and Laird, is 18.36 (95% CI5.35
- 62.96)
Figure 7.2 shows forest plots for trials of cyclosporin versus placebo, arranged by dose in ascending
order. There is a hint of a dose-response relationship. The results for the trials by Guenther
(Guenther 91) and Engst (Engst 89) appear to be outliers and it should be noted that Guenther used
a low success criterion and the trial by Engst had only five participants in each group.
Inorder to test the influence of cyclosporin dose a meta-regression analysis was performed. This
was a logistic regression using the logarithm of the dose (logru_) as the regressor. It showed that
the dose contributed to the overall effect (coefficient 1.85 (Cl 0.71- 2.98) p=O.OOI).
Figure 7.3a-c show the relationships between the dose, observed effect size (as log OR) and
predicted effect size (as predicted log OR) based on the regression equation
Figure 7.3a shows the observed OR versus dose for all trials of cycIosporin compared with placebo
(all doses). The points are widely scattered and, despite the strong statistical significance of the
regression, the graph only weakly suggests that there might be a relationship between effect size
(OR) and dose. However, a graph of raw data such as this is potentially misleading as it does not
reflect the weights given to the different trials in the way that forest plots of meta-analyses do.
Figure 7.3b shows the predicted log odds ratio versus log dose. This illustrates the theoretical odds
ratios that would be generated for given doses using the regression equation that best fits the data
Inorder to show visually how close this relationship is, the predicted log odds ratio was plotted
aginst the logarithm of the observed odds ratio (Figure 7.3c). Had the 'variations in dose accounted
for all the differences in effect size then the points on this graph should lie on a straight line. The
fact that they do not suggests that other factors also contribute to the observed effect
Further logistic regressions were carried out and no statistical relationship was found between
duration of treatment and overall effect Relationships between baseline disease severity and
success criterion were not explored statistically. These undoubtedly refresent a source of variation
but the variation would arise from the way in which these measures were used by the clinicians
conducting the studies. Although they appear to be clear objective measures, both "body surface
area affected" and the psoriasis area and severity score require the physician who makes the
assessment to estimate the proportions of body surfaces affected by psoriasis. Studies have shown
that individual practitioners are reasonably consistent (little intra-individual variation) but that
there is often marked inter-practitioner variation, (Marks 1989),
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7.7 Sensitivity analysis
The sensitivity of the result to the removal of trials involving unusually high and low doses was
tested. This showed that as such trials were removed from the analysis, the pooled effect size
increased. Removal of the trials using the most extreme doses (1.25 mg/kg/day and 14 rug/kg/day)
gave an odds ratio of 19.75 which is little different from the overall pooled value of 18.36.
However, removal of the trials using doses of 2.5 mg/kg/day, increased the odds ratio for success
with cyclosporin treatment to 40.03. Although this sounds dramatic, it should be remembered that
the relationship between odds ratio and event rate (experirnental event rate) is not linear. The
relationship is approximately linear when the event rate is below 20%. It is clear from Table 7.4
that the experimental event rates ('success rate- intervention') are all above 35%. In this area of
the event rate/odds ratio curve a small change in event rate causes a large change in odds ratio.
Including only trials that used doses in the range 3.0 - 5.5 mg/kg/day, resulted in a pooled odds
ratio for success of 29.60. This is a particularly important finding as this is the dose range that is
currently recommended. Even given that the result is derived from only four trials involving a total
of 117 patients and the associated confidence interval is very wide, it still demonstrates the strongly
positive effect of cyclosporin cornpared to placebo in this condition. Overall, it is safe to conclude
that estimated effect size is stable and is not changed markedly by the removal of trials using very
unusually large or srnall doses.
Table 7.3 Effect of removing trials using high and low doses of cyclosporin
Sensitivity analysis Effect Pooled effect size (95-;. Q-testlor
measure Cl) heterogeneity
(model) (P)
Rernoval of high (>7.5 OR 19.75 (8.61 - 45.32) 9.79 (0.134)
mg) and low doses (fixed) [df= 6]
«2.5 mg)
Removal of all doses OR 40.03 (ll.41 • 140.35) 3.63 (0.459)
except 3.0 -7.5 mg/kg (fixed) [df= 4]
Removal of all doses OR 29.60 (7.42· 118.04) 2.33 (0.506)
except 3.0 - 5.5 mg/kg (fixed) [df= 3]
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7.8 Conclusions
CycIosporin is an effective treatment for moderate-severe psoriasis. Given the marked
heterogeneity, both methodological and statistical, between trials it is difficult to give a precise
estimate of the effect size. The odds ratio for success for the dose range 3.0 - S.S mg/kg/day was
approximately 30. A further insight into the effect size is provided by the 'therapeutic gain' and
the number needed to treat (NNT)-which are described in Chapter 11.
The effect of dose was difficult to demonstrate with the available data The prevailing clinical
impression is that doses of less than 3.0 mglkg are ineffective. It appears that a dose of 1.25
mg/kg/day is not effective but doses of 2.5 rug/kg/day and more are effective and there appears to be
a dose-response relationship.
Cyclosporin was more effective than etretinate and no difference in the risks of withdrawal due to
side effects or lack of efficacy was demonstrated
There was no evidence that reformulation (to the micro-emulsion) changed the efficacy or side
effects rates for cyclosporin treatment.
In general, information about side effects was scarce in the majority of studies reviewed (except for
those mentioned in section 7.4) and so it has not been possible to give an accurate estimate of the
range or frequency of side effects. The majority of the trials included in the review were of
relatively short duration and itmust be acknowledged that long-term observational studies would
provide more reliable information about side effects.
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Figure 7.2: Forest plots showing odds ratios of trials of cyclosporin (all doses, in ascending order
by dose) vs. placebo analysed by random and fixed effects methods
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Figure 7.3a: Odds ratio for success versus dose for trials of cyc1osporin vs. placebo (all doses). This
shows the actual calculated odds ratio for each trial plotted against the dose of cyc1osporin.
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Figure 7.3b: Predicted log odds ratio versus log dose for trials of cyclosporin vs. placebo (all doses)
This illustrates the theoretical odds ratios that would be generated for given doses using the
regression equation that best fits the data
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Figure 7.3c Predicted log odds ratio versus the logarithm actual odds ratio for trials of cyclosporin
vs. placebo (all doses). Jfvariations in dose accounted for all the differences in effect size then the
points on this graph should lie on a straight line. The fact that they do not suggests that other
factors also play a role.
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Chapter 8
Systematic review of trials of oral retinoids
Summary
Thirty-three eligible RCTs, were locatedfor this review. The trials are grouped according to the
seven different types of comparisons involved: placebo controlled trials of retinoids; comparisons
of acitretin with etretinaie; comparisons involving retinoid-Pill/A combinations; comparisons
involving retinoid-Ul/B combinations; comparisons involving retinoid-topioal treatment
combinations; comparisons of etretinaie with cyclosporin and comparisons of different dosage
schedules for acitretin. The results ofsimilar trials were pooled using different measures of effect
size and both fixed and random effects models. Potential sources of heterogeneity are identified.
8.1 Search results
Trials of oral retinoids were identified using the search strategy described in Chapter 6. One
hundred and seventy-nine citations were identified for retinoids and psoriasis. Of these, 120 were
reports or studies of retinoids, including RCI's, controlled trials (non-randomised), cohort studies,
retrospective studies, case reports & small series. Titles and abstracts were reviewed by two people
independently (the author and a consultant dermatologist) to identify RCI's. Fifty-seven citations
appeared to be reports of RCI's and of these, 31 concerned the use of etretinate, 24 concerned the
use of acitretin, one the use of topical l3-cis-retinoic acid and one the use of tazarotene. All of
these were retrieved and read.
Twenty-four studies were excluded from the final review (see figure 8.1, table 8.1) Twelve were
non-randomised studies, two were subsets of a multicentre study, two contained results that were
published in two languages under different lead authors' names and three contained data that were
published more fully elsewhere. Three were not prospective studies (one editorial and two large
case series). These 22 reports were excluded from the final list along with the reports of topical
treatment with 13-cis-retinoic acid or tazarotene. Thirty-three RCI's were therefore available for
inclusion in this review.
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Figure 8.1: Flow chart to show retinoid studies excluded
57 apparent RCTs
31 etretinate
24 acitretin
1 topical 13-cis retinoic acid
1 tazarotene
Studies excluded
Non-random studies 12
Subsets of others. 2
Duplicate publications 2
Study superseded 3
Not prospective studies 3
Topical treatment 2
Tota124
Studies included
31- induction of remission
1 - maintenance of remission
1 - induction and
maintenance of remission
Total33
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Table 8.1: Retinoid trials excluded
First author and year of Reason for exclusion
publication
1 Bayed 1992 Data area subset of Mahrle 1995
2 Bergner 1991 Same data as Ruzicka 1990
3 Bjerke 1989 Data published in full later
4 Bischoff 1992 Topical retinoic acid
5 Darouti 1988 Non-randomised study
6 Goerz 1978 Non-randomised study
7 Gollnick 1983 Large case series
8 Gruca 1984 Same data as Jacubowicz 1987
9 Gupta 1989 Data published in full later
10 Koh 1995 Non-randomised study
11 Lane Brown 1987 Non-randomised study
12 Langner 1995 Non-randomised study
13 Lawrence 1983 Data published in full later
14 Murray1991 Non-randomised study
15 Orfanos 1979 Large case series
16 Park 1987 Non-randornised study
17 Rosinska 1987 Non-randomised study
18 Schulze 1991 Data area subset of Mahrle 1995
19 Snodgrass Cowart 1982 Editorial
20 Sonnichsen 1983 Non-randomised study
21 Stem 1995 Non-randomised study
22 Takashima 1988 Non-randomised study
23 Weinstein 1997 Mild-moderate psoriasis
24 Wanqing 1995 Non-randomised study
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8.2. Description of trials
The thirty-three trials included in the review fell into seven categories (summarised in tables 8.2-
8.8):
• comparisons of retinoids with placebo (Table 8.2)
• comparisons of acitretin with etretinate (Table 8.3)
• comparisons of retinoid-PUV A combinations with other treatments (Table 8.4)
• comparisons of retinoid-UVB (broadband and narrowband) combinations with other treatments
(Table 8.5)
• comparisons of retinoid-topical treatment combinations with other treatment (Table 8.6)
• comparisons of etretinate with cyclosporin (Table 8.7)
• comparison of different dosage schedules for acitretin (Table 8.8)
8.2.1. ReI's of retinoids to induce remission of psoriasis
In order to determine whether or not the data from the separate trials could reasonably be pooled
statistically the reports were examined to determine the degree of similarity between them
Thirteen trials concerned the use of etretinate, 11 acitretin and a further eight were comparisons of
the two drugs, either alone or in combination with PUV A (the combination known as cRePUV A').
As with the cyclosporin trials, there were considerable variations in the initial severity of the
disease, drug (retinoid) dose, success criterion and duration of treatment. Other factors which may
have contributed to the variability in the results were the mix of patients (according to disease and
gender) and compliance with the dosage regimens. Although trials involving patients with chronic
plaque psoriasis were selected (and those involving exclusively palmo-plantar pustular psoriasis
were excluded) several series contained a small number of patients with paImo-plantar pustular
psoriasis. One study specifically included patients with guttate psoriasis. (Green 1992) As
expected, in view of the documented teratogenicity of oral retinoids, the trials included a majority of
male patients, although specific exclusions for fertile females were not consistently reported.
Twelve of the 31 trials for induction of remission of psoriasis used an objective disease severity
criterion for inclusion Eleven of these were a threshold value for the percentage of body surface
area affected (range 5-2(010) and one was a threshold PAS! value (>15). The remainder of the
studies gave a description, for example, "severe psoriasis", "extensive psoriasis" or "longstanding
psoriasis" except for two in which there was no explicit criterion
Sixteen of the studies used an objective (or quasi-objective) criterion for success, such as a 75%
decrease in PASI, Psoriasis Severity Index (pSI, a modified PASn or global score. Four studies
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did not report a success criterion as such and the remainder used descriptions such as, "complete
remission", "clear", "almost clear" or "markedly improved".
The daily retinoid dose was described either as a fixed quantity or adjusted to the patient's body
weight. Almost all trial protocols allowed some modification of the dose during the trial.
Etretinate doses ranged from 30-100mglday or 0.5 -1. 0 mg/kg/day, Acitretin doses were 10-75
mg/dayor 1 mg/kg/day
The duration of treatment ranged from 8-16 weeks for trials for induction of remission. One study
(Lassus 1987) addressed both induction and maintenance of remission, reporting results at two and
six months.
8.2.2. ReI's of retinoids to maintain remission
Two trials were concerned with maintenance of remission ofpsoriasis. Dubertret and colleagues
(Dubertret 1985) selected patients with '<widespread psoriasis" affecting at least 40010 body surface
area and gave "clearance treatment" which comprised etretinate Img/kg/day in combination with
PUVA. three times per week Providing clearance (defined as a 90% reduction in initial clinical
score) was achieved within 10 weeks, patients were entered into a randomised comparison of
etretinate with placebo over a period of 52 weeks. The etretinate dose was half the highest dose
tolerated during clearance treatment. Both groups received PUVA treatment once a week for the
first two months of the maintenance treatment phase.
Lassus and colleagues (Lassus 1987) enrolled patients with "long-standing, severe psoriasis" into
their study. They compared three different doses of acitretin with placebo for both induction of
remission (8 week phase) and then for maintenance treatment (26 week phase). Inaddition to the
systemic treatment patients were allowed to use 0.1% difluocortolone valerate ointment
8.3. Comparative efficacy of retinoids
8.3.1. ReI's comparing retinoids with placebo
Nine trials compared either etretinate or acitretin with placebo. Results were extractable from six
of these trials, giving 11 patient series involving a total of 310 participants. Table 8.9 shows the
outcome criteria and response rates and figure 8.2 shows the odds ratios for the 11 patient series
and the pooled value. In spite of the factors mentioned above, heterogeneity was not demonstrated
and so a fixed effects model was used to obtain the pooled effect size (OR = 5.02, 95% Cl 2.97 -
100
8.49). It should be noted that three of the trial protocols (Lassus 1980. Lassus 1987. Melis 1984)
permitted the use of topical steroids. which. in theory. would contribute further to heterogeneity in
the results.
8.3.1.1. Sensitivity analysis
The effect size for retinoids versus placebo was calculated by different methods for all doses of
retinoids and then for doses above SO mg/day, (Fixed effects models were used for RR and OR.; the
random effects model was applied to the RD because the data were heterogeneous.) The results are
shown in Table 8.10. The conclusion that retinoids are superior to placebo is is not altered by the
method of analysis and is therefore robust However. the removal of the lower dose series clearly
increases effect size. for example the rate difference increases from 0.27 (95% Cl 0.09 - 0.45) to
0.37 (95% Cl 0.13 - 0.61). Figure 8.3 shows the corresponding forest plot for the OR It can
therefore be concluded that the effect size is sensitive to changes in dose.
8.3.2. RCI's comparing acitretin with etretinate
Five trials compared acitretin with etretinate. Results were extractable from four of these trials.
Four patient series, involving a total of 419 participants, compared equal doses of acitretin and
etretinate. Table 8.11 shows the outcome criteria and response rates and figure 8.4 shows the odds
ratios and the pooled value (OR = 1.00, 95% Cl 0.64 - 1.57) for these four series. The 95%
confidence interval for each of the individual results includes the value of zero, the data are
statistically homogeneous and the pooled value, as expected, falls on the Cline of no difference'.
This suggests that etretinate and acitretin were equally efficacious in inducing remission of
psoriasis.
8.3.3. ReI's comparing retinoid-PUV A combinations with otber treatments
Seven trials compared acitretin or etretinate in combination with PUV A against PUVA alone (with
or without placebo tablets). Results were extractable from five of these trials, involving a total of
283 participants. Table 8.12 and figure 8.5 show the odds ratios for six patient series from seven
trials for which results were available in a suitable form. Table 8.13 shows the corresponding mean
differences in number ofPUV A treatments (insufficient data were available to compare mean
differences in time to clearance or total PUV A doses). Two trials (Parker 1984, Sornmerburg 1993)
very nearly demonstrated a positive odds ratio for RePUV A versus PUVA (see table 8.12. figure
8.5). The data were statistically homogeneous and the pooled value shows a small positive effect
for RePUV A treatment The corresponding data for PUV A exposure were reported differently in
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the different studies (e.g. reduction in total PUV A dose or reduction in "time to clearance") and so
it was not possible to demonstrate a consistent reduction in PUVA exposure. Table 8.13 shows
that, in five trials for which results were available, there was a clear trend towards a reduction in
the UVA dose required. Differences in the way in which the data were collected may account for
the observed variability.
8.3.4. RCfs comparing etretinate with cyclosporin
Table 8.14 and Figure 8.6 show the success rates for two patient series from two RCI's involving
286 participants. These were both large studies and the results clearly show that etretinate was less
efficacious in inducing remission of psoriasis than was cyclosporin (odd ratios were 0.08, 95% Cl
0.01- 0.62 (Finzi 1993) and 0.11,95% Cl 0.05 -0.24 (Mahrle1995». Nevertheless it should be
noted that the response rate to etretinate in the study by Finzi and colleagues (Finzi 1993) was 0.73
(29/40), which, in itself is a very satisfactory response rate. This study used a daily etretinate dose
ofO.75 mg/kg whereas in the study by Mahrle and colleagues (Mahrle 1995) a dose ofO.5 mg/kg
was used. These trials have been described previously in section 7.3.1. The pooled odds ratio for
cyclosporin versus etretinate was 9.34 (95% Cl 4.69 - 8.62) and the reciprocal of this figure gives
the odds ratio for etretinate versus cyclosporin, 0.11 (0.05 - 0.21). As both the point estimate and
the limits of the 95% confidence interval are less than one, etretinate is clearly shown to be less
effective than cyc1osporin.
8.3.5. RCfs comparing retinoid-UVB (broad-band and narrow-band) combinations with other
treatments
Table 8.15 shows the response rates in five patient series from four trials for which results were
available in a suitable form. Three series compared a retinoid-UVB (or retinoid NBUVB)
combination with UVB alone (Green 1992, Ruzicka 1990, lest 1989). On each occasion the
combination appeared to be superior to phototherapy alone (pooled OR 4.48,95% Cl 1.95 -10.27)
(see figure 8.7). Inaddition, lest and Boer (lest 1989) compared the combination of acitretin and
UVB with acitretin alone, and again, the combination was superior to the single treatment (OR 28.
95% Cl 2.07 - 379). Green and colleagues (Green 1992) also compared a retinoid-NBUVB
I
combination with a retinoid and PUV A combination and reported no difference in success rates.
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8.3.6 Refs comparing retinoid-topical treatment combinations with other treatment s
Table 8.16 shows the success rates differences for six patient series from four trials. Three series
compared a combination of retinoid and topical steroid with a topical steroid (and placebo) (Binazzi
1981, Christiansen 1982b. van der Rhee 1980b). The results showed that the combination was
more effective than topical corticosteroids alone (pooled OR 2.63,95% Cl 1.45 - 4.71) (see figure
8.8). Two series compared the combination with systemic retinoid and placebo cream or ointment
(Christiansen 1982a. van der Rhee 1980a). Again, the combinations were superior to retinoid
alone (pooled OR 2.98,95% Cl 1.53 - 5.81).
One series compared the combination of acitretin and calcipotriol with acitretin and placebo
ointment (van de Kerkhof 1998). Once again, the combination was superior to the single treatment
(OR2.98, 95% Cl 1.47- 6.03).
8.3.7 RCfs of retinoids to maintain remission
Two trials, involving 116 participants, examined the effects of retinoids in maintaining remission.
Dubertret and colleagues (Dubertret 1985) compared etretinate with placebo over a 12 month
period. Both groups also received PUV A for the first two months. They reported that relapses
occurred more frequently in the placebo-treated group than in the etretinate treated group. Lassus
and colleagues (Lassus 1987) compared acitretin at three different dose levels with placebo. After
six months' treatment there were no significant differences between the four groups. The authors
pointed out that the final evaluation was carried out in the summer when many patients experience
"at least partial spontaneous remission", however, patients in all groups were also allowed to use
steroid ointment as required
8.4 Side effects of oral retinoids
Side effects were reported in a number of different ways (e.g. percentage of patient-weeks when
specific side effects were reported, percentage of patients reporting side effects etc) which makes it
difficult to make direct comparisons between trials. Most authors commented that skin and
mucous membrane effects were common amongst patients receiving retinoids but there was no
consistent reporting of drop-outs due to side-effects.
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8.S Discussion
This review confirmed that acitretin was as effective as etretinate in the treatment of chronic plaque
psoriasis and therefore it seemed justified to combine the results.
Comparisons of retinoids with placebo produced vel)' variable results that can. in part be explained
by the small numbers in the study by Goldfarb (Goldfarb 1988). A suggestion of a dose response
relationship is discernible with doses below 75mg/day or Img/kg/day generally performing no
better than placebo. However, the effects of concurrent topical steroid treatment (Lassus 1980,
Melis 1984 and Lassus 1987) could have improved the responses in the placebo-treated groups.
Furthermore, the mix of patients (by psoriasis type) could also have influenced the results as some
participants with palmo-plantar pustular psoriasis were included in some trials. This condition is
more difficult to treat and the inclusion of these participants may therefore have reduced the
apparent effectiveness of the retinoid treatment.
The combination of retinoid and PUV A ('rePUV A') has been recommended by leading
dermatologists for some time and this review confirms that the combination is not only superior to
PUV A alone but also appears to permit a reduction in the cumulative UVA dose required to achieve
a satisfactory response. The combination of a retinoid with UVB or. more recently, narrow-band
UVB (NBUVB) is less well known but it may offer a safer alternative to rePUV A This review
showed that the combinations of retinoid plus UVB or retinoid plus NBUVB were both more
effective than the retinoid alone. Two of the three studies concerned (Jest 1989 and Ruzicka 1990)
achieved positive results using low doses of retinoid (30 or 35 mg/day of acitretin). Only one study
compared the retinoid plus NBUVB combination with rePUV A and reported no differences in
efficacy (Green 1992). This maybe an important avenue for future research, given the perceived
advantages of NBUVB and the possibility that lower systemic retinoid doses may be required
When compared with cyclosporin, etretinate appeared to be relatively ineffective, but the individual
response rates tell a different story. In one study (Finzi 1993) etretinate was given at a dose of 0.75
mg/kgldayresulting in a success rate of 73%, which is better than the success rate achieved in all of
the placebo-controlled trials. In the other trial (Mahrle 1995) a dose of 0.5 rug/kg/day was given
and the success rate was only 16%, which lends further support to the view that doses of less than
O.75mg/kg/day are not effective.
Trials of combinations of systemic retinoids with topical treatments involved either steroids (three
trials) or calcipotriol (one trial). These trials generally had larger numbers of participants than the
other trials in this review and the results suggested a clear trend in favour of the combinations.
However, it should be noted that the endpoints of these trials were subjective for the most part.
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8.6 Conclusions
Acitretin is as effective as etretinate in the treatment of chronic plaque psoriasis, however, systemic
retinoids (acitretin and etretinate) are only modestly effective as a monotherapy for severe psoriasis.
Mucocutaneous side-effects (such as dry mucous membranes and peeling skin around the lips and
nose) occur in the majority of patients and other risks such as hyperlipidaemia and teratogenicity
must be borne in mind
Combination treatments, using a retinoid plus PUVA or a retinoid plus UVBINBUVB offer ways of
obtaining the benefits of both treatments with a lower dose of one of the treatments. Combinations
with topical corticosteroids are also more effective than either treatment alone.
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Figure 8.2: Forest plot showing odds ratios of trials of retinoids (all doses) vs. placebo.
Fixed effects (Mantel-Haenszel)
Study -
Jaoubowlcz 80
La •• us 80
Melis 84
Wol!.k.83
Goldfarb 8h
Goldfarb 88b
Goldfarb 880
Goldfarb 8ad
Lassus a7b
Lassus 87c
Lassus 870
....
i
I.
I
- I_I
!
... 1
P-"':'!. '•-r-
<±>Overall (95'11.Cl)
.00d263
Odds ratio
(95%Cl) %Weight
27.35 (1.30,1530.83) 2.0
3.07 (0.70,12.M) 19.0
.107.40 (7.37,3801.54) n.e
10.23 (1.12,93.34) 5.0
0.70 (0.02.20.03) e.r
0.70 (0.02.20.03) e.r
2.44 (0.19.31.53) 0.0
7.33 (0.48.111.1II) 2.7
2.00 (0.52.7.72) 23.0
4.50 (1.17.17.37) 15.3
8.00 (1.154,23.38) 13.1
5.02 (2.97,8.49)
I
3801.64
Odds ratio
Heterogeneity chi-squared = 11.88 (df. = 10) p= 0.293; Test ofOR=1 : z= 6.03 p = 0.000
Figure 8.3: Forest plot showing odds ratios of trials ofretinoids (doses of 50m~day and above) vs.
placebo.
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Figure 8.4: Forest plot showing odds ratios of trials comparing acitretin (doses of 30mty'day or
above) with etretinate.
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Figure 8.5: Forest plot showing odds ratios of trials comparing RePUV A with PUV A with or
without placebo.
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Figure 8.6: Forest plot showing odds ratios of trials comparing etretinate with cyclosporin
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Figure 8.7: Forest plot showing odds ratios of trials comparing ReUVB with UVB alone
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Figure 8.8: Forest plot showing odds ratios of trials comparing retinoid-steroid combinations with
topical steroids alone.
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Chapter 9
Systematic review of trials of oral methotrexate for severe psoriasis
Summary
Methotrexate has been used in the treatment of psoriasis for many years, no eligible RCTs were
located for this review. It was therefore not possible to derive estimates of effect size based on the
level of evidence demanded by the project protocol.
9.1 Search results
One hundred and eleven citations were identified for methotrexate and psoriasis. Thirty-one
citations concerned the therapeutic use of methotrexate for psoriasis. The titles and abstracts were
reviewed by two people independently (the author and a consultant dermatologist) to identify
possible RCTs. Twenty-nine proved to be case series, retrospective reviews or individual case
reports. Two appeared to be reports of RCTs. Both were retrieved and read but failed to fulfil the
criteria for inclusion (see Table 9.1). No RCT was identified in which standard methods of
methotrexate administration for psoriasis were compared either with placebo or with any alternative
treatment modality in patients with chronic plaque psoriasis.
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Figure 9.1 Flow chart to show trials of methotrexate excluded
Therapeutic use of MTX :
31 citations
29
Case series,
Retrospective reviews,
Case reports
Unconventional use of MTX
Insufficient data
1
1
2 Apparent RCI's
JJ
No trials available
for review
Total 2
Table 9.1 Methotrexate studies excluded
First autbor and year of publication Reason for EIclusion
1 Liang 1995 Not a RCI' of methotrexate in the conventional sense.
(Participants were randomised to receive either a large,
single intramuscular dose of methotrexate or no injection
before receiving a variety of other systemic and topical
therapies. Patients included those with all types of
psoriasis (guttate, plaque. erythrodermic or pustular»
2 WilIkens 1984 Results not extractable: Study designed to examine
efficacy of methotrexate in psoriatic arthritis rather than
psoriasis; no baseline data on psoriasis severity included;
minimal assessment of changes in psoriasis severity
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9.2 Discussion
The absence of randomised, controlled trials of methotrexate in the treatment of severe psoriasis is
an interesting finding as the drug has had a role in the management of this condition for about
thirty years (Said 1997). The results of this study most probably reflect the fact that methotrexate
was introduced at a time before the RCI' was the standard method for assessing drugs. It is not an
expensive drug per se, and by the time its role in psoriasis was recognised and established, its
patent had expired and there was no commercial interest in conducting RCTs. Nevertheless. there
remains a substantial clinical interest in formal assessment of this drug. This will be necessary in
order to determine its effect size relative to other treatments for severe psoriasis and to perform
economic evaluations. These would be particularly important as the drug itself is inexpensive but
the risk of serious side effects and consequent requirement for rigorous monitoring make the picture
more complex than might, at first, be expected
9.3 Conclusions
On the basis of this systematic review it is not possible to provide an estimate of effect size for
methotrexate. This is not to say that no evidence for the effectiveness of methotrexate exists, but
that no evidence of the standard required by the protocol, that is, RCI's, could be found
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Chapter 10
Systematic review of trials of phototherapy and photochemotherapy for severe
psoriasis
Summary
Fi.fty eligible RCTs. reporting 55 comparisons were locared for this review. The trials ore grouped
into six broad categories according to the types of comparisons involved: psoralen
photochemotherapy treatment schedules; UVB treatment schedules; photochemotherapy versus
other phototherapy; phototherapy in combination with retinoids; photochemotherapy using
sunlight and phototherapy with topical treatments. There were insufficient similarities between
trials to allow pooling of the results. The results are shown as rate differences together with
differences in the doses of UV radiation.
10.1 Search Results
Trials of phototherapy and photochemotherapy for psoriasis were identified using the search
strategy described in Chapter 6. Three hundred and thirty two citations were identified for
psoriasis and PUVA, UVA or UVB. These included studies of the therapeutic use ofPUV A, UVA
or UVB (ReI's, cohort studies, retrospective studies, case reports & small series) together with
reviews and studies of biochemical effects of phototherapy. The titles and abstracts were reviewed
by two people independently (the author and a consultant dermatologist) to identify ReI's. Ninety-
six records that appeared to be reports of ReI's were retrieved and read. Thirty-six were excluded
because they were non-randomised studies (or partially-randomised). Two animal studies were also
excluded. A further four studies were excluded because they involved non-randomised, left/right
comparisons and four were excluded as the evaluation depended on the response in target lesions
only. Non-randomised, left-right comparisons were excluded because this design leaves open the
possibility that the investigator could select patients with particular patterns of disease, although,
theoretically, only patients with perfectly symmetrical disease would be eligible for such studies.
Studies that assessed the response in target lesions only were excluded because this is not an
approach that reflects the real-life treatment situation and the results of such studies were not
considered comparable with the others included in the review. These 46 reports were excluded from
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the final list (See Table 10.1) Thus, 50 RCfs, providing 55 comparisons, were available for
inclusion in this review. (See Figure 10.1)
Figure 10.1: Flow chart to show phototherapy and photochemotherapy trials excluded.
Non-random trials
Animal trials
Non-random LIR
Target lesions only
Total 46
36
2
4
4
96 Apparent RCI's
Trials included
PUVA treatment schedules
UVB treatment schedules
PUV A vsother phototherapy
PUV AI UVB and retinoids
UV from sunlight
PUBA!UVB and topical treatment
Total 55
[Note - some trials appear in more than one
category]
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9
5
5
10
3
23
Table 10.1 Studies excluded from phototherapy & photochemotherapy review
First author and year of publication Reason for exclusion
1 Bedi.1979 Non-randomised allocation
2 Berne 1990 Target lesions evaluated
3 Boer 1984 Non-randornised allocation
4 CaIzavara Pinton, 1994a Non-randomised allocation
5 Calzavara Pinton 1994b Non-randomised allocation
6 Coven 1997 Non-randomised allocation
7 Danno 1983 Non-randomised left/right
comparison
8 Darouti, 1988 Non-randomised allocation
9 Diette, 1984 Non-randomised allocation
10 Dubertret, 1979 Animal study, non er
11 Dubertret, 1979 Animal study, non er
12 Galosi, A; Dorn, M, and Przybilla, B. 1985 Non-randomised allocation
0-
13 Eells 1984 Target lesions evaluated
14 Elbracht, 1983 Non-randomised allocation
15 Fischer 1977 Non-randomised allocation--
16 Fotiades, 1995 Non-randomised allocation
17 George 1993 Non-randomised allocation
18 Gould, 1978 Non-randomised left/right
comparison
19 Grupper 1981 Non-randomised allocation
20 Hofmann 1980 Non-randomised allocation
21 Honigsmann 1977 Non-randomised allocation
22 Kar 1994 Non-randomised allocation
23 Karvonen 1989 Non-randomised allocation
24 Kenicer 1981 Non-randomised allocation
25 Kokelj 1996 Non-randomised allocation,
26 Lane Brown 1981 Non-randomised allocation
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Table 10.1 continued
First author and year of publication Reason for exclusion
27 Langner 1976 Non-randomised allocation
28 Ledo1981' Non-randomised left/right
comparison
29 Lowe 1986 Non-randomised allocation
30 Melski 1917 Partirulyrandomised
allocation
31 Momtaz 1984 .Non-randomised allocation
32 Nowakowski, 1979 Non-randomised allocation
33 Ortel,1993 Non-randomised allocation
34 Park, 1985 Non-randomised allocation
35 Paul 1982 Non-randomised allocation
36 Petzelbauer, 1990 . Non-randomised allocation
37 Pullmann,1976 Non-randomised allocation
38 Roenigk 1979 .. Non-randomised allocation
39 Sonnichsen,I983 Non-randomised allocation
40 Speight 1994 Non-randomised left/right
comparison
41 Swanbeck 1975 Non-randomised allocation
42 Takashima 1988 Target lesions evaluated
43 Talwa1kar1981 .Non-randomised allocation
44 Wainwright 1998 T-arget lesions evaluated
45 Wolff 1976 Non-randomised allocation
46 Zhang 1983 Non-randomised allocation
10.2 Description of trials
The characteristics of the trials are summarised in Tables 10.2 -10. 7
These SS comparisons may conveniently be divided into:
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• comparisons of treatment schedules for psoralen photochemotherapy (Table 10.2)
• comparisons ofUVB treatment schedules (Table 10.3)
• comparisons of photochemotherapy with other phototherapy treatment schedules (Table
10.4)
• comparisons of phototherapy and retinoids with phototherapy or retinoids (Table 10.5)
• photochemotherapy trials using sunlight as the UV source (Table 10.6)
• comparisons of phototherapy and/or topical treatment schedules (Table 10.7)
Inorder to decide whether or not the data from the separate trials could reasonably be pooled
statistically the reports were examined to determine the degree of similarity between them.
Twenty-two trials concerned the use of UVA. 21 the use of UVB and five trials involved both UVA
and UVB. The remaining three trials used natural sunlight as the UV source.
Although trials involving patients with chronic plaque psoriasis were selected (and no studies of
phototherapy specifically for guttate psoriasis were found) several series contained a number of
patients with guttate psoriasis. In none of these was randomisation stratified by psoriasis type.
Thirteen of the trials used an objective disease severity criterion for inclusion. All of these were
threshold values for the percentage of body surface area affected (range 10-40%). The remainder
of the studies gave a description such as "severe psoriasis", "widespread psoriasis", ''psoriasis
severe enough to require PUV A" or simply "psoriasis",
Phototherapy regimens were described in detail (dose. frequency and dose adjustments). The
duration of treatment was described in weeks or by the number of phototherapy exposures and trial
periods varied between two and ten weeks.
Nineteen of the trials used an objective (or quasi-objective) criterion for success such as a 75%
decrease in PAS!, modified PAS! or global score, similar to trials of.oral agents. The remainder
either did not report a success criterion or relied on descriptions such as "clear", "complete
remission", or "satisfactory response". This reflects the established practice with phototherapy and
photochemotherapy, where treatment is continued until the skin is clear. The mixture of outcome
criteria makes it difficult to compare many of the trials directly.
Inaddition to the mixture of outcome criteria, there were considerable variations in the initial
severity of the disease, phototherapy doses, success criteria and duration of treatment Other factors
that may have contributed to the variability in the results are the mix of patients, both in terms of
type of psoriasis and skin type. and compliance with treatment
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10.3 Comparative efficacy
10.3.1 RCI's comparing treatment schedules for psoralen photochemotherapy (pUV A):
RCI's involving oral psoralens
Six trials compared different treatment regimens using oral psoralens (Table 10.2).
RCTs comparing psoralen doses
Two trials, involving a total of 162 patients, examined the effects of different psoralen doses for
PUVA. Andrew and colleagues (Andrew 1981) showed that 8-methoxypsoralen (8-MOP) at a dose
of 40mg was associated with a greater success rate than 8-MOP at a dose of 10mg (RD = 0.72, 95%
Cl 0.54 - 0.90). Furthermore, a lower mean cumulative UV dose was required to achieve success
(54.0 J/crn2; range 14.5 - 115. compared with 77.0 J/cm'2; range 46-113. respectively). Similarly.
Tanew and colleagues (Tanew 1988) showed that 5-methoxypsoralen (S-MOP) cleared psoriasis
with a significantly lower mean cumulative UVA dose when given at ~ dose of 1.2 mg/kg (53 ± 33
J/cm'2) rather than 0.6 mg/kg (132 ± 87 J/cm2).
RCTs comparing psoralens and psoralen formulations
Liquid versus crystalline psoralen
Lowe and colleagues (Lowe 1987) compared different formulations of the same psoralen in a group
of 47 patients. Liquid 8-MOP appeared to be more effective than crystalline 8-MOP, but just failed
to show a difference in effect size (RD = 0.25,95% Cl -0.01- 0.51). There was no significant
difference in the total energy requirements for the two groups (68.7 J/cm2 for liquid vs 80.8 J/cm2
crystalline psoralen).
OralS-MOP versus oral 5-MOP
Two studies compared oral8-MOP with oral 5-MOP. (Berg 1994, Tanew 1988) In the study by
Tanewand colleagues (Tanew 1988). involving 106 patients. two doses of S-MOP (0.6 mg/kg and
1.2 mg/kg; see above) were compared with 8-MOP 0.6 mg/kg, They found no difference in the
mean cumulative UVA dose required to achieve clearance between 8-MOP, 0.6 mg/kg (45 ± 32
J/cm2) and 5-MOP 1.2 mg/kg (53 ± 33 J/cm2). but the lower dose of 5MOP. 0.6 mg/kg, required a
much larger mean dose of UV A (132 ± 87 J/cm2). Berg and Ros (Berg 1994), on the other hand, in
a trial involving 38 patients, observed lower success rates at both six ~d nine weeks with 5-MOP
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1.2 mg/kg than with 8-MOP 0.6 mg/kg, The 8-MOP group required a significantly lower UV dose
(ISS vs 187 J/cm2, p<O.OS) and cleared significantly more rapidly (61 days vs 68 days. P<O.OS).
The results may be partially explained by slow absorption of the S-MOP, which appeared not to
reach peak plasma levels until 3 hours after ingestion although UVA was given at 2 hours. Side-
effects (severe erythema, pruritus and nausea) were reported in 18 patients receiving 8-MOP but
only in 4 patients receiving high dose S-MOP and in no patients receiving low dose S-MOP.
Tanning started earlier with S-MOP and developed more rapidly than with 8-MOP.
RCTs comparing different UVA schedules
Two trials compared the effects of a minimal phototoxic dose (MPD) of UVA with a dose based on
skin type. Collins and colleagues (Collins 1996) reported no difference in the success rates (RD =
0.03,95% er -0.14 - 0.20) in a trial involving 74 patients. However, the MPD group required
fewer exposures (11 vs.14) but a greater cumulative UVA dose (62.9 J/cm2 vs. 39.5 J/cm2).
Buckley and colleagues (Buckley 1995), in a trial involving 83 patients also found no difference in
success rates (RD = O.03~95% Cl -0.12 - 0.18). They showed that the MPD group took
significantly longer to clear (50.0 days, 95% Cl 43.0 - 66.0 vs. 41.0 days, 95% er 36.0 - 50.0~
p<O.OS) and, again, required a higher median cumulative UVA dose (78.5 J/cm2 95% er 59.5-
113.0 vs. 66.5 J/cm2 95% er 44.0- 90.0) although this did not reach statistical significance. Skin
types I and IT(fair, easily burnt and poorly tanning skin) required significantly higher cumulative
UVA doses using the MPD method than with the method based on skin type (70.0 J/cm2. 95% er
55.5 - 112.5 vs 55.8 J/cm2 QS% Cl 36.5 - 71.5~ p< 0.05).
RCTs involving topical psoralens
Bath PUVA versus oral PUVA
Two trials compared bath PUV A with oral PUVA Collins and R<>&ers(Collins 1992), in a trial
I
involving 44 patients, showed no difference in success rates between bath (8-MOP) and oral (8-
MOP) PUV A (Rn = 0, 95% Cl -0.28 - 0.28). A 4-fold difference in cumulative UVA dose (14.5 ±
9.8 J/cm2for bath PUVA and 60.1± 25.4 J/cm2for oral PUVA) was reported. Similarly, in a trial
involving 93 patients, Turjanmaa and colleagues (Turjanmaa 1985) compared trioxsalen bath
PUV A with oral 8-MOP and showed no difference in success rates (RD = -0.02, 95%CI -0.17 -
0.13) but a similar reduction in mean cumulative UVA dose required for clearance (23.5 J/cm2•
range 0.7 -143 vs. 131.1 J/cm2 range 7.5 - 543).
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Bath (5-MOp) PUVA versus bath (8-MOp) PUVA
CaIzavara-Pinton and colleagues, in a trial involving 10 patients (CaIzavara-Pinton 1997) found
little difference in efficacy between topical5-MOP and topical 8-MOP. All patients in both groups
were treated until their psoriasis had cleared. There was no difference in mean total UVA dose
(56.8 ± 39.2 SDvs. 59.1± 27.9 SD J/cm2) or number of exposures (20.0 ± 5.7 vs. 21.6 ± 4.7),
however, given the numbers involved, it is unlikely that this trial would have had the power to
detect the modest difference that might have been expected
10.3.2 RCI's comparing UVB phototherapy treatment schedules
Table 10.3 shows the results of the five trials that compared UVB treatment schedules. All five
trials used a randomised left/right comparison and 107 patients were randomised Larko (Larke
1989), Picot (Picot 1992) and Storbeck (1993) compared NEUVB with conventional broad band
(BBUVB) in left/right randomised studies. From the data reported it was not possible to calculate
response rates in the two groups (sides). InLarke's study, both sides improved and no differences
were recorded in symptom scores (erythema, infiltration. desquamation and itching). The low
power of the lamps used in this trial meant that irradiation times with NBUVB were on average
1.74 times longer than with BBUVB but the average UV energy required was considerably lower
than with BBUVB (0.83 J/cm2 for NBUVB and 4.8J/cm2 for BBUVB). Storbeck and colleagues
compared NEUVB and BBUVB but also allocated 13 of 23 patients to receive dithranol treatment
Narrow-band UVB was reported to be more effective. The mean cumulative UVB doses were 14.68
± 9.84 J/cm2 (NEUVB) and 1.43 ± 1.13 J/cm2(BBUVB). Picctand colleagues reported average
reductions in PAS! score of 78.5% (NBUVB) and 73.9l'1o(BBUVB). These differences were
reported to be statistically significant (p<O.OI), however, results are reported for 15 patients
although 21 were originally enrolled No details are given about the reasons for withdrawal from
the study. In the absence offurther detail it is difficult to be confident in the authors' conclusion
that NEUVB is more effective than BBUVB. In this study, the mean cumulative UV doses were
15.1 ±3.8 J/cm2(NBUVB}and 7.6 ±4.2 J/cm2(BBUVB). The authors suggested that this was due
I
to the rarity and mildness of episodes of erythema caused by TL-Ollamps (NEUVB), allowing
steady increases in UV dose.
The two other studies compared different regimens for NEUVB. Dawe and colleagues (Dawe
1998) compared a fixed number of UVB exposures delivered either as a thrice weekly or 5-times
weekly regimen Psoriasis cleared more quickly with the 5-times weekly regimen but this was
achieved at the expense of a higher UVB dose and more treatments. Expressed in multiples of the
individuals' MEDs, the5 ..times-weekly sides received a median UVB dose of94 (range 27-164)
compared with 64 (range 23-125) for the 3-times-weekly sides. Hofer and colleagues (Hofer 1998)
compared NEUVB regimens with initial doses of different intensity (starting doses of 35% MED vs
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70% MED). After three weeks of treatment there was no difference in success rate (RD = -0.23
95% Cl -0.58 - 0.12). The group that had started with low-intensity irradiation required a median
of 16 treatments compared with 12 but received a total cumulative UV dose of9.1 J/cm2 (range
6.28 - 24.32) compared with 14.0 J/cm2(range 7.29 -21. 7) for the group that had the high-intensity
starting dose.
10.3.3. RCI's Comparing PUVA with other phototherapy schedules
Five trials compared PUV A with other phototherapy schedules (Table 10.4). Van Weelden (Van
Weeldon 1990) compared oral 8-MOP PUV A with NBUVB. In this trial the therapeutic
effectiveness of the two treatments was compared by means of "overall impression". in a left/right
comparison in 10 patients. Seven patients preferred NBUVB and three preferred PUV A. Neither
total UV doses nor the number of exposures were reported De Berker and colleagues (de Berker
1997) compared oral PUV A with psoralen plus NBUVB (PNBUVB). in 100 patients. There was no
difference in success rates (RD = -0.1295% Cl -0.28 - 0.04) or the number of exposures required
for clearance but the UVA group received a median cumulative dose of 72.1 J/cm2 compared with
19.1 J/cm2 in the UVB group.
Two trials compared PUV A. using topical 8-MOP, with UVA alone. Pai and Srinivas (Pai 1994)
reported a success rate difference of 0.67 (95% Cl 0.38 - 0.96), using a "bathing suit" delivery
system. Mizuno and colleagues (Mizuno 1980) compared PUV A using topical 8-MOP lotion with
UVA and a placebo solution but the results were not extractable.
Van Weelden and colleagues (Van Weeldon 1980) compared oral 8-MOP PUV A with combined
UVB plus UV A given with placebo capsules (pUV AB). There was no difference in the mean
number of exposures required to achieve 80010clearance (25 ± 5 for PUV A and 28 ± 6 for
pUVAB). The average final doses ofUVA were similar (14.4 ± 1.6 J/cm2for the PUVA group vs
13.2 - 13.8 J/cm2 for the pUV AB group) however the pUVAB group also received an average final
dose of 2416 ± 693 mJ/cm2 of UVB. The authors concluded that UVB +UVA phototherapy was as
effective as oral PUV A. It is not possible to determine how either of these schedules compares with
BBUVB alone.
10.3.4. ReTs comparing phototherapy and retinoids with phototherapy or retinoids
Trials comparing phototherapy and retinoids with phototherapy or retinoids are summarised in
Table 10.5. The results have been described in detail in Chapter 8.
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10.3.5 RCI's comparing photochemotherapy using sunlight as the UV source
Three trials used natural sunlight as the UV light source (Table 10.5). Two trials, involving a total
of 52 participants compared sunlight plus psoralen with sunlight alone and one trial compared two
different psoralens. None of the trials compared the effects of natural sunlight with artificial
radiation. Sehgal and Parikh (Sehgal 1981) showed that 8-MOP and trimethyl-psoralen were
equally effective, although the response rates in both groups were low (6/17 vs 6/23). Sadananda-
Naik(Sadananda-Naik 1981) showed that the combination of natural sunlight and an unspecified
psoralen was considerably more efficacious for clearing psoriasis than sunlight alone. (RD 0.6, 95%
Cl 0.39 - 0.81)
10.3.6 RCI's comparing phototherapy and/or topical treatment schedules
Eighteen trials in which phototherapy was compared with various forms of topical therapy or
combined topical and phototherapy were located They are summarised in Table 10.6
Phototherapy or photochemotherapy vs. dithranol
Larko(Larko 1983) compared a special formulation of dithranol (psoradrate®) with UVB in a trial
involving 100 participants. Success rates were unfortunately not reported
Rogers and colleagues (Rogers 1979) and Vella-Briffa and colleagues (Vella-Briffa 1978) reported
different aspects of the same trial comparing PUVA with a standard dithranol regimen. There were
224 participants in the trial. The response rates for both treatments were high (0.91 [pUVA] vs
0.82 [dithranol]) but the time required for clearance was significantly greater in the PUVA-treated
group (34.4 ± 1.8 (se) days [PUVA] vs 20.4 ± 0.9 (se) days [dithranol]).
Treatment schedules involving phototherapy and dithranol
Five trials compared different combinations of phototherapy with dithranol. Three involved the use
ofUVB and one the use ofPUVA Brandt (Brandt 1989) undertook a left/right trial of3%
dithranol sticks compared with 0.5 - 1.0010dithranol in white soft paraffin. Treatment was
combined with either sub-erythematous UVB (seUVB) starting before dithranol treatment or
minimally erythematous UVB (meUVB) starting 3 days after dithranol treatment There was no
difference in response to the two dithranol preparations or in the cumulative UVB doses. The time
taken to achieve clearance was, however, shorter in the seUVB group (4.9 weeks) than in the
rneUVB group (6.2 weeks). Christensen and colleagues (Christensen 1989) compared the
combination of UVB with either micro-encapsulated dithranol 1% or extemporaneously prepared
1% dithranol in a left/right, within-patient trial. There was no difference between the treatments,
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both clearing psoriasis in 21 of 37 patients in a period of 2-6 weeks. Paramsothy and colleagues
(paramsothy 1988) compared short contact dithranol in combination with tar and UVB with short
contact dithranol in combination with an emulsifying ointment bath in a trial involving 53
participants. There was no difference in success rates (RD 0.12 95% Cl -0.13-0.37) but the UVB
treatment regimen appeared to postpone relapse (10.6 weeks versus 18.9 weeks, p<O.OS). Morison
and colleagues (Morison 1978) compared concurrent PUV A and dithranol with PUV A preceded by
6 weeks of dithranol treatment. Although there was no difference in success rates, (RD -0.11,95%
Cl -0.37 - 0.15) the concurrent treatment cleared psoriasis in 60 days compared to 108 days. The
corresponding cumulative UVA doses were 12 (range 4-35) J/cm2 compared to 13 (range 5-27)
J/cm2•
In each of these trials it appears that the addition of phototherapy reduced response time or, in the
case of Morison, prolonged remission..
Treatment schedules involving phototherapy and tar
Three trials compared phototherapy treatment schedules with and without tar. Menkes and
colleagues (Menkes1985) compared suberythematous UVB in combination with tar oil with
maximally erythematous UVB and emollients. There was no difference in success rates but the
cumulative UV dose required for clearance was significantly lower for patients treated with tar oil
(2.53 vs 4.57 J/cm2• p<0.05). Morison and colleagues (Morison 1978) compared concurrent PUVA
and tar with PUV A preceded by six weeks of tar treatment As only two patients were entered into
the sequential arm of the study it is difficult to draw conclusions from this study. Similarly. a study
by Williams (Williams 1985) comparing PUV A with a UVB and tar combination involved only six
participants. and so it was not possible to draw any firm conclusions.
Treatment schedules involving phototherapy and vitamin D~ analogues
Seven trials compared combinations of phototherapy and vitamin D3 analogues with phototherapy
alone or vitamin D analogue alone.
Two trials, involving 127 participants, compared the combination ofPUVA and calcipotriol (D-
PUV A) with PUV A and placebo cream. Aktas and colleagues (Aktas 1995), in the smaller of the
two trials (20 participants) reported no difference between the two treatments but Frappaz and
colleagues (Frappaz 1993) showed a success rate difference ofO.19 ( 95% Cl 0.01 -0.37). In this
trial the cumulative UVA dose was significantly lower in the D-PUV A group (30 J/cm2 vs 57 J/cm2,
p= 0.021)
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One trial compared the combination of NEUVB phototherapy and calcipotriol with phototherapy
alone. (Bourke 1997) Although success rates could not be extracted from their trial, Bourke and
colleagues reported a significantly greater fall in PAS! in the group receiving combination
treatment than in the group receiving UVB alone.
Three trials (Kragballe 1990, Kerscher 1994, Molin 1993) compared combinations of calcipotriol
and either BBUVB or NBUVB with calcipotriol alone. In each trial, the combination was reported
to be superior to treatment with calcipotriol alone. The trial reported by Kragballe did not
demonstrate a success rate difference between the two treatments (RD = 0.2, 95% Cl -0.06 - 0.46).
Rocken and colleagues (ROcken 1998) compared the combination of tacalcitol and NBUVB with
tacalcitol alone. Treatment success rates could not be extracted from this trial but the authors
reported a significantly greater fall in the mean severity score for the combination treatment after
three weeks.
Treatment schedules involving phototherapy and steroids
Five trials compared combinations of phototherapy and topical steroids with a variety of
comparators. Three concerned combinations with UVB phototherapy and two involved PUVA.
Larka and colleagues (Larke 1984) compared the combination ofUVB and clobetasol propionate
with each treatment alone. The success rate differences did not differ between the three treatments.
Lidbrink and colleagues (Lidbrink 1986) compared a UVB/dithranoVsteroid combination with the
UVB/dithranol combination. Although there was no difference in treatment success rates, the time
to healing was significantly faster in the steroid treated group (2.5 vs. 4.0 weeks. P<0.05). Horwitz
and colleagues (Horwitz 1985) examined the effects of the addition of steroid (hydrocortisone
valerate) to a combination of sub-erythematous UVB and tar. There was no difference in success
rates and the addition of steroid cream did not reduce the number of treatments required for
clearing. The average duration of remission was significantly shorter for the steroid treated group
(5.9 weeks versus 17.9 weeks for the control group). Hanke and colleagues (Hanke 1979) examined
the effects of the addition of betamethasone valerate to PUVA treatment. There was no difference
in success rates but the combination took effect more quickly and required a lower cumulative UV
dose than PUVA alone (69.96 J/cm' [range 26.5 - 171.5] versus 133.71 J/cm' [range 44.5 -284]).
Morison and colleagues (Morison 1978) compared concurrent PUVA and topical steroid with
PUVA preceded by 6 weeks of steroid treatment There was no difference in success rates or in the
cumulative UVA doses required for clearance (1111cm', range 3-25 compared to 12J/cm', range 0-
18) although the sequential treatment took longer to clear psoriasis (l08 days vs 59 days)
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Treatment schedules involving phototherapy and fish oil
Gupta and colleagues (Gupta 1989) examined the effects of the addition of fish oil to low dose UVB
phototherapy. Treatment success rates could not be extracted from this trial.
10.4Withdrawal from treatment due to adverse effects or lack of efficacy
It was not within the scope of this study to extract data on withdrawals from treatment due to
adverse effects or lack of efficacy.
10.5 Sources of heterogeneity
It was not possible to pool any of the data from the trials identified because of marked heterogeneity
of trial design. The sources of heterogeneity included initial severity of disease, phototherapy doses
and regimens, success criteria, duration of treatment, the mix of psoriasis sub-types, the mix of skin
types and compliance. Because of these factors and the small size of many of the trials, conclusions
can only be tentative.
10.6 Discussion
PUVA.
Although PUVA is a well-established treatment for psoriasis only one trial comparing oral PUV A
with UV A alone was located (pai 1994) and one trial comparing topical PUV A with UVA alone.
As expected. these trials showed that UVA alone did not clear psoriasis.
Oral PUV A was first used in 1974 (parrish 1974) when randomised controlled trials were rapidly
gaining acceptance as the standard means of assessment for new treatments. The absence of a
number ofRcrs here probably reflects the fact that different standards have been applied to the
adoption of 'instrumental' techniques for treatment Furthermore, the market for psoralens in
small and the products have not been attractive to any major pharmaceutical company. In the UK,
psoralens are still unlicensed medicines.
A number of trials were concerned with comparisons of PUV A treatment schedules. Broadly, these
were designed to elucidate the optimum dose and mode of delivery of psoralen and the most
effective way of dosing UVA. The trials showed that PUV A using 8-MOP or 5-MOP in doses of O. 6
·1.2 mglkg was effective in clearing psoriasis. There was a dose-response relationship and the dose
of psoralen appeared to be inversely related to the dose of UVA required PUV A using topical
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psoralen ("Bath PUV A") was as effective as oral PUV A but required a lower cumulative UVA dose
(Collins 1992. Turjanmaa 1985). This is an important observation that could be used to justify
greater use ofbath-PUVA. Other arguments in favour ofbath-PUVA include the fact that patients
receiving oral PUV A are obliged to wear sunglasses (to minimise the risk of cataract formation)
and avoid sunlight on the day of treatment (to avoid accidental sunburn) and suffer occasional
nausea from the oral psoralen.
Two trials (Collins 1996, Buckley 1995) had compared dosing of UVA according to MPD with
dosing based on skin type and had produced conflicting results. Both trials showed that the MPD-
dosed group required a higher cumulative UVA dose but in the earlier trial (Buckley 1995) more
treatments were required and in the later trial (Collins 1996) fewer treatments were required The
explanation for these observations is not clear. Both trials had similar proportions of participants
with skin types I and II (approximately 66%) and similar total numbers, however, Buckley used a
parallel group design and Collins used a half-body. within-patient comparison. Clearly. Collins
and colleagues had the stronger design and so their results should be given greater weight.
UVB
UVB has been used in the treatment of psoriasis for many decades. No trials comparing UVB with
placebo were located. This presumably reflects the established position of UVB in the conventional
treatment hierarchy for psoriasis.
It has been suggested that "narrow-band" UVB (311nm) offers the possibility of clearance with
fewer episodes of erythema and, possibly, a lower cumulative dose of UYB. The five trials that
were found concerned comparisons of UVB and narrow-band UV.B and comparisons of dosing
methods for NBUVB. Comparisons of UV.B and NBUVB suggested that NBUVB was at least as
effective as BBUYB and was associated with a lower risk ofburning. allowing a progressive
increase in dose. This might explain why, in two trials, the cumulative dose of UVB was higher
using NBUVB.
The two trials that examined dosing methods for NBUYB produced broadly concordant results
(Dawe 1998, Hofer 1998). They showed that clearance could be accelerated but only at the expense
of a higher UVB dose and more exposures. Given the presumed (but unknown) carcinogenicity of
UVB most photobiologists would recommend the lowest dose that produces the desired effect. On
the basis of these trials. three-times-weekly dosing could be recommended, starting with doses of
less than 70% of the MED.
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Other trials
On the basis of the trials located the following tentative conclusions can be drawn:
It is not known how narrow-band or broad-band UVB compares with PW A. UVB plus W A may
have similar efficacy to PW A.
PW A or UVB in combination with retinoids appears to be more effective than either treatment
alone (discussed in detail in Chapter 8). Furthermore, the combination of systemic retinoids, i.e.
acitretin or etretinate, with PUVA reduces the cumulative dose of PW A required for clearance and
it has been suggested that this may slow the development of skin cancers.
There are no evaluable RCTs that compare the effects of adding topical tar to either PW A or UVB
with PWA or UVB alone.
One trial shows that PUVA is as effective as daily dithranol in clearing psoriasis but there are no
trials that evaluate the effects of adding PUV A to dithranol treatment.
Combinations of phototherapy or photochemotherapy with vitamin D3 analogues suggest that the
combinations are superior to each agent alone.
Combinations of phototherapy or photochemotherapy with topical steroids suggest that the
combinations are superior to each agent alone.
10.7 Conclusions
Although it is not possible to derive effect sizes for PUVA. BBUVB or NBUVB from placebo-
controlled trials, the response rates in the arms of trials that have used these treatment modalities
suggest that all three are able to clear psoriasis in 80-90010of patients treated The major concern
with the use PUVA, particularly in the long-term, is the increased incidence of non-melanoma skin
cancer. For this reason guidelines recommend that the maximum cumulative UVA dosage should
not exceed 1000 l/cm2• NBUVB holds the promise of effective treatment without the risk of
burning associated with BBUVB. It is also attractive to patients because treatment does not involve
tablets or baths. However, the risks of skin cancer with BBUVB and NBUVB are as yet unknown.
Although UVB does not penetrate the skin to the same depth as UVA. it is much more energetic
and capable of altering DNA directly (Ortel 1998». Long-term surveillance will be needed to
determine the level of risk associated with its use. In the meantime long-term and short-term
randomised, controlled trials are required to compare PUVA and NBUVB.
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Chapter 11
Therapeutic Gain and NNTs
Summary
Therapeutic gain' is a term thai can be used to describe the difference between experimental and
control treatments. It is also known as the absolute benefit increase (ABI). The reciprocal of the
ABI gives the number needed to treat (NN1). ABIs and NNTs have been calculatedfor treatments
for severe psoriasis involving cyolosporin, retinoids, phototherapy and photochemotherapy. The
results show that the calculated NNTs mainly fall into the accepted range for effective treatments.
11.1 Description of effect size as therapeutic gain or absolute benefit increase
'Therapeutic gain' is a concept that is particularly relevant to treatments that deliver beneficial
effects, such as cure or clearance of disease, rather than those that prevent or delay the occurrence
of undesirable effects. It may be defined as the difference between the proportions of patients
achieving the effect with the experimental and control treatments. In numerical terms it is the same
as the absolute risk difference (or rate difference). Confusion arises because many early studies in
the EBM arena were concerned with the effects of treatment on the reduction of risks, for example,
the reduced risk of cardiac death following the use of thrombolytic agents. As a result, the absolute
risk reduction (ARR) is commonly cited in textbooks. However, when a treatment causes a positive
beneficial effect the 'risk' of improvement increases. This could be described as an absolute risk
increase, but the terminology is uncomfortable for non-statisticians, and so the term 'absolute
benefit increase (ABI)' has been adopted (Sackett 2000). An alternative expression for 'absolute
benefit increase' is 'therapeutic gain'. This has the merit that it is immediately understandable for
clinicians as it answers the question, 'How many more patients improve on this treatment relative
to the control treatment?'
One of the reasons why the ABI is understandable for clinicians is that it distinguishes and
preserves the baseline risk, whereas relative descriptions of effect size do not reflect risk of event
without therapy and therefore cannot distinguish between large and small treatment effects. For
example, a treatment that cures 60010 of patients compared with a placebo response rate of 30%, has
a relative benefit increase (RBI) of 100010, however, a treatment that cures 1% of patients compared
with a placebo response rate of 0.5%, will also have a RBI of 100010. The corresponding ABIs
would be 0.3 and 0.005.
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The other advantage of the ABI is that it can readily be converted into the 'number needed to treat
(NNT)'. that is the number of patients that need to be treated in order to achieve one additional
beneficial outcome. This is numerically equivalent to the reciprocal of the AB!. Using the figures
from the example above, the first case has an ABI of 30% (0.3) which is equivalent to a NNT of
four (calculated value = 3.3). By convention, NNTs are always rounded up to the nearest whole
number, as it is not possible to treat a fraction of a patient. The second case has an ABI of O.5%
(0.005), which is equivalent to a NNT of 200. These numbers fit comfortably with the intuitive
clinical view that a treatment that benefits an extra 30% of patients will bring more clinical
'successes' than one which benefits an extra 0.5% of patients.
The NNT is a derived quantity that relates to the conditions under which the trial was carried out
and it has an associated confidence interval that is related to the precision of the original ABI
estimate. The confidence interval for the NNT is the reciprocal of the confidence interval for the
AB!. (Cl: lICI ABluppcorto llCI ABI1 ........ ).
The NNT is usually expressed in the form. 'in order to avoid one additional adverse outcome!
achieve one more beneficial outcome, X patients need to be treated with the intervention in question
for a period of y time'. It follows that if a pooled value for the ABI is used then it must be based on
reasonably similar trials, otherwise a nonsensical answer will be derived. Once again the issues of
heterogeneity, or intrinsic differences in the ways in the trials were designed and carried out, are
important. Inparticular, the periods of treatment need to be similar. (Sackett 2000) describes a
method for adjusting NNTs for different follow-up times based on the assumption that the relative
risk reduction (RRR) from treatment is constant over time, that is to say, a treatment is assumed to
exert the same relative benefit in year one as it does over each of the pext few years. Sackett cites
the example of treatments for hypertension: treatment of severe hypertension for 1.5 years has a
NNT of3, whereas treatment of mild hypertension for 5.5 years has a NNT of 128. Inorder to
compare these, the results need to be adjusted so that they relate to the same time period, resulting
in a hypothetical NNT. In this example, the NNT for treatment. of mild hypertension can be
adjusted to the hypothetical value for 1.5 years using the formula:
NNTbypoth«ioaI= NNT"'-vecI x (observed timelhypothetical time)
Which gives: NNT1.'. 128 x (5.5/1.5) = 470
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This means that 470 patients with mild hypertension would need to be treated for 1.5 years to
prevent one additional adverse outcome compared with three patients with severe hypertension.
Where positive differences are sought this would equate to an assumption that the RBI is constant
over time. Whereas it is reasonable to assume that RRRs may ~ constant when a preventive
treatment is given. it is not reasonable to assume that RBIs are constant when a curative or
'clearing' treatment is given. because these processes have ceilings. It is therefore inappropriate to
adjust NNTs for these types of trials in this way.
11.2 Therapeutic gain in severe psoriasis treatment
In chapters 7-10 effect sizes for trials were reported as odds ratios. In this chapter the data will be
re-examined to provide ABIs and NNTs. Where possible, summarr ABIs have been calculated
using data from trials of comparable durations.
11.2.1 Cyclosporin
The ABIs and NNTs for trials using cyclosporin are shown in Table 11.1. The most striking
feature of the latter is their small values, which show that only modest numbers of patients need to
be treated in order for many patients to experience benefits. For example, the NNT with
cyclosporin, in the dose range 2.5 - 7.5 rug/kg/day, for 8-10 weeks, compared with placebo, is two
(95% Cl 2-4). This means that two patients would need to receive this treatment in order for one to
have a successful outcome. NNTs of this order are commonly seen with antibiotic treatments and
they contrast markedly with the NNTs seen with preventativ~ treatments (EBM website).
11.2.2 Retinoids
The ABIs and NNTs for trials using retinoids are shown in Table 11.2. Once again. all the NNT
values are relatively low, except for the NNT for acitretin compared to etretinate. In this case the
value is infinity, indicating that an infinite number of patients would need to be treated with
acitretin compared to etretinate in order to achieve one more beneficial outcome. The combination
of a retinoid with PUV A (RePUV A), compared with PUV A alone, has an NNT of 9, with a wide
I
confidence interval (.S-50). This shows that the additional benefit conferred by the retinoid is
relatively small. Inpractice this would have to be weighed against the risk of additional side effects
arising from the retinoid treatment and the further benefit of the reduced UVA dose required by
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patients receiving RePUV A (see table 8.13). The effect of adding a retinoid to UVB treatment was
larger, giving an AB! of 0.28 and a NNT of 4 (95% Cl 3-7).
11.2.3 Phototherapy and photochemotherapy
The ABIs and NNTs for trials using phototherapy or photochemotherapy are shown in Table 11.3.
(AB!s and NNTs have been derived only for comparisons in which a difference was shown.)
In this series several of the NNTs are derived from single trials and therefore need to be interpreted
with caution The effectiveness of PUVA using 40 mg 8MOP compared to 10mg 8MOP over a
four-week period is clearly shown by the NNT of 2 (2-2). Similarly the superiority of PUVA over
UVA is shown by the NNT of 2 (1-3). In this latter study the time period for treatment was not
reported. Sadananda-Naik (Sadananda-Naik 1981) reported the same phenomenon in a study that
compared the effects of sunlight plus psoralen with sunlight alone. Once again. this produced a
large AB! (0.60,95% Cl 0.39- 0.81) and a NNT of2 (95% Cl 2-3).
The effects of adding retinoids to either PUVA or UVB have been discussed above. One series also
compared the combination of UVB and acitretin with acitretin alone. As might be expected, the
combination was superior, giving an ABI ofO.67 (95% Cl 0.33 -1.01) and a NNT of2 (95% Cl 1-
3).
A pilot study comparing PUV A with the Goeckerman regimen recruited only six patients and
showed a difference in favour ofPUVA Although the ABI was 0.50, the associated 95%
confidence interval was 0.01 - 0.99, suggesting that the size of the true difference is likely to lie
I
anywhere between one and 99 percent In this case, although the NNT is only 2, the 95%
confidence interval is (1.100), showing that it may be necessary to treat 100 patients with PUV A
instead of Goeckerman therapy in order to achieve one more beneficial outcome. Both figures
clearly illustrate the well-known phenomenon of imprecise estimates, arising from small samples.
Frappaz and colleagues (Frappaz 1993) examined the effects of adding calcipotriol ointment to
UVA treatment Over a ten-week treatment period. the AB! was 0.19 (95% Cl 0.01- 0.37) and the
NNT was 6 (95% Cl 3-100).
11.3 Discussion
The AB! or therapeutic gain is a helpful way of describing the response to treatment in therapeutic
trials, because it indicates the additional proportion of patients that is likely to have a beneficial
outcome from the active treatment compared with the control treatment
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The NNT provides an intuitively understandable way of describing the impact of treatment.
Although it is fundamentally the same information as that provided by the AB! (as it is the
reciprocal of the ABn the fact that it is always expressed as a whole number of patients, makes it
easier to relate to the clinical situation. An additional benefit of the NNT is that, in indicating the
number of patients that will need to be treated in order for one to benefit, it also shows how many
will be exposed to the risks of treatment (without necessarily benefiting) and how many will
consume resources in the process of achieving one beneficial outcome. Both of these attributes are
useful in clinical decision-making.
Neither the AB! nor the NNT is an answer in itself. Inaddition to the considerations outlined
above they need to be interpreted in the light of the likelihood of harmful effects from a given
treatment.
The ideal NNT is 1, that is to say that every patient treated will achieve a beneficial outcome. In
practice this is unlikely to occur for a number of reasons. The main reasons are that few treatments
are 100010 effective and many control groups exhibit some response. The convention of rounding
the NNT value up to a whole number of patients means that calculated NNTs of 1.1 and 1.9 will
both be rounded up to 2. A more subtle influence is that of intention to treat analysis. The
inclusion in the analysis of all the subjects that were originally randomised will almost invariably
result in a response rate to active treatment that is less than 100%. and therefore. even in the
presence of completely inactive control, it would be impossible to achieve an AB! of 1.
The NNTs calculated for treatments for severe psoriasis were all in the range 2-9. It is recognised
that the NNTs for effective treatments are generally in the range 2-4 (Wiffen 2001). It could
therefore be expected that the treatments that have been shown to be ,effective in the treatment of
psoriasis in earlier chapters would have NNTs in or near to this range, and it is satisfying to see
that this is the case.
11.4 Conclusions
The ABI and NNT provide a useful way if looking at the individual and pooled results of clinical
trials. Inorder to use these indices in clinical practice it is necessary to take into account the
factors that influence the AB! and NNT and other aspects of treatment, such as the likelihood of
harm and the costs of treatment.
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Chapter 12
Observational studies
Summary
This chapter contains reports of two linked observational studies. Thefirst concerned a series of
256 patients for whom standardised psoriasis assessment forms had been completed. Theform
covered several aspects of disease severity along with details of related factors such as alcohol and
tobacco use. Analysis of the data in the forms provided a profile of the types of patient routinely
seen in the psoriasis specialist clinic. The second project examined treatment pathways for
patients in thefirst project. Those who werefound to have received treatment with cyclosporin,
methotrexate, acitretin, PUVA or UVB were selected to determine howfor the actual treatment
pathways matched those which were assumed in the decision-analytic model proposed by Einarson
and colleagues (Einarson 1994).
12.1 Introduction and background
Einarson and colleagues (Einarson 1994) reported an economic analysis that compared four oral
treatment regimens (cyclosporin, methotrexate, etretinate and PUVA) for psoriasis. (See Chapter 5)
This analysis was based on a decision-analytic model. The treatment ~thways were based on
published therapeutic guidelines, validated by an expert panel and success rates for treatments were
derived from meta-analyses. In the present study, success rates have been derived through a
systematic review and, where appropriate, meta-analyses. These have been described in the
preceding chapters. This chapter describes two, linked observational studies that were undertaken
to test the validity of the assumptions about treatment pathways in the real-life, UK situation.
The setting for these studies was the psoriasis specialty clinic at Hope Hospital in Salford This
weekly clinic is operated by two senior consultant dermatologists, together with Special Practice
Registrars and specialist dermatology nurses. The clinic handled exclusively patients with
confirmed or presumed psoriasis. Patients were referred by GPs and dermatologists throughout the
(former) North West NHS Region During 1995 a psoriasis assessment form had been developed
for routine use for new patients attending the clinic. The form provided a systematic means of
gathering large amounts of information about the patients who attended the speciality clinic. at one
point in time. It therefore appeared that the psoriasis specialty clinic, with its detailed records,
would provide an excellent testing ground to check some of the assumptions made in the published
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decision-analytic model. Two studies were undertaken; the first utilised data from the assessment
forms to characterise the patient population at one point in time and the second was a longitudinal
study in which the progress of patients receiving oral treatments or phototherapy was followed and
the outcomes recorded
A third aspect of the observational studies was concerned with observation and timing of clinic
procedures in order to determine resource inputs (staff time and procedures) to patients attending
the psoriasis speciality clinic. These will be reported in Chapter 13.
12.2 Psoriasis assessment forms study
12.2.1 Method
Psoriasis assessment forms completed during the two-year period 1- January 1996 to December 31-
1991were collected An Access (Microsoft) database was constructed and all the details except for
the sketch showing areas of the body affected were entered
12.2.2 Results
Age and sex distribution
256 assessment forms were completed during the study period. There were 145 male and 111
female patients in this sample and the average age was 40.1 (± 16.5 SD) years.
Types of psoriasis
The most common diagnosis was chronic plaque psoriasis (208 cases) followed by guttate psoriasis
(31 cases). Two patients had pustular psoriasis, one was record as flexural psoriasis and no
diagnosis was recorded in 14 cases. The age of onset of psoriasis ranged from birth to 16 years with
an average of 23.1 years (± 15.4 SO).
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Family history of psorlasls
Table 12.1 shows the prevalence offamily histories of psoriasis.
Category Number
First degree relative affected 79
Second degree relative affected 29
First and second degree relatives 30
affected
No family history of psoriasis 112
Data missing 6
Approximately 55% of the sample had a relative with psoriasis whilst about 44% reported no
family history of the condition.
Arthritis
Sixty-seven patients (26%) were recorded as having arthritis.
Alcohol and tobacco intakes
246 patients provided data on their use of alcohol and tobacco.
Eighty-five patients did not drink alcohol. For those who did. (161 patients) the average number of
units of alcohol per week was 19.2 (± 22.2 SD). The distribution of alcohol intake was positively
skewed. with a median value of 12.0 and a maximum of 154 units per week.
One hundred and fifty-one patients did not smoke. For the 9S who did, the average number of
cigarettes per day was 17.6 (± 9.76 SD). The distribution of cigarette smoking was positively
skewed. with a median value of 20.0 and a maximum of 60 cigarettes per day.
PAS/scores
PAS! scores in the sample ranged from 0 -55 with an average of8.79 (± 6.65 SD).
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12.2.3 Discussion.
Previous studies have shown that psoriasis occurs with the same frequency in men and women
(Farber 1974). In this sample, 145 (57%) were male and 111 (43%) were female, which was
broadly in line with the expected 50:50 distribution. The mean age of the group was 40.1 years, but
the age range was from 16-76 years. This was consistent with the observation that psoriasis can
start at any age, although there are two recognised peaks, at 16-22 years of age and at 57-60 years
of age, and then follows a relapsing and remitting course (Greaves 1995). It is well known that
psoriasis tends to run in families and recent studies have shown associations between psoriasis and
human lymphocyte antigen (HLA) markers. (Ortonne 1999). It has been estimated that one third
of patients with psoriasis have a positive family history of the condition. (Krueger 1994) In this
group, 138 (55%) patients reported having one or more relatives with psoriasis. It is not
immediately obvious why this figure should be so high. One explanation could be that the
background prevalence of psoriasis is higher in the UK population than in the sample used for the
previous estimate. Another possibility is that the specialty clinic was attracting a greater proportion
of patients with so-called 'early-onset' psoriasis. Early onset psoriasis starts between the ages of 16
and 22 years, has a strong hereditary association, is frequently associated with the presence of
HLA-CW-6 and tends to cause disease of greater severity than the late onset type. (Ortonne 1999)
This explanation would also fit with the age profile of the group.
Estimates for the prevalence of arthritis in association with psoriasis vary from 5% (Hunter 1995)
to 15% (Stern 1997). In this group, 26% of patients reported having arthritis. It is not clear
whether this figure reflects over-reporting or a genuinely high prevalence.
The roles of alcohol and tobacco have been the subjects of much speculation as both are known to
be associated with psoriasis. The question of whether there is a causal relationship has not yet been
satisfactorily answered, although it has been suggested that smoking might account for as many as
a quarter of all cases of psoriasis. (Williams 1994)
The PASI scale runs from 0-72; a value of less than 8 is often used in trials to indicate a minimal
level of disease and a value of 20 or more is said to indicate severe disease. The mean PASI score
for the group was 8.79, which appears to be low. This may be the result of a number of factors.
Given the relapsing and remitting nature of the disease, it may not necessarily have been at its
worst when the assessment was made. Alternatively, because the PASI takes no account of the
psychological impact of the disease, a low score could, nevertheless, represent disease which is
disabling by virtue of being in a visible or distressing place and, finally, it could reflect a good
response to treatment prior to the clinic visit It is of interest that in a systematic study of one GP
practice 75 confirmed cases of psoriasis were identified (from a register of 5395) (Nevitt 1996).
The distribution of PASI score was positively skewed with a median value of 2.4 and a maximum of
10. Compared with this group, therefore, the present study group had appreciably worse disease.
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Overall, the demographic features of the group suggest that the patients attending the psoriasis
specialty clinic may be suffering from more severe disease than average. The mean PAS! score is
not consistent with this assessment but it should be noted that the PAS! is useful for monitoring the
progress of disease (or response to treatment) rather than for providing an index of the overall
severity of the condition.
In summary, the group of patients attending this clinic appeared to be suffering from moderate-
severe psoriasis and it was therefore appropriate to use it as the source for information about
treatment pathways.
174
12.3 Treatment pathways study
12.3.1 Method
The medical records for each of the patients in the psoriasis assessment forms study were located
and details of the patients' treatment pathways were extracted and recorded on a standard form.
12.3.2 Results
Records were traceable for 166 patients. For the remainder, the records were missing or the
patients had been discharge or had died In addition, a number of records were unavailable because
a major project was underway to merge records within the Trust. Part of this involved
microfilming the records. Records that had been removed for microfilming were not available for
the study.
Forty-eight patients received treatment with oral agents (cyclosporin, methotrexate or etretinate),
photochemotherapy (pUV A) or UVB. Several patients received more than one of these treatments.
MethotrexaJe
Fourteen patients received treatment with methotrexate (7 male, 7 female; average PAS! 11.9 ± 1.5
(SEM). Eight patients were already taking methotrexate at the time of assessment and 6 started
treatment after assessment. (See Table 12.2)
On eight occasions methotrexate treatment was discontinued The reasons for discontinuation were
intolerable side effects 4, intercurrent illness 2. restoration offertility 1. and no reason recorded
Methotrexate was restarted in three patients (those in whom it had been stopped for intercurrent
illness or restoration of fertility). Inthe remaining five cases, one switched to PUV A, three were
given topical treatment and one was hospitalised for a severe exacerbation of psoriasis.
The recorded reasons for prescribing methotrexate showed that it was selected for patients with
extensive or severe psoriasis when:
• The disease was difficult to treat with topical agents
• There was co-existing arthritis
• Cydosporin treatment was not appropriate because there was a history of cancer. the patient
was too young or did not wish to take cydosporin
• Other systemic treatments had been ineffective or poorly tolerated
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Cyc/osporin
Seventeen patients received treatment with cyclosporin (10 male, 7 female; average PAS! 21.4 ±
3.3 (SEM). (See table 12.3) One patient was already taking cyclosporin at the time of assessment
and 16 started treatment after assessment In total there were 25 new courses of cyclosporin.
Fourteen courses were discontinued (9 - clearance of psoriasis, 3 - side effects. 1 - intercurrent
illness, 1 - other) and 11 were ongoing. On three occasions cyclosporin was discontinued because of
intolerable side effects. In one case methotrexate treatment, which had been successful in the past.
was reinstated. In another case, acitretin was prescribed and in the remaining case, although
methotrexate was considered, topical treatment was eventually selected in accordance with the
patient's preference.
Five patients received more than one course of cyclosporin and each repeat course followed a
successful response to cyclosporin.
The recorded reasons for prescribing cyclosporin showed that it was selected for patients with
extensive or severe psoriasis when:
• The disease had failed to respond to MTX
• Continued systemic treatment was required and fertility (male) was required
• MTX was contra-indicated (e.g. because of high alcohol intake)
• The patient was unable to attend for phototherapy
• CSA had been effective in the past
• The patient expressed a marked preference for CSA and was aware of the risks
Adtretin
Six patients received seven course of treatment with acitretin (6 male, 0 female; average PAS! 10.0
± 3.S (SEM). Four patients were already taking acitretin at the time of assessment and two started
treatment after assessment (see Table 12.4)
Four courses were discontinued (1- satisfactory response, 1- intercurrent illness (alcohol
detoxification), 1- exacerbation of disease, 1- did not attend clinic for assessment and re-supply).
Inone case, where there had been a satisfactory response to treatment with acitretin, a further
course of the same treatment was recommended in the event of a relapse. In the two other cases, in
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which a positive decision to discontinue acitretin was made, alternative treatments were prescribed
In one case this was in-patient treatment using dithranol and UVB and in the other, cyclosporin,
which had been effective in the past, was recommenced In the case where acitretin was
discontinued by default. the disease had relapsed and acitretin was reinstated
In one case where the disease seemed particularly difficult to treat, the combination of acitretin with
cyclosporin was tried. but the cyclosporin had to be discontinued because of rising blood pressure.
A trial of combined acitretin and UVB was then planned. as this had been effective in the past for
this patient.
The recorded reasons for prescribing acitretin showed that it was selected for patients with
extensive or severe psoriasis when the patient was male and when:
• The disease had failed to respond to other systemic treatments
• Other systemic treatments were contra-indicated
PUVA
Six patients were referred for PUV A treatment (5 new course and one in the past). There was one
female and five male patients (average PAS! 10.0 ± 3.0 (SEM)) In none of the five cases of new
treatment was any outcome data available. On four occasions treatment had not started and in the
remaining case there was insufficient information in the medical record to show the status of the
PUV A treatment.
The recorded reasons for prescribing PUVA showed that PUV A was selected for patients with
extensive or severe psoriasis when:
• The response to MTX or CSA was inadequate or complicated by intolerable side effects
• MTX, CSA and ACI were contra-indicated
• Intensive (often in-patient) topical treatment was unsuccessful
UVB
Nineteen patients were referred for 21 courses of UVB treatment (9 female 10 male, average PASI
10.5 ± 1.8 (SEM)). (See Table 12.6) UVB was given in combination with coal tar, with dithranol
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and alone. however the details were not clear in the medical records. No records of the actual
treatment (doses of UVB, narrow band or broad band etc were made in the main medical record
On eight occasions there was no record of the outcome of treatment (2 referred but not started, 4 did
not return to the clinic, 1 referred but did not attend for UVB treatment, 1 referred but suffered a
flare up of psoriasis requiring methotrexate treatment before UVB could be started) UVB treatment
was ineffective in one case and treatment was changed to oral cyclosporin. In the remaining 12
cases UVB treatment was judged to be partially or completely successful.
The recorded reasons for prescribing UVB showed that UVB was selected for patients with
extensive or severe psoriasis when:
• The disease was predominantly small plaque or guttate psoriasis
• UVB had been effective in the past
• There was some, but insufficient, response to out-patient topical treatment (often involving a
combination of coal tar products. steroids, calcipotriol and antifungal agents. in addition to
specific scalp products)
AgeandPASI
Table 12.7 shows the age and PASI characteristics for each of the treatment groups. In this sample,
patients in the groups receiving methotrexate. acitretin and PUV A treatments were older than those
in the groups receiving cyclosporin or UVB.
The PASI characteristics also differed Patients in the group receiving cyclosporin had a mean
PASI score approximately twice that of patients in the other treatment groups.
12.3.3 Discussion
Itwas disappointing to find that such a large proportion of the medical records was missing.
Repeated attempts were made to trace the missing records over a period of three months.
Originally, it had been assumed that the majority of patients attending the psoriasis speciality clinic
would have moderate-severe disease that would require systemic treatment It was therefore
surprising to find that only 48 out of the 166 cases whose records could be traced, fell into this
category.
It is clear from the analysis of the psoriasis assessment forms that many patients did not have severe
disease according to their PAS! scores at the time of assessment The shortcomings of the PAS!
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score in this respect are well-recognised (see Chapter 3) and their disease was clearly severe enough
by their own assessment and/or their GP's assessment to warrant a specialist referral. The situation
may be complicated by the limited facilities for effective management of psoriasis in primary care.
Moreover, the time lag between referral and the actual clinic appointment can be several months,
during which time the disease has gone into remission, either spontaneously or as a result of
successful topical treatment
The analyses of treatment pathways are therefore based on a small sample and are almost certainly
insufficient for quantitative evaluation. Nevertheless, they provide useful insights into the
qualitative aspects of treatment that can be built into future models. (See Chapter 13)
The reasons for the choice of systemic treatments followed the accepted, published guidelines.
(Gawkrodger 1997).
In this small sample it appeared that cyclosporin, methotrexate and UVB treatments were used
more commonly than PUVA This is likely to reflect two aspects of the local situation. First. there
was considerable expertise in the use of cyc1osporin and methotrexate in the Dermatology
department and second, there was a long waiting list for PUV A treatment. None of the five
patients who were referred for PUV A treatment in this sample had received the treatment during
the study period. This appears to be a widespread problem and it is of interest that Einarson
(Einarson 1994) also noted that shortage of PUVA facilities was an obstacle to its use.
Analysis of the treatment groups by age and PAS! score suggests the possibility that different
approaches were used in this clinic for different groups of patients. For example, patients in the
group receiving cyclosporin were younger than those receiving methotrexate, acitretin or PUV A
and had significantly worse disease, according to their PAS! scores. This finding is interesting
because, in discussions, the consultant dermatologists would stress the importance of using
cyclosporin later rather than earlier in order to avoid exposing patients to the risk of renal damage
early in life. The low average age may reflect the fact that young patients with very severe disease
are preferentially referred to the clinic or may reflect a group of young well-informed patients who
demand cyclosporin treatment. or a combination of these factors. UVB was used more frequently
than had been expected, although it was difficult to determine consistently from the medical records
which patients received UVB alone and which patients received UVB in combination with
dithranol or coal tar. Similarly, it was not clear whether narrow band or broad band UVB was in
use. The frequency of use ofUVB-based treatment, coupled with the fact that the median age of the
patients who received it was 26 years, suggests that young patients with severe disease were guided
towards this treatment rather than a systemic treatment A more likely explanation for this
observation is that all patients with guttate psoriasis, who tend to be young patients, often with their
first episode of psoriasis, were prescribed UVB.
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The other important question to be answered by these studies was whether the patterns of
treatments observed in this UK sample would be consistent with the decision-analytic model
proposed by Einarson (described in Chapter 5). In essence, the model says that if treatment of
psoriasis with a given agent ('primary treatment') is successful, then a future episode of psoriasis in
the same patient can be treated with the same agent again. If. at any stage, the chosen primary
agent is ineffective then it is assumed that a secondary agent will be used. Einarson' s study
involved four treatments - eyclosporin, methotrexate, etretinate and PUV A In the model the
secondary treatment for methotrexate, etretinate and PUV A was cyclosporin and the secondary
treatment for cyc1osporin was methotrexate.
The purpose of any model is to codify what happens in reality and this necessarily involves a degree
of simplification. The patterns of treatment seen in this sample of patients broadly followed the
Einarson model (see Figure S. I). Where a treatment had been effective in the past it was usually
repeated for subsequent episodes. InEinarson's study, the assumptions about secondary treatments,
in particular, the definitions of 'success' and 'failure' were not explicit. If 'failure' is defined
broadly as either lack of efficacy or manifestation of intolerable side effects. then the model is
applicable to the situation in this study. The only remaining problem is the choice of secondary
treatment. Einarson's model uses cyclosporin as the secondary agent for the three other treatments,
which implicitly assumes that it is usually appropriate. In the present series, methotrexate was
chosen as the primary treatment in three cases because cyclosporin was not suitable (by reason of a
history of cancer, patient preference or because the patient was considered too young to be exposed
to the risks of cyclosporin treatment). Clearly in these situations, cyclosporin would not be a
satisfactory secondary treatment, however, if these considerations affect a relatively small
proportion of patients then the model is not invalidated.
12.4 Conclusions
Taken together, the results of the assessment forms study and the treatment pathways study suggest
that the profile of the group of patients attending the psoriasis speciality clinic broadly conforms to
profile of patients with moderate-severe psoriasis who have been recruited to published Rcrs. This
confirms that is appropriate to combine data drawn from published Refs with cost data derived
from this group, in an economic analysis.
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Table 12.2: Treatment pathways for patients receiving methotrexate
Study No PASI MTX Reason for choice of Reason for
Rx methotrexate treatment discontinuation/next
treatment
165 12.0 New Extensive CPP with LFTs raised
arthritis. Does not drink MrXD/C
alcohol. Referred for PUVA
163 10.4 Cont Widespread small plaque Fertility.
psoriasis. CSA (MTX restarted
after 6 months CSA -
wife pregnant)
154 17.1 Cont. Extensive CPP
UVB ineffective; ACI -
bad side effects;
Ccr/dithranol- bums.
MIX 'works brilliantly'
106 17.8 Cont. Extensive CPP
RIo breast cancer
105 8.5 Cont Not recorded MCVraised
MTXD/C
Hospitalised
103 3.0 Cont. Cpp + arthritis
100 13.7 New Extensive psoriasis. Nausea, bloating,
difficult to treat topically headache & dizziness.
MrXD/C
Topical treatment
97 3.9 New Extensive guttate lesions Nausea, anorexia,
a + large plaques on constipation
limbs and buttocks. MrXD/C
Patient not keen to take Topical treatment and
CSA. natural sunlight
80 7.4 Cont. Extensive small plaque
psoriasis.
Mucocutaneous SEs with
ACI. PMH of non-
melanoma skin cancer.
MIX well-tolerated
76 19.3 New Extensive CPP Flu
MrXD/C
MTX restarted
7 11.4 New Rapidly relapsing Jaundice (unrelated to
psoriasis. CSA not ideal MTX)
as in view of patient's MTXD/C
aze. (young) MTX restarted
8 17.0 New Severe psoriasis - had
responded to Skin-Cap -
now discontinued
9 20 Cont Not recorded
29 5.4 Cont No reason recorded
MTXD/C
Topical treatments
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Table 12.3: Treatment pathways for patients receiving cyclosporin
Study No PASI CSA Reason for choice of Reason for
RI cyclosporin treatment discontinuation/next
treatment
163 10.4 New Restoration of fertility 9/12 treatment. Raised
(on MIX) serum creatinine. DIC
MTX reinstated.
161 11.4 New Severe psoriasis 2112 treatment (clinical
trial). Clear.
Tingling in fingers and mild
headache
New Relapse 1112 treatment. Clear.
Tingling in fingers
New Relapse 2/12 treatment. Clear.
New Relapse 6/52 treatment. Clear.
New Relapse 2/12 treatment Clear.
Tingling in fingers
New Relapse
159 3.2 New Severe scalp psoriasis 2152 treatment
Nausea +++. D/C. MfX
discussed. Topical treatment
prescribed.
155 31.9 New Severe psoriasis, long
history.
151 39.4 New Severe disease 15152 treatment. 75% clear.
BP 160/118
New Mild flare up
149 28 Cont
133 36 New Unstable CPP, erythema 2/12 treatment. Good
++. alcohol problem control. BP 140/95
Flare up of psoriasis 5/12 treatment Good
control. Swelling of legs - ?
due to CSA?
127 25 New Active psoriasis - failed • Also taking acitretin
to respond to MTX
101 16.3 New Widespread CPP on face
and scalp.
91 55 New Brvthrodermic psoriasis
56 20.6 New Widespread active
psoriasis. Inpatient
treatment not possible.
54 11.8 New Widespread disease, 3/12 treatment Clear
difficult to treat
topically, unable to
attend for phototherapy
New Extensive CPP
53 15.9 New Extensive CPP
57 20.9 New Widespread CPP
60 2.7 New CPP + probable psoriatic 4/12 treatment Viral illness
arthritis
New
25 22.7 New Severe psoriasis 2112 treatment BP raised in
spite of nifedipine. DIe.
Change to acitretin
33 12.8 New Widespread small plaque 2152 treatment Did not
psoriasis attend clinic.
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Table 12.4: Treatment pathways for patients receiving acitretin
Study No PASI Acitretin Reason for choice of Reason for
RI acitretin treatment discontinuation/next
treatment
128 13.0 New Mixed plaque & guttate 7/12 treatment Die
50mgld psoriasis; wants during alcohol detox,
inpatient treatment; ACI Psoriasis still bad-
protem. PAS! lS.9-admitted
for !PT with dithranol
andUVB.
127 25.0 New HlO treatment with 7/12 treatment. Die
SOmgld PUV A & ETR Failed to when did not attend
respond to MTX. clinic.
Extensive disease - ACI
addedtoCSA
New Extensive disease - AeI eSA Die. Plan to add
restarted (CSA UVB to ACI (effective
continued) in past)
91 55 Cont Erythrodermic psoriasis D/C - thought to be
7Smgld contributing to
erythroderma Restart
CSA (effective in D3St)
87 0.0 Cont Totally clear on low dose Excellent control.
20/10mg ACI Continue ACI.
alternate
days,
then
20mg/d
80 7.4 Cont Long history of systemic Continue ACI +MTX
20mgld treatment. Non-
melanoma skin Ca - no
further phototherapy
possible.
Extensive small plaque
psoriasis. ACI +MTX
42 8.9 Cont History of treatment with 2112 ACI +
20mgld phototherapy and MIX calcipotriol. Much
Extensive psoriasis. improved. D/C ACI.
Calcipotriol added Start again if disease
flares.
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Table 12.5: Treatment pathways for patients receiving PUV A
Study No PASI PUVA Reason for choice of Progress/response
PUV A treatment
165 12.0 New Little response to MTX; Referred for PUV A but
2/wkfor risingALT not yet started
12wks
119 5.6 New (no Relapse ('scattered large, Referred for PUV A but
details) inflamed plaques + not yet started
multiple small eruptive
spots'). Unsuitable for
MTX, CSA or ACl
116 4.1 New Cannot cope with topical PUV A not started -
treatment; depressed. very limited disease -
referred for UVB.
108 3.9 New Responds well to daily Referred for PUV A but
dressings (clinic) with not yet started
coal tar but less well to
home use of coal tar
7 11.4 New Episode of gallstones & Record does not show
jaundice whilst taking whether PUV A started
MTX. MTX D/Cd
25 22.7 Past Side effects with CSA PUV A caused burns
andMTX.
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Table 12.6: Treatment pathways for patients receiving UVB
Study No PASI UVB Reason for choice of Progress/response
UVB treatment
153 19.5 New Inadequate response to 1152: Psoriasis
topical coal tar and improving: UVB
steroids continued + coal tar
150 5.7 New Inadequate response to 2152: Psoriasis
topical coal tar, steroids improving: UVB
& calcipotriol scalp continued + topical
lotion steroid
143 11.1 New Extensive small plaque Improved with UVB
psoriasis + palmo- and daily dressings.
plantar pustular UVBD/Cd
psoriasis. Patient is
reluctant to use systemic
treatment Plan:
dithranol +UVB as in-
patient
Flare-up due to job Did not attend clinic -
stress. UVB and topical no record of UVB tx.
treatments restarted
135 5.0 New Inadequate response to Improved with UVB
2/wkfor topical coal tar. steroids but flared when patient
8wks & c1otrimazole had exams. Did not
return to clinic
130 10.0 New Inadequate response to 4/12 treatment. 'UVB
24 topical dithranol. UVB not really helping -
sessions effective in past PAS! 15.3. Plan for
CSA.
122 14.3 New Extensive CPP. UVB 2/12 >90% clear on
effective in past. UVB + betamethasone
ointment 1 in 4.
116 4.1 New Cannot cope with topical Referred for UVB but
treatment; depressed did not attend
109 6.7 New Inadequate response to Course completed.
21wkfor topical dithranol. Good control.
8wks steroids and salicylic
acid UVB effective in
past
97 3.9 New Inadequate response to Topical coal tar and
21wkfor calcipotriol and topical salicylic acid
8wks steroids. prescribed - caused
flare before UVB
started - MTX Rxd
UVB not given
96 15.9 New Small plaque/guttate Referred for UVB but
psoriasis not yet started
95 9.0 New Extensive plaque 30 sessions completed.
3/wk psoriasis. Good response Partialirnprovement
to tacalcitol, Add UVB (Topical treatments not
used)
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Table 12.6: Treatment pathways for patients receiving UVB (continued)
Study No PASI UVB Reason for choice of Progress/response
UVB treatment
94 16.2 New Widespread thin plaques Course completed:
2/wkfor > 90010 clear. Topical
12wks treatment-
calcipotriol, steroids,
coal tar and anti-fungal
cream ran out!)
Continue with topical
tx.
New Flare of guttate psoriasis 2/12 Good progress.
on trunk and limbs.
UVB effective in past
93 3.8 New Thin, small plaques 00 Did not attend clinic -
(excludes· ·For3 limbs + guttate lesions no record of UVB tx.
trunk) ... wks
89 9.8 New Very active small plaque Did not attend clinic -
psoriasis no record of UVB tx.
85 17.1 New Extensive annular CPP Did not attend clinic -
over trunk, limbs and no record of UVB tx.
scala
66 6.4 New Scattered guttate and 10/52: UVB + topical
3/wk plaque psoriasis calcipotriol and
Daktacort 19 sessions:
95% improvement
Pt discharged
65 32.8 New Thick inflamed plaques 20 treatments given:
2/wk on legs, arms and trunk patient 'very pleased
Good response to topical with results ofUVB'.
treatment with coal Pt discharged
tar/salicylic acid and
steroids. Add UVB
27 5.4 New Psoriasis mainly on Referred for UVB but
lower limbs. Inadequate - not yet started
response to topical coal
tar and steroids
49 3.0 New Moderately thickand . ·12 sessions: improving
3lwkfor scaly plaques - 4%BSA
20wks
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Table 12.1: Summary of characteristics (age and PASn for each treatment group
MTX CSA ACI PUVA UVB
14 patients 17 patients 6 patients 6 patients 20 patients
Age±SEM 41.7 ±3.4 33.6± 3.5 50.3 ± 7.4 49.5 ± 7.0 33.4± 4.3
(years)
Median age 44.5 31 48 46 26
(years)
PASI±SEM 11.9±1.5 21.4± 3.3 10.0 ± 3.5 10.0 ± 3.0 10.5 ± 1.8
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Chapter 13
Economic analysis o( treatments (or severe psoriasis
Summary
The procedure adoptedfor application of the previously published decision analytic model are
described, including the assumptions made, and the identification of treatment success and relapse
probabilities. The analyses performed provide a rank order for the treatment strategies considered
and give additional insights into the relative cost-effectiveness of the four strategies. The potential
sources of variation are identified and recommendations for future analyses are made
ll.1 Introduction and background
A critique of previous analyses of psoriasis treatment has already been presented in Chapter 4.
The original plan for this project was to repeat the analysis described by Einarson and colleagues
(Einarson 1994) using information derived from the systematic reviews described in Chapters 7-10
and current UK cost data to populate the decision analytic model. However. close examination of
Einarson's report revealed a number issues that required clarification before further application of
the model. (These were discussed in detail in Chapter 5.) Inparticular, clarification was needed
concerning
• Whether treatments were continuous or intermittent
• Dosage and duration of treatment
• Relapse rates
• Time frame for the model
Continuous or intermittent treatment
In line with current treatment recommendations. the model should incorporate continuous treatment
with methotrexate and acitretin, but intermittent treatment with cyclosporin and PUVA.
(Gawkrodger 1997)
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Dosage and duration of treatments
In general, the doses used in the model should reflect the doses used in the trials on which the
estimates of effect size are based For cyclosporin and acitretin these are 3-5 rug/kg/day and 0.5-
0.75 mglkglday. For methotrexate there were no ReI's on which to base estimates of effect size and
so cohort studies were used to derive a response rate (see table 13.3) and the dose was taken from
current guidelines (Gawkrodger 1997). For PWA a course of 20 sessions is assumed as this is
commonly prescribed in practice and in the trial situation. The duration of treatment should represent
the time in which the majority of patients could be expected to have responded. For all treatments
this was assumed to be 8-12 weeks.
Relapse rates and time frame
One of the important elements of the model is the anticipated times to relapse after treatment
Patients with psoriasis are at a continuous risk of recurrence (relapse) but, in order to embrace this in
the framework of a decision analytic model, the probabilities of relapse at specified time intervals
need to be incorporated
A previous history of severe or 'resistant' psoriasis is believed to be a major factor influencing
relapse rates, (Higgins 1989) and for this reason the same relapse rate Was used for all treatments in
the model. Published studies show that, for many patients, relapse occurs within three months of
discontinuation of treatment For example, the multi-centre study of intermittent cyclosporin use
reported by Ho and colleagues (Ho 1999) showed that the median time to relapse after abrupt
discontinuation of cyclosporin was 109 days. In this one-year study patients were allowed to have as
many course of eyclosporin as were required The numbers of patients who required one, two three
and four courses of treatment were 400, 259, 117 and 26,respectively. For the purposes of the
model a relapse rate of 0.35 at twelve weeks after discontinuation of treatment was used. This
corresponds to the observed rate in the study by Ho and colleagues (Ho 1999). The 'on-treatment'
relapse rate for patients receiving maintenance treatment with methotrexate or acitretin was
arbitrarily set at 0.1 at twelve weeks after initial clearance.
Time frame for decision analytic model
If twelve-week treatment periods and twelve-week 'relapse evaluation' periods are incorporated into
Einarson's decision analytic model, as shown in figure 13.1, then the model covers a period of
approximately one year (48 weeks).
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13.2 Data sources
The data required to populate the decision analytic model are treatment success rates (at 12 weeks),
relapse rates at 24 weeks (i.e. 12 weeks after discontinuation of PUV A or CSA, 24 weeks after
starting acitretin or methotrexate), and the costs of treatment
13.2.1. Success rates
The success rates for cyclosporin, acitretin and PUVA treatments were calculated by a weighted
pooling of the success rates (on an 'intention to treat' basis) of the appropriate RCTs identified in the
systematic review (see tables 13.1. 132. 13.4). ReI's using ineffective doses or out-dated dosage
regimens were excluded Thus, for cyc1osporin, only trials using doses of 3 mg/kg/day or above were
included and the single study that used a dose of 14 mglkglday was excluded The success rate for
methotrexate was taken from two open trials (see table 13.3).
Confidence intervals for success rates were calculated according to the method for determination of
the confidence interval for a binomial population parameter described by Altman (Altman 1991) and
implemented using Intercooled Stata 6.0 for Wind0'Y5 (Stata Corporation, Texas)
Primary treatment success rate (average success rates; 95% 0)
CSA
MTX
ACl
PUVA
0.70 (95% Cl 0.67 - 0.73)
0.61 (95% Cl 0.51- 0.71)
0.45 (95% Cl 0.38 - 0.52)
0.79 (95% Cl 0.77- 0.82)
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Table 13.1: Cyclosporin success rates
Cyclosporin response rate (aU series, dose> 2.S mg/kglday
Authorlyear Number of Number Comparator
successes in group
Van Joost 88 7 10 plo
Engst 89 3 6 plo
Ellis 91a 9 25 plo
Ellis 9Ib 13 20 plo
Ellis 91c 12 15 plo
Guenther 91 11 12 plo
Meffert 95 12 44 plo
Finzi 93 35 36 etr
CSCG91 40 79 bet
Christophers 92a 60 121 csa
Christophers 92b 41 60 csa
Laburte 94 117 132 csa
Elder 95 neo 16 18 csa-sim
Elder 95 sim 16 19 csa-neo
K0095 neo 122 152 csa-sim
K0095 sim 122 156 csa-neo
Cyc1osporin average success rate 0.70 (95% Cl 0.67 - 0.73)
Table 13.2: Acitretin success rates
Success rates - Acitretin doses SOmglday, 0.7Smg/kg or greater
Author/year Number of Number Comparator
successes ingroup
Goldfarb 88c 2 11 plo
Lassus 87c 14 20 plo
Gollnick 88c 9 43 etr
Bauer 83 29 71 etr
Finzi 93 29 40 csa
Acitretin average success rate 0.45 (95% Cl 0.38 - 0.52)
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Table 13.3: Methotrexate success rates
Success rates - Methotrexate
Author/year Number of Number
successes in group
Nyfors 70 41 50
Weinstein 71 20 50
Methotrexate average success rate 0.61 (95% Cl 0.51- 0.71)
Table 13.4: PUVA success rates
PUV A response rates (all series)
Author/year Number of Number
successes in group
Andrew81 24 26
Berg 94 24 38
Buckley 95 72 83
Collins 96 61 74
Lowe 87 32 47
Tanew88 166 169
Collins 92 28 44
Twjanmaa85 79 93
Pai 94 9 12
Williams 85 2 4
De Berker97 37 50
RogersIVB 79 103 113
Lauharanta 81 16 20
Parker 84 9 15
Sommerburg 19 44
Tanew91 20 30
Frappaz93 29 53
PUV A average success rate 0.79 (95% Cl 0.77- 0.82)
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13.2.2 Costs
Resource inputs comprised staff time, laboratory investigations. clinic visits. treatment costs (PUV A
treatment or costs of medicines and dispensing).
Staff time
Staff time (doctors, nurses, phlebotomist, receptionists, medical records and pharmacy staff) along
with clinic overheads (heating, lighting, capital charges) are all embraced in the out-patient
attendance cost of £76. 00. (source: Finance Department at Hope Hospital) Although originally
observational studies had been performed to determine the amounts of time spent by clinical staff
(doctors, nurses. phlebotomists) it had not been possible to capture accurately the time spent by
secretarial staff and medical records staff. After discussion with the Deputy Director of Finance, it
was decided that the aggregate figure would provide the more accurate data
Laboratory costs
The costs of routine laboratory tests are covered in the out-patient attendance cost but non-routine
items, such as X-rays or invasive procedures are not and were therefore costed separately. The costs
of relevant laboratory tests were taken from current (2001) hospital costs. (See Table 13.6)
Table 13.6: Costs of laboratory tests and investigations
Test Cost (£)
Biochemical profile 8.08
Urea. electrolytes & creatinine 2.96
Lipid profile 5.85
PIIINP* 8.00
Glomerular filtration rate" 8.00
Full blood count 1.89
Pregnancy test 6.17
X-ray spine 106.00
Liver biopsy 650.00
(Source: Finance department Hope Hospital. Salford * exact prices not available, tests charged at
average rate.)
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Drug costs
The costs of the drugs used was taken from the British National Formulary number 42 (October
2001) except for 8-methoxypsoralen (8-MOP). 8-MOP is unlicensed in the UK and the price was
obtained from the manufacturer.
Table 13.7 Drug costs
Drug Strength Pack size Price Unit price Dose Cost/12wks
(£) (£) treatment
Methotrexate 2..5 100 11.41 0.114 J5mglwk 8.22
Methotrexate 10 100 55.07 0.551 20mglwk 13.22
Neoral (CSA) 100 30 76.33 2.544 400mgld 854.90
Neoral (CSA) 100- 30 76.33 2.544 300mgld 641.17
Acitretin 10 56 25.34 0.453 35mgld 126.21
Acitretin 25 56 58.8 1.05 50mgld 176.40
8-MOP 10 100 34.00 0.34 40mg 27.20*
8-MOP 20 50 50.00 1.00 40mg 40.00*
Folic acid 5 20 0.49 0.025 2.06
*assumes 20 PUVA treatment sessions
PUVAcosts
PUVA costs were based on the number of out-patient attendances. For the purposes of this analysis
it was assumed that each patient would receive twenty treatments and that the cost of each treatment
session was £76.00.
13.3 Analysis
Einarson's model was redrawn using the conventional notation and substituting <clearance' or "no
clearance' for success and failure. (Figure 13.2) The final outcomes are also shown as "clearance' or
"no clearance', rather than "success' or "re-evaluate' as in the original These terms are more helpful
and are genuine outcomes, whereas, for example, <re-evaluate' is not an outcome, as such, but an
action to be taken in the event of an unsatisfactory outcome.
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Spreadsheets were constructed as described in Chapter 5 to determine the cumulative probabilities of
clearance/no clearance with each of the treatment strategies. Costs were then incorporated into the
model in order to calculate the cost of each strategy. A cost-effectiveness ratio was calculated by
dividing the cost by the overall success rate to give a 'cost per cleared case' .
As an example, table 13.8 shows the calculations for the strategy that uses cyclosporin first and
methotrexate as a back up treatment
A number of assumptions are made in using the model and it is important that they be recognised:
• All patients receive the full course of treatment
• All patients are carefully monitored and severe adverse effects (requiring discontinuation of
treatment) of treatment are avoided
Table 13.9 shows the average probabilities of clearance with each of the four strategies and the 'base
case' cost-effectiveness ratios
13.3.1 Sensitivity analyses
Once the base-case cost-effectiveness (CE) ratio had been calculated for each of the treatment
strategies, then the effects of varying key assumptions were tested The results are shown in table
13.10. Decreasing the relapse rate had a modest effect on all the CE ratios. Varying the success rate
of the primary treatment between the calculated confidence limits had modest effects on the
treatment strategies that used cyclosporin or PUVA as the primary treatments but more marked
effects on those that used methotrexate or acitretin. Inboth these cases the calculated confidence
intervals were relatively wide and the corresponding CE ratios differed considerably from the base
case, but the overall ranking did not change
Attendance at the outpatient clinic attracts a cost of £16.00. The base case assumes that all patients
attend the clinic once a month. The effect of reducing the frequency to once every three months was
examined but it had little effect on the overall CE ratio. Furthermore, it is doubtful that patients
taking methotrexate or cyclosporin could be adequately monitored in this situation.
The base case analyses show that the strategy using methotrexate as the primary treatment delivers a
considerably lower CE ratio than any of the other three strategies. It should be noted however, that
this analysis excludes the cost of a liver biopsy. If this is incorporated into the pathways that include
twelve months' treatment with methotrexate then the CE ratio rises to 2042, which still compares
favourably with the cyclosporin-methotrexate strategy.
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None of the substitutions used for sensitivity analyses changed the rank order of the treatment
strategies.
13.4 Discussion
The use of the cost-effectiveness ratio - the cost per cleared case - provides a way of taking account
of the fact that the different treatment strategies result in different outcomes. Although each of the
chosen strategies can lead to clearance of psoriasis, the probabilities of a successful outcome vary
between 77% and 90% (see table 13.9). It is therefore not appropriate simply to compare the costs
of each strategy, as in a cost-minimisation analysis. A cost-effectiveness analysis, which
incorporates a natural measure of outcome, in this case clearance of psoriasis, is the appropriate
method to provide a meaningful comparison.
Methotrexate given as the primary treatment with cyclosporin as the secondary treatment appears to
be the most cost-effective option, however, further analyses would be necessary before this could be
recommended as a routine treatment policy. As noted above, if an annual liver biopsy is required
(Gawkrodger 1997) then the expected cost of treatment approaches that of the cyclosporin-
methotrexate strategy. Furthermore, the costs of the cyc1osporin-methotrexate strategy may be over-
estimated, because a dose of 5mglkglday was assumed, whereas in one large trial that used
intermittent treatment with cyclosporin, the average dose used did not exceed 4ms'kg (Ho 1999).
However, reducing the dose of cyclosporin in the model to 300 mg/d only reduces the CB ratio to
2025. Inaddition., the effectiveness of the strategy may be under-estimated because the analysis was
based on doses of cyclosporin ranging from 2.5 - 7.5 rug/kg/day. Ifdoses below 3mWkg/day are
excluded then the success rate improves.
The PUVA-cyclosporin strategy is the least cost-effective in this analysis, and this is clearly related
to the expense of hospital attendance.
Inview of recent developments an additional treatment strategy needs to be added to this
comparison. The observational study showed that UVB treatment was in regular use although it was
not clear what proportion of this was narrowband UVB and what was therapy with the Ingram
regimen. Given the growing popularity of narrowband UVB as a single therapy, it would be
appropriate now to build in an arm to examine effects of this treatment
Perhaps the most fundamental issue to address is whether the model itself is appropriate. The
purpose of a decision-analytic model is to represent all the possible pathways and outcomes in a
given situation. Although Einarson's model satisfies this requirement in some respects, in others it
does not For example, no time frame was given in the original description and this is important for
a meaningful analysis. If it is assumed that the model spans a one-year period then there may need
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to be an allowance for another repeat treatment with the primary treatment. In the original model.
patients following pathway number 1 achieve clearance in the first treatment period and have no
relapse for next nine months. In the study by Ho and colleagues (Ho 1999) more than 25% of the
participants required a third course of treatment within a one-year period. This is a large enough
proportion to merit inclusion in the model. This is further indirectly reinforced by the results of the
observational study, which showed that on many occasions, a treatment was selected because it had
worked in the past One way of incorporating these two elements would be to construct branches of
the decision tree that reflect these possibilities. Ifpathways were also included that allowed
treatment to be changed at any stage, for example if side effects became intolerable, then a more
accurate representation of the real situation may be possible. Figure 13.3 shows how this could be
done for the cyclosporin branch.
Another important aspect of the model is that it makes no allowance for the adverse effects of
treatment. It is assumed that monthly clinic visits are made and that all the appropriate monitoring
and dosage adjustments are carried out, and in this way adverse events are avoided. This approach
has been used by Davies and colleagues (Davies 1997), but their analysis was concerned with short
course cyclosporin for mild-moderate psoriasis, where the assumption may have been more easily
justified. Inthe present study, concerned with moderate-severe disease, rare but costly adverse
events could alter the conclusions of the analysis considerably. Ideally, data for this should be taken
from long-term follow-up studies, in the real-life situation, and be built into the model.
Both the original model and the modifications proposed above assume that relapses occur three
months after the end of treatment to induce remission of psoriasis. In real life. patients are at
continuous risk of relapse and some will relapse earlier than three months, but others will not relapse
until much later. One way of taking account of this type of dynamic process is through the use of
Markov modelling. A Markov model is essentially a much more complex decision tree that shows
all the possible health states that a patient could be in at a pre-determined point in time (Drwnmond
1997). Thus for patients one month after successful treatment with cyclosporin, possible health
states are cleared and receiving no treatment, relapsed and receiving no treatment, relapsed and
receiving re-treatment with cyclosporin. Inorder to analyse a Markov model the length of the
Markov cycle has to be determined (how often patients would be evaluated) and the transition
probabilities (the rate at which patients will move from one health state to another) need to be
calculated. Perhaps the most serious limitation of a Markov model is that it assumes 'zero memory'.
that is, the transition probabilities depend only on the health state a patient is in and not on how long
they have been there or how they got there. In the case of psoriasis, where a previous history of
severe or 'resistant' disease is believed to be a major factor influencing relapse rates, (Higgins 1989)
this assumption could not possibly hold.
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A useful alternative approach to all of these issues would be to use a consensus panel of
dermatologists to determine the treatment pathways to be incorporated into the model. This would
confer a degree of validity that can never be achieved by the theoretical approach alone.
This analysis has been performed from the perspective of the health service and is concerned with
costs and effectiveness. which has been defined largely by clinicians. The results of the clinical
trials on which the analyses are based are predominantly physicians' assessments of responses to
treatment Another useful perspective could be gained by performing a cost-utility analysis for the
four treatment strategies. This would involve first determining patients' preferences for the
difference types of treatment A previous study concerned with economic analyses of methotrexate
versus Goeckerman therapy for psoriasis reported a trend towards a greater cost-effectiveness when
patient utilities rather than physician utilities were used (Chen 1998).
13.S Conclusions and recommendations
This preliminary economic analysis using a previously-published decision-analytic model has
provided a rank order of cost-effectiveness for the four treatment strategies compared and has raised
a number of issues about the model itself.
The analyses that have been performed provide some insights into the relative costs and
effectiveness of the treatment of moderate-severe psoriasis however. before these could be used for
policy decisions, a more detailed model is required. Such a model would need to be tested out with
expert dermatologists to ensure that it reflected current approaches to treatment In particular, more
detail about monitoring and follow-up is required. For example, the effects of having some
monitoring done by the GP could be explored.
The frequency of unpredictable adverse effects of psoriasis treatments should be determined, if
possible, in the real-life situation rather than from clinical trial data
The use of narrowband UVB should be incorporated into future analyses.
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Chapter 14
Discussion and Overall Conclusions
Psoriasis is a common disease that affects up to 2% of the population of the UK. Although severe
psoriasis accounts for only about a quarter of cases - those that are treated in secondary care - the
prevalence of moderate-to-severe psoriasis is still equivalent to the prevalence of rheumatoid
arthritis or diabetes mellitus. Both of these conditions are perceived as common. disabling and
worthy of research efforts. The high prevalence of psoriasis, coupled with its chronic, recalcitrant
nature and consequent severe psychosocial disabling effects. mean that it should be no less
prominent.
A working knowledge of the effectiveness and tolerability of the treatments available for severe
psoriasis, based on firm evidence, is essential for decision-makers in the NHS. Sources of evidence
include systematic reviews ofRCI's, observational studies of the real-life situation and modelled
data. These techniques offer different insights into the effectiveness and utility of treatment
strategies. Together they can help health care decision-makers. individual clinicians and patients to
select treatments that represent an acceptable balance of clinical effectiveness, utility and cost.
The studies reported here - a systematic review of the effectiveness of treatments for severe psoriasis
and a preliminary cost-effectiveness analysis of four treatment strategies - have recorded and
synthesised the available evidence. The trials reviewed cover the period up to June 1999. Further
work is required to bring the database up-to-date with recently-published trials, and to examine the
tolerability of the treatments in more detail and to improve the economic analysis.
The main body of this project was concerned with a systematic review of RCI's of psoriasis
treatments. In this area a number of difficulties were encountered. notably the lack of a universally
accepted definition of severe psoriasis, the low power of many trials and the standards of reporting.
Severe psoriasis can usually be defined as psoriasis involving body surface area >20010and/or a
psoriasis area severity index (pASn of ~12, however this was not applied in all the trials included in
the review. Moreover, the PAS! reflects clinical severity and not the important dimension of
psychosocial disability. Although this could be said of many clinical measurement scales, a special
case can be made for skin diseases where psychosocial disability is an important element of the
impact of the disease. Low-powered studies per se need not necessarily be a problem, particularly if
a meta-analysis is possible. However, a large number of trials included in the review had very small
numbers of participants (many had 30 or fewer in each group) and therefore gave rise to results with
very wide confidence intervals. Some reports of RCI's were insufficiently detailed to allow their
inclusion in the review. In addition. the results of some trials were described on a per protocol basis
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and others on an intention to treat (l'IT) basis. This can have a major impact on the apparent
effectiveness of a treatment. Schiffner and colleagues (Schiffner 2(01) recently described "striking
differences in the therapeutic effect" of treatments for psoriasis and eczema according to the method
of analysis that was used For the purposes of this review all results that were extracted were
corrected to reflect the ITI sample. Previous authors have called for improvements in the quality of
trial reporting in the dermatological literature (Adetugbo 2000) and the experience of this review
suggests that this is justified
In the reviews of treatments, effect sizes have been presented as odds ratios and risk (rate)
differences. The odds ratio is the preferred tool of statisticians and epidemiologists. It is used
because of its mathematical properties and because many of the standard meta-analytical methods
rely on the use of the odds ratio. However. as Wiffen has observed (Wiffen 2001). "few people have
a natural ability to interpret event ratios that are reported in terms of odds ratios." For this reason the
results presented in Chapters 7-10 have been recalculated to give the 'number needed to treat' (NNT)
in Chapter 11. The most striking feature of the NNTs is their small values, indicating the marked
effectiveness of the treatments. No previously published NNTs for psoriasis treatments were located
during the preparation of these reviews.
The two observational studies described in Chapter 12 provided real-life data that validated some of
the assumptions made in the decision-analytic model that formed the basis of the economic
evaluation One interesting feature to emerge from these studies was the fact that the patients
receiving UVB and cyclosporin treatments were younger than those receiving the other forms of
treatment. The patients receiving cyclosporin also had higher mean PASIs. suggesting that they may
be a subgroup of young patients with particularly severe disease.
The preliminary economic analysis reported in Chapter 13 provided a rank order of cost-
effectiveness for the four treatment strategies compared but raised a number of issues about the
model itself. According to the analysis. the primary treatments. in order of cost-effectiveness. would
be methotrexate, cyclosporin, acitretin and PUVA Inpractical terms, acitretin can only really be
considered for men and post-menopausal women, because of the risks of teratogenicity. The
absence of narrowband UVB from the analysis is a major omission in the present day treatment
setting and this should be incorporated into future analyses.
A detailed consideration of the evidence of effectiveness of treatments is the logical starting point for
the formulation of treatment guidelines. Both Einarson and colleagues (Einarson 1994) and Spuls
and colleagues (Spuls 1998) have made recommendations for treatment guidelines. According to
Einarson's analysis. the primary treatments. in order of cost-effectiveness were cyclosporin,
etretinate, methotrexate and PUVA It should be noted that Einarson's team used a cyclosporin dose
of Sm!r/kg/dayfor six weeks. whereas the present study allowed for 12 weeks treatment (on the basis
of trials that show a full response takes from 8-12 weeks to develop). Spuls and colleagues
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developed and tested a set of guidelines based on their earlier systematic review. Taking into
account efficacy, safety and tolerability they recommended that treatment should follow the
sequence: UVB, PUVA. methotrexate, acitretin, cyclosporin A flowchart was constructed to guide
the choice of treatment and it was designed in such a way as to prompt rotation of treatments. No
information is given about the relative costs of the treatments. The authors comment that
quantitative measures of patients' preferences should be further investigated It would be useful to
combine the treatment flow chart with UK cost data to examine the economic effects of this scheme
and to compare the options that it generates with the model used in the present study.
The therapeutic modalities assessed by this review can be classified as either having firm evidence
for their use or lacking such evidence. It is important to note that this does not necessarily preclude
the use of accepted management strategies for psoriasis such as in-patient or day-treatment regimens,
including Goeckermann and Ingram therapies.
Interventions for which RCT evidence of efficacy can be demonstrated are:
• Cyclosporin
• Systemic retinoids (acitretin and etretinate) particularly in combination with PUVA
• Phototherapy and photochemotherapy: - PUVA, BBUVB and NBUVB
• Combinations of topical calcipotriol and steroids with phototherapy
Interventions for which firm RCT evidence of effICacyis lacking
• Methotrexate
Research recommendations
In view of the lack ofRcr evidence in several areas the following trials are recommended:
• A comparison of cyclosporin with methotrexate.
• Comparisons of systemic therapy/phototherapy with inpatients andlor day treatment
• Comparison of acitretin with methotrexate for long-term treatment
• A comparison ofNBUVB versus PUVA for both short term efficacy and long term safety.
Further studies of the cost-effectiveness and cost-utility of treatments for severe psoriasis are
required. Future models will need to incorporate the costs of adverse effects of treatment
Economic evaluations should consider not only systemic and phototherapy options but also inpatient
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or day treatment centre management of psoriasis. Inaddition, combination therapies should be built
into future models, so that the real life situation is more accurately reflected
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APCs
BBUVB
BSA
Cl
CSA
DB
Goeckerman therapy
Ingram therapy
]
MED
MOP
MPD
NB
NBUVB
NR
OR
PASI
PNBUVB
PSI
PUVA
Rcr
RD
RePUVA
SAPASI
SB
SD
SEM
TMP
Glossary
Antigen presenting cells
Broad band UVB (290-320 run)
Body surface area
Confidence iinterval
Cyclosporin A
Double blind
A form of treatment for psoriasis involving the use of UVB and tar
A form of treatment for psoriasis involving the use of UVB. tar and
dithranol
Joule
Minimum erythematous dose (a measure used for UVB)
Methoxypsoralen
Minimum phototoxic dose (a measure used for UVA)
Not blinded
Narrowband UVB (approx. 311nm)
Not reported
Odds ratio
Psoriasis Area and Severity Index
Psoralen plus narrowband UVB
Psoriasis severity index ( a modified PASn
Psoralen plus UVA
Randomised controlled trial
Rate difference (also known as risk difference)
The combination of a retinoid with PUV A treatment
Self-administered psoriasis area and severity score
Single blind
Standard deviation
Standard error of the mean
Trimethoxypsoralen
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UVA
UVB
VAS
WI'P
Ultraviolet A (320 - 400 run)
Ultraviolet B (290 - 320 run)
Visual analogue scale
Willingness to pay
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Appendix 1
Medline Search Stra~y to Identify Randomised Controlled Trials
The search strategy below will detect a high proportion of studies which are randomised controlled
trials, but may also retrieve some non-randomised studies. The search is in three sections and the
sections trade-off recall and precision with the first search (#10) having high precision and lowest
recall and the third search having high recall and low precision The final search line (#31)
combines all three searches, but it is also possible to just combine #30 and # 10 for high precision if
desired.
# 1 randomized controlled trial. pt.
#2 randomized controlled trials. sh.
#3 random allocationsh.
#4 double blind method. sh.
#S single blind methodsh.
#6 1 or 2 or 3 or 4 or S
#7 animal. sh.
#8 human Sh.
#9 7 not (7 and 8)
#10 6not 9
#11 clinical trial.pt
#12 exp clinical trials.sh.
#13 (clinS adj3 trialS).ti,ab.
#14 ({singiS or doublS or trebS or tripl$) adj3 (blind$ or mask$». ti,ab.
# 15 placebos. sh.
# 16 placebos, ti.ab,
# 17 random ti,ab.
#l8 research designsh.
#19 11 or 12 or 13 or 14 or 15 or 160r 17 or 18
#20 19 not 9
#21 20 not 10
#22 comparative study.sh.
#23 exp evaluation studies.sh.
#24 follow-up studies.sh.
#25 prospective studies.sh.
#26 (controlS or prospective or volunteers), ti.ah
#27 21 or 22 or 23 or 24 or 2S
#28 26 not 9
#29 28 not (10 or 21)
#30 **subject search terms··
#31 30 and (10 or 21 or 29)
This is a translation of the search suggested by Dickersin, Scherer and Lefebvre, in the British
Medical Journal 1994; 309: 1291 (NHS CRD 1996)
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Appendix 2
Data Extraction Sheet for a Review of Volume and Quality of CABG Surgery
Paper Reference Number
A DETAILS OF PUBLICATION
1 Author
2 Title
3 Reference
4 Institution
B SOURCE OF DATA
1 Where was the data from?
2 What years was the data collected for?
3 How was the data obtained (eg discharge abstracts, database)?
C HOSPITALS AND PATIENTS INCLUDED IN THE REVIEW
1 Did the patients undergo CABG surgery?
2 What cut-points for hospital volume can be used from the paper?
3 What cut point is closed to 200?
4 Number of hospitals above this cutpoint?
5 Number of hospital below this cut-point?
6 What mortality rate(s) does the paper report? (over what period)
D ADJUSTMENTS MADE IN ANALYSIS
1 What factors were adjustments made for?
2 How was this data obtained?
3 What statistical methods were used for the adjustments?
4 What grade does this correspond with?
230
E RESULTS
1 How many patients in the high volume group?
2 How many patients in the low volume group?
3 What is the crude mortality rate in the high volume group? How many deaths is this?
4 What is the crude mortality rate in the low volume group? How many deaths is this?
5 What is the adjusted mortality rate in the low volume group? Approximately how many deaths
is this?
6 What is the crude odds ratio for volume?
7 What is the adjusted odds ratio for volume?
F OTHER INFORMATION
1 Does the paper report on physican volume? Whatevidence does it report?
2 Other comments
(NHS Centre for Reviews and Dissemination 1996)
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Appendix 3
Details of calculations (or economic analyses
Costs of monitoring
Test
CSA Unit cost First visit Repeat
viSit
Urea/elecslcreat 2.96 2.96 2.96
Pregnancy 6.17 3.09 0
GFR 8 8 0
14.05 2.96
MTX
FBC 1.89 1.89 1.89
Biochem profile 8.08 8.08 8.08
PIIINP 8 8 8
Pregnancy 6.17 3.09 0
Uver DOPSY 600
21.06 17.97
Acitretin
FBC 1.89 1.89 1.89
Biochem profile 8.08 8.08 8.08
Upid profile 5.85 5.85 5.85
X-ray spine 106 106 0
Pregnancy 6.17 3.09 0
124.91 15.82
PUVA
Biochem profile 8.08 8.08 0
Note: All routine biochemistry. haematology, radiology etc costs are accounted for in the fully-
absorbed clinic visit cost of £76.00. Therefore, only exceptional or unusual items (shown in bold)
have been added in the analyses.
Drug costs
Drug Strength Pack size Price Unit price Dose Costl12wks
treatment
MTX 2.5 100 11.41 0.1141 15mg/wk 8.22
MIX 10 100 55.07 0.5507 20mglwk 13.22
Neoral 100 30 76.33 2.544333 400mg/d 854.90
Neoral 100 30 76.33 2.544333 300mg/g 641.17
Neoral 50 30 40.22 1.340667
Acitretin 10 56 25.34 0.4525
Acitretin 25 56 58.8 1.05 75mg/d 264.60
Acitretin 25 56 58.8 1.05 SOmg/d 176.40
Folic acid 5 20 0.49 0.0245 2.06
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Cyclosporin primary - methotrexate secondary treatment
Pathway Cost elements
1 12 visits + 12 Vv1<s CSA
2 12 visits + 2 x 12 Vv1<s CSA
3 12 visits + 2 x 12 Vv1<s CSA + 12v.i<s MTX
4 12 visits + 2 x 12 Vv1<s CSA + 12¥A<s MTX
5 12 visits + 12 Vv1<s CSA + 12Vv1<sMTX
6 12 visits + 12 ~s CSA + 2 x 12¥A<s MTX
7 12 visits + 12 ~s CSA + 2 x 12v.i<s MTX
8 12 visits + 12 Vv1<s CSA + 12 ~ MTX
Note: All methotrexate treatment costs included the cost of concomitant folic acid treatment (Smg
daily).
Methotrexate primary - cyclosporin secondary treatment
Patway Cost elements
1 12 visits + 2 x 12 ~s MTX (15mglwk) + 2 x 12 wks MTX
(15mglwk)
2 12 visits + 2 x 12 ~ MTX (15mg/wk) + 1x 12 wks MTX
(20mg/wk) + 1 x12 Vv1<s MTX 1Smglwk
3 12 visits + 2 x 12 ~ MTX (1Smg/wk) + 1x 12 Vv1<s MTX
(20mglwk) + 1 x12 Vv1<s CSA
4 12 visits + 2 x 12 Vv1<s MTX (15mglwk) + 1x 12 wks MTX
(20mg/wk) + 1 x12 wks CSA
5 12 visits + 1 x 12 wks MTX (1Smglwk) + 1 x 12 ~s CSA
6 12 visits + 1 x 12 wks MTX (1Smg/wk) + 2 x 12 wks CSA
7 12 visits + 1 x 12 wks MTX (15mglwk) + 2 x 12 wks CSA
8 12 visits + 1 x 12 ~ MTX (1Smg/wk) + 1 x 12 wks CSA
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Acitretin primary - cyclosporin secondary treatment
Pathway Cost elements
1 12 visits + 2 x12 wks ACI (SOmgld) + spine Xray + 2 x 12 wks ACI
(SOmgld)
2 12 visits + 2 x12 wks ACI (SOmgld) + spine Xray + 1 x 12 wks ACI
75mg/d + 1 x 12 wks ACI (SOmg/d)
3 12 visits + 2 x12 wks ACI (SOmg/d) + spine Xray + 1 x 12 wks ACI
75mg/d + 1 x 12 wks CSA
4 12 visits + 2 x12 wks ACI (SOmgld) + spine Xray + 1 x 12 wks ACI
75mgld + 1 x 12 wks CSA
5 12 visits + 1 x12 wks ACI (SOmg/d) + spine Xray + 1 x 12 wks CSA
6 12 visits + 1 x12 wks ACI (SOmg/d) + spine Xray + 2 x 12 wks CSA
7 12 visits + 1 x12 wks ACI (SOmgld) + spine Xray + 2 x 12 wks CSA
8 12 visits + 1 x12 Yv1csACI (50mgld) + spine Xray + 1 x 12 wks CSA
PUVA primary - cyclosporin secondary treatment
Pathway Cost elements
1 12 visits + 20 PUVA sessions
2 12 visits + 2 x 20 PUVA sessions
3 12 visits + 2 x 20 PUVA sessions + 1 x 12Yv1<.sCSA
4 12 visits + 2 x 20 PUVA sessions + 1 x 12wks CSA
1---.-
12 visits + 20 PUVA sessions + 1 x 12Yv1<.sCSA5
6 12 visits + 20 PUVA sessions + 2 x 12 wks CSA-_=- "12 visits + 20 PUVA sessions + 2 x 12 wks CSA7
8 12 visits + 20 PUVA sessions + 1 x 12 wks CSA
Calculation of the cost-effectiveness ratio:
1. For each pathway the cumulative probability of the outcome is calculated by multiplying the
probabilities for each stage.
2. The probabilities for all the successful outcomes are then added together to give the overall
probability of success. The process is repeated for the pathways that end in failure. (See Chapter
1.Table 1.1} The sum of the overall probabilities of success and failure must be equal to one.
3. The cost rH each pathway is calculated by multiplying the cumulative probability for the
pathway by the sum rH all the cost elements in the pathway.
4. The total cost of treatment is the sum of the costs of each pathway.
S. The cost effectiveness ratio is calculated by dividing the total cost by the cumulative success
rate, which gives a "cost per success".
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